Institution: MODENA MED CLINIC Sign In as Individual
-------------------------------------------------------------------------------Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Blood 90: 3844-3852.
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Blood First Edition Paper, prepublished online April 3, 2003; DOI 10.1182/blood-2002-12-3837
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Blood 95: 3687-3692.
-------------------------------------------------------------------------------Abstract 1 of 5 Blood, 1 October 2000, Vol. 96, No. 7, pp. 2399-2404
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Tarun Kewalramani, Andrew D. Zelenetz, Eric E. Hedrick, Gerard B. Donnelly, Sonia Hunte, Anna
C. Priovolos, Jing Qin, Nancy Coady Lyons, Joachim Yahalom, Stephen D. Nimer, and Craig H.
Moskowitz
From the Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose chemoradiotherapy (HDT) with autologous stem cell transplantation (ASCT) is the
treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma (NHL). However,
its role in the treatment of patients with primary refractory disease is not well defined. The
outcomes of 85 patients with primary refractory aggressive NHL who underwent second-line
chemotherapy with ICE with the intent of administering HDT/ASCT to those patients with
chemosensitive disease were reviewed. Patients were retrospectively classified as induction partial
responders (IPR) if they attained a partial response to doxorubicin-based front-line therapy or as
induction failures (IF) if they had less than partial response. Forty-three patients (50.6%) had ICEchemosensitive disease; there was no difference in the response rate between the IPR and the IF
groups. Intention-to-treat analysis revealed that 25% of the patients were alive and 21.9% were
event-free at a median follow-up of 35 months. Among 42 patients who underwent transplantation,
the 3-year overall and event-free survival rates were 52.5% and 44.2%, respectively, similar to the
outcomes for patients with chemosensitive relapsed disease. No differences were observed between
the IPR and IF groups, and there were no transplantation-related deaths. More than one extranodal
site of disease and a second-line age-adjusted International Prognostic Index of 3 or 4 before ICE
chemotherapy were predictive of poor survival. These results suggest that patients with primary
refractory aggressive NHL should receive second-line chemotherapy, with the intent of
administering HDT/ASCT to those with chemosensitive disease. Newer therapies are needed to
improve the outcomes of patients with poor-risk primary refractory disease.
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
From the Department of Hematology and Bone Marrow Transplantation, City of Hope National
Medical Center, Duarte, CA; and the Bone Marrow Transplant Program, Stanford University
Medical Center, Stanford, CA
We have conducted a pilot study to investigate the role of high-dose therapy and autologous bone
marrow/stem cell transplantation (ASCT) during first complete or partial remission in 52 patients
with poor-risk aggressive lymphoma. There were 42 patients with intermediate-grade or
immunoblastic lymphoma who were considered to be high (60%) and high-intermediate risk (40%)
groups at diagnosis based on the age-adjusted International Prognostic Index (IPI) and 10 patients
with high-grade, SNCCL (small non-cleaved cell, Burkitt's, and non-Burkitt's), who at presentation
had poor-risk features defined as elevated serum lactate dehydrogenase level, stage IV, and bulky
mass 10 cm. The median age was 34 years (range, 16 to 56 years). Thirty-nine were transplanted in
first complete remission and 13 in first partial remission after conventional therapy. Conditioning
regimens consisted of total body irradiation (TBI) administered as a single fraction 750 cGy in 3
patients and in fractionated doses for a total of 1,200 cGy in 44 patients, in combination with 60
mg/kg etoposide and 100 mg/kg cyclophosphamide. Five patients with prior radiotherapy received
450 mg/m2 carmustine instead of TBI. Stem cell sources were either bone marrow and/or peripheral
blood. No in vitro purging was used. All patients engrafted. Two SNCCL patients died of
venoocclusive disease at 25 days and acute leukemia at 27 months posttransplantation. There were
six relapses at 1.5 to 12.8 months posttransplantation. At a median follow-up of 44 months (range, 1
to 113 months), the estimated 3-year overall survival (OS) and disease-free survival (DFS) for all
patients was 84% (95% confidence interval [CI], 70% to 92%) and 82% (95% CI, 68% to 91%),
respectively. In the subset of patients with intermediate-grade and immunoblastic lymphoma, the 3year DFS was 89% (95% CI, 74% to 96%) for all patients, 87% (95% CI, 67% to 96%) for highrisk patients, and 92% (95 CI, 61% to 99%) for high-intermediate risk patients. The 3-year OS and
DFS for SNCCL patients were identical at 60% (95% CI, 30% to 84%). These results suggest that
high-dose therapy and ASCT during first remission may improve the survival and prognosis of
patients with poor-risk intermediate- and high-grade lymphoma. A prospective randomized study
comparing high-dose therapy and ASCT with conventional chemotherapy in IPI high-risk patients
with aggressive non-Hodgkin's lymphoma should be undertaken.
Blood, Vol. 90 No. 10 (November 15), 1997: pp. 3844-3852
© 1997 by The American Society of Hematology.
[Full Text of Nademanee et al.] [Reprint (PDF) Version of Nademanee et al.]
-------------------------------------------------------------------------------Abstract 3 of 5
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose
Chemotherapy and Autologous Hematopoietic Cell Transplantation
Laurie H. Sehn, Joseph H. Antin, Lawrence N. Shulman, Peter Mauch, Anthony Elias, Marshall E.
Kadin, and Catherine Wheeler
From the Hematology-Oncology Division, Brigham and Women's Hospital; Hematology-Oncology
Division and Department of Pathology, Beth Israel Hospital; Joint Center for Radiation Therapy,
Division of Medical Oncology, Dana-Farber Cancer Institute; and Harvard Medical School, Boston,
MA.
We performed a retrospective analysis of 35 patients with primary diffuse large B-cell lymphoma of
the mediastinum treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus
autologous hematopoietic cell transplantation to determine outcome and prognostic features for
progression-free survival (PFS). Thirty-five patients with primary diffuse large B-cell lymphoma of
the mediastinum in first response (complete remission [CR] or partial remission [PR]) with poor
prognostic features, with primarily refractory disease, or with relapsed disease following
conventional chemotherapy, were treated with CBV and autologous hematopoietic cell
transplantation. PFS and overall survival were assessed by the Kaplan-Meier method. Patient
characteristics before transplantation were examined by univariate analysis using the log-rank test
and by Cox's proportional hazards regression analysis to determine predictors of PFS. Estimated 5year PFS varied significantly with patient disease status at transplantation. Patients transplanted in
first response had an estimated 5-year PFS rate of 83%, compared with 58% and 27% for primarily
refractory and relapsed patients, respectively (P = .02). The strongest predictor of PFS was
chemotherapy responsiveness immediately before transplantation. Patients with chemotherapyresponsive disease had a significantly greater PFS rate than patients with chemotherapynonresponsive disease (risk ratio, 3.60; 95% confidence interval [CI], 1.14 to 11.4). No other factors
were found to be significant on univariate or multivariate analysis. Patients with primary diffuse
large B-cell lymphoma of the mediastinum can achieve prolonged PFS following high-dose
chemotherapy and autologous hematopoietic cell transplantation. Outcomes are strongly correlated
with disease status (first response v refractory v relapsed) at transplantation and chemotherapy
responsiveness immediately before transplantation.
Blood, Vol. 91 No. 2 (January 15), 1998: pp. 717-723
© 1998 by The American Society of Hematology.
[Full Text of Sehn et al.] [Reprint (PDF) Version of Sehn et al.]
-------------------------------------------------------------------------------Abstract 4 of 5
Submitted December 19, 2002
Accepted March 20, 2003
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz*
Department of Medicine - Lymphoma Service, Memorial Hospital, Memorial Sloan-Kettering
Cancer Center, New York, NY, USA; Department of Medicine - Hematology Service, Memorial
Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Department of Radiation Oncology, Memorial Hospital, Memorial Sloan-Kettering Cancer Center,
New York, NY, USA
Department of Biostatistics, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New
York, NY, USA
* Corresponding author; email: moskowic@mskcc.org.
Second-line chemotherapy followed by high dose therapy (HDT) with autologous stem cell
transplantation (ASCT) cures less than half of patients with relapsed or refractory diffuse large B
cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In three
sequential clinical trials, conducted from 1/93 to 8/00, we treated 150 patients with relapsed or
primary refractory DLBCL with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy
followed by HDT/ASCT for patients with chemosensitive disease. We evaluated the age-adjusted
international prognostic index at the initiation of second-line therapy (sAAIPI) as a predictor of
progression free survival (PFS) and overall survival (OS). At a median followup of 4 years, the PFS
and OS are 28% and 34% by intention to treat and 39% and 45% for only those patients with
chemosensitive disease. Three risk groups with different PFS and OS were identified by the
sAAIPI: low risk (0 factors) 70% and 74%; intermediate risk (1 factor) 39% and 49%; and high risk
(2 or 3 factors) 16% and 18% (p<0.001 for both PFS and OS). The sAAIPI also predicts the PFS
and OS for patients with ICE chemosensitive disease: low risk 69% and 83%; intermediate risk
46% and 55%; and high risk 25% and 26% (p<0.001 PFS and OS). The sAAIPI predicts outcome
for patients with relapsed or primary refractory DLBCL in both intent-to-treat and chemosensitive
populations. This powerful prognostic instrument should be used to evaluate new treatment
approaches and to compare results of different regimens.
[Reprint (PDF) Version of Hamlin et al.]
-------------------------------------------------------------------------------Abstract 5 of 5
Blood, Vol. 95 No. 12 (June 15), 2000: pp. 3687-3692
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
From the Département d'information hospitalier and Service d'hématologie clinique Hôpital Henri
Mondor, AP-HP, Créteil, France; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Institut
d'hématologie, Hôpital Saint Louis, AP-HP, Paris, France; Service d'hématologie, Centre Léon
Bérard, Lyon, France; Service d'hématologie, Centre Hospitalier du Dr Schaffner, Lens, France;
Service d'hématologie, CHU de Bordeaux, Pessac, France; Service d'hématologie, Institut Paoli
Calmette, Marseille, France; Service d'hématologie, Centre Jolimont, La Louvière, Belgium; and
Service d'hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of
both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin
lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was
applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541
patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS)
curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1), secondary
toxicity (Tox2), time without symptom and toxicity (TWiST), and relapse (Rel). Areas under
survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT
increased, but not significantly, TWiST (+2.4 months in AUC, P = .17) and decreased Rel (3
months, P < .01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for
OS, 39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a
significant benefit in DFS (AUC 28.8 versus 24.9 months, P < .01) but not in OS (AUC 37.3 versus
36 months, P = .27). Sensitivity analysis, performed by varying QOL coefficients, demonstrated
significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients,
a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in
these patients with adverse prognostic factors in the first CR, even after adjusting for QOL using the
Q-TWiST method.
[Full Text of Mounier et al.] [Reprint (PDF) Version of Mounier et al.]
--------------------------------------------------------------------------------
-------------------------------------------------------------------------------Blood Online is sponsored by an
unrestricted grant from Shire
Copyright © 2003 by American Society of Hematology.
Institution: MODENA MED CLINIC Sign In as Individual
-------------------------------------------------------------------------------Download ALL Selected Citations
to Citation Manager
Selected Abstracts
Returned: 5 citations and abstracts. Click on down arrow or scroll to see abstracts.
Tarun Kewalramani, Andrew D. Zelenetz, Eric E. Hedrick, Gerard B. Donnelly, Sonia Hunte,
Anna C. Priovolos, Jing Qin, Nancy Coady Lyons, Joachim Yahalom, Stephen D. Nimer, and Craig
H. Moskowitz
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Blood 96: 2399-2404.
Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Blood 90: 3844-3852.
Laurie H. Sehn, Joseph H. Antin, Lawrence N. Shulman, Peter Mauch, Anthony Elias, Marshall E.
Kadin, and Catherine Wheeler
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose
Chemotherapy and Autologous Hematopoietic Cell Transplantation
Blood 91: 717-723.
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Blood First Edition Paper, prepublished online April 3, 2003; DOI 10.1182/blood-2002-12-3837
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Blood 95: 3687-3692.
-------------------------------------------------------------------------------Abstract 1 of 5 Blood, 1 October 2000, Vol. 96, No. 7, pp. 2399-2404
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Tarun Kewalramani, Andrew D. Zelenetz, Eric E. Hedrick, Gerard B. Donnelly, Sonia Hunte, Anna
C. Priovolos, Jing Qin, Nancy Coady Lyons, Joachim Yahalom, Stephen D. Nimer, and Craig H.
Moskowitz
From the Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose chemoradiotherapy (HDT) with autologous stem cell transplantation (ASCT) is the
treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma (NHL). However,
its role in the treatment of patients with primary refractory disease is not well defined. The
outcomes of 85 patients with primary refractory aggressive NHL who underwent second-line
chemotherapy with ICE with the intent of administering HDT/ASCT to those patients with
chemosensitive disease were reviewed. Patients were retrospectively classified as induction partial
responders (IPR) if they attained a partial response to doxorubicin-based front-line therapy or as
induction failures (IF) if they had less than partial response. Forty-three patients (50.6%) had ICEchemosensitive disease; there was no difference in the response rate between the IPR and the IF
groups. Intention-to-treat analysis revealed that 25% of the patients were alive and 21.9% were
event-free at a median follow-up of 35 months. Among 42 patients who underwent transplantation,
the 3-year overall and event-free survival rates were 52.5% and 44.2%, respectively, similar to the
outcomes for patients with chemosensitive relapsed disease. No differences were observed between
the IPR and IF groups, and there were no transplantation-related deaths. More than one extranodal
site of disease and a second-line age-adjusted International Prognostic Index of 3 or 4 before ICE
chemotherapy were predictive of poor survival. These results suggest that patients with primary
refractory aggressive NHL should receive second-line chemotherapy, with the intent of
administering HDT/ASCT to those with chemosensitive disease. Newer therapies are needed to
improve the outcomes of patients with poor-risk primary refractory disease.
© 2000 by The American Society of Hematology.
[Full Text of Kewalramani et al.] [Reprint (PDF) Version of Kewalramani et al.]
-------------------------------------------------------------------------------Abstract 2 of 5
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
From the Department of Hematology and Bone Marrow Transplantation, City of Hope National
Medical Center, Duarte, CA; and the Bone Marrow Transplant Program, Stanford University
Medical Center, Stanford, CA
We have conducted a pilot study to investigate the role of high-dose therapy and autologous bone
marrow/stem cell transplantation (ASCT) during first complete or partial remission in 52 patients
with poor-risk aggressive lymphoma. There were 42 patients with intermediate-grade or
immunoblastic lymphoma who were considered to be high (60%) and high-intermediate risk (40%)
groups at diagnosis based on the age-adjusted International Prognostic Index (IPI) and 10 patients
with high-grade, SNCCL (small non-cleaved cell, Burkitt's, and non-Burkitt's), who at presentation
had poor-risk features defined as elevated serum lactate dehydrogenase level, stage IV, and bulky
mass 10 cm. The median age was 34 years (range, 16 to 56 years). Thirty-nine were transplanted in
first complete remission and 13 in first partial remission after conventional therapy. Conditioning
regimens consisted of total body irradiation (TBI) administered as a single fraction 750 cGy in 3
patients and in fractionated doses for a total of 1,200 cGy in 44 patients, in combination with 60
mg/kg etoposide and 100 mg/kg cyclophosphamide. Five patients with prior radiotherapy received
450 mg/m2 carmustine instead of TBI. Stem cell sources were either bone marrow and/or peripheral
blood. No in vitro purging was used. All patients engrafted. Two SNCCL patients died of
venoocclusive disease at 25 days and acute leukemia at 27 months posttransplantation. There were
six relapses at 1.5 to 12.8 months posttransplantation. At a median follow-up of 44 months (range, 1
to 113 months), the estimated 3-year overall survival (OS) and disease-free survival (DFS) for all
patients was 84% (95% confidence interval [CI], 70% to 92%) and 82% (95% CI, 68% to 91%),
respectively. In the subset of patients with intermediate-grade and immunoblastic lymphoma, the 3year DFS was 89% (95% CI, 74% to 96%) for all patients, 87% (95% CI, 67% to 96%) for highrisk patients, and 92% (95 CI, 61% to 99%) for high-intermediate risk patients. The 3-year OS and
DFS for SNCCL patients were identical at 60% (95% CI, 30% to 84%). These results suggest that
high-dose therapy and ASCT during first remission may improve the survival and prognosis of
patients with poor-risk intermediate- and high-grade lymphoma. A prospective randomized study
comparing high-dose therapy and ASCT with conventional chemotherapy in IPI high-risk patients
with aggressive non-Hodgkin's lymphoma should be undertaken.
Blood, Vol. 90 No. 10 (November 15), 1997: pp. 3844-3852
© 1997 by The American Society of Hematology.
[Full Text of Nademanee et al.] [Reprint (PDF) Version of Nademanee et al.]
-------------------------------------------------------------------------------Abstract 3 of 5
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose
Chemotherapy and Autologous Hematopoietic Cell Transplantation
Laurie H. Sehn, Joseph H. Antin, Lawrence N. Shulman, Peter Mauch, Anthony Elias, Marshall E.
Kadin, and Catherine Wheeler
From the Hematology-Oncology Division, Brigham and Women's Hospital; Hematology-Oncology
Division and Department of Pathology, Beth Israel Hospital; Joint Center for Radiation Therapy,
Division of Medical Oncology, Dana-Farber Cancer Institute; and Harvard Medical School, Boston,
MA.
We performed a retrospective analysis of 35 patients with primary diffuse large B-cell lymphoma of
the mediastinum treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus
autologous hematopoietic cell transplantation to determine outcome and prognostic features for
progression-free survival (PFS). Thirty-five patients with primary diffuse large B-cell lymphoma of
the mediastinum in first response (complete remission [CR] or partial remission [PR]) with poor
prognostic features, with primarily refractory disease, or with relapsed disease following
conventional chemotherapy, were treated with CBV and autologous hematopoietic cell
transplantation. PFS and overall survival were assessed by the Kaplan-Meier method. Patient
characteristics before transplantation were examined by univariate analysis using the log-rank test
and by Cox's proportional hazards regression analysis to determine predictors of PFS. Estimated 5year PFS varied significantly with patient disease status at transplantation. Patients transplanted in
first response had an estimated 5-year PFS rate of 83%, compared with 58% and 27% for primarily
refractory and relapsed patients, respectively (P = .02). The strongest predictor of PFS was
chemotherapy responsiveness immediately before transplantation. Patients with chemotherapyresponsive disease had a significantly greater PFS rate than patients with chemotherapynonresponsive disease (risk ratio, 3.60; 95% confidence interval [CI], 1.14 to 11.4). No other factors
were found to be significant on univariate or multivariate analysis. Patients with primary diffuse
large B-cell lymphoma of the mediastinum can achieve prolonged PFS following high-dose
chemotherapy and autologous hematopoietic cell transplantation. Outcomes are strongly correlated
with disease status (first response v refractory v relapsed) at transplantation and chemotherapy
responsiveness immediately before transplantation.
Blood, Vol. 91 No. 2 (January 15), 1998: pp. 717-723
© 1998 by The American Society of Hematology.
[Full Text of Sehn et al.] [Reprint (PDF) Version of Sehn et al.]
-------------------------------------------------------------------------------Abstract 4 of 5
Submitted December 19, 2002
Accepted March 20, 2003
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz*
Department of Medicine - Lymphoma Service, Memorial Hospital, Memorial Sloan-Kettering
Cancer Center, New York, NY, USA; Department of Medicine - Hematology Service, Memorial
Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Department of Radiation Oncology, Memorial Hospital, Memorial Sloan-Kettering Cancer Center,
New York, NY, USA
Department of Biostatistics, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New
York, NY, USA
* Corresponding author; email: moskowic@mskcc.org.
Second-line chemotherapy followed by high dose therapy (HDT) with autologous stem cell
transplantation (ASCT) cures less than half of patients with relapsed or refractory diffuse large B
cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In three
sequential clinical trials, conducted from 1/93 to 8/00, we treated 150 patients with relapsed or
primary refractory DLBCL with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy
followed by HDT/ASCT for patients with chemosensitive disease. We evaluated the age-adjusted
international prognostic index at the initiation of second-line therapy (sAAIPI) as a predictor of
progression free survival (PFS) and overall survival (OS). At a median followup of 4 years, the PFS
and OS are 28% and 34% by intention to treat and 39% and 45% for only those patients with
chemosensitive disease. Three risk groups with different PFS and OS were identified by the
sAAIPI: low risk (0 factors) 70% and 74%; intermediate risk (1 factor) 39% and 49%; and high risk
(2 or 3 factors) 16% and 18% (p<0.001 for both PFS and OS). The sAAIPI also predicts the PFS
and OS for patients with ICE chemosensitive disease: low risk 69% and 83%; intermediate risk
46% and 55%; and high risk 25% and 26% (p<0.001 PFS and OS). The sAAIPI predicts outcome
for patients with relapsed or primary refractory DLBCL in both intent-to-treat and chemosensitive
populations. This powerful prognostic instrument should be used to evaluate new treatment
approaches and to compare results of different regimens.
[Reprint (PDF) Version of Hamlin et al.]
-------------------------------------------------------------------------------Abstract 5 of 5
Blood, Vol. 95 No. 12 (June 15), 2000: pp. 3687-3692
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
From the Département d'information hospitalier and Service d'hématologie clinique Hôpital Henri
Mondor, AP-HP, Créteil, France; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Institut
d'hématologie, Hôpital Saint Louis, AP-HP, Paris, France; Service d'hématologie, Centre Léon
Bérard, Lyon, France; Service d'hématologie, Centre Hospitalier du Dr Schaffner, Lens, France;
Service d'hématologie, CHU de Bordeaux, Pessac, France; Service d'hématologie, Institut Paoli
Calmette, Marseille, France; Service d'hématologie, Centre Jolimont, La Louvière, Belgium; and
Service d'hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of
both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin
lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was
applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541
patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS)
curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1), secondary
toxicity (Tox2), time without symptom and toxicity (TWiST), and relapse (Rel). Areas under
survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT
increased, but not significantly, TWiST (+2.4 months in AUC, P = .17) and decreased Rel (3
months, P < .01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for
OS, 39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a
significant benefit in DFS (AUC 28.8 versus 24.9 months, P < .01) but not in OS (AUC 37.3 versus
36 months, P = .27). Sensitivity analysis, performed by varying QOL coefficients, demonstrated
significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients,
a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in
these patients with adverse prognostic factors in the first CR, even after adjusting for QOL using the
Q-TWiST method.
[Full Text of Mounier et al.] [Reprint (PDF) Version of Mounier et al.]
--------------------------------------------------------------------------------
-------------------------------------------------------------------------------Blood Online is sponsored by an
unrestricted grant from Shire
Copyright © 2003 by American Society of Hematology.
Institution: MODENA MED CLINIC Sign In as Individual
-------------------------------------------------------------------------------Download ALL Selected Citations
to Citation Manager
Selected Abstracts
Returned: 5 citations and abstracts. Click on down arrow or scroll to see abstracts.
Tarun Kewalramani, Andrew D. Zelenetz, Eric E. Hedrick, Gerard B. Donnelly, Sonia Hunte,
Anna C. Priovolos, Jing Qin, Nancy Coady Lyons, Joachim Yahalom, Stephen D. Nimer, and Craig
H. Moskowitz
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Blood 96: 2399-2404.
Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Blood 90: 3844-3852.
Laurie H. Sehn, Joseph H. Antin, Lawrence N. Shulman, Peter Mauch, Anthony Elias, Marshall E.
Kadin, and Catherine Wheeler
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose
Chemotherapy and Autologous Hematopoietic Cell Transplantation
Blood 91: 717-723.
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Blood First Edition Paper, prepublished online April 3, 2003; DOI 10.1182/blood-2002-12-3837
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Blood 95: 3687-3692.
-------------------------------------------------------------------------------Abstract 1 of 5 Blood, 1 October 2000, Vol. 96, No. 7, pp. 2399-2404
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Tarun Kewalramani, Andrew D. Zelenetz, Eric E. Hedrick, Gerard B. Donnelly, Sonia Hunte, Anna
C. Priovolos, Jing Qin, Nancy Coady Lyons, Joachim Yahalom, Stephen D. Nimer, and Craig H.
Moskowitz
From the Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose chemoradiotherapy (HDT) with autologous stem cell transplantation (ASCT) is the
treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma (NHL). However,
its role in the treatment of patients with primary refractory disease is not well defined. The
outcomes of 85 patients with primary refractory aggressive NHL who underwent second-line
chemotherapy with ICE with the intent of administering HDT/ASCT to those patients with
chemosensitive disease were reviewed. Patients were retrospectively classified as induction partial
responders (IPR) if they attained a partial response to doxorubicin-based front-line therapy or as
induction failures (IF) if they had less than partial response. Forty-three patients (50.6%) had ICEchemosensitive disease; there was no difference in the response rate between the IPR and the IF
groups. Intention-to-treat analysis revealed that 25% of the patients were alive and 21.9% were
event-free at a median follow-up of 35 months. Among 42 patients who underwent transplantation,
the 3-year overall and event-free survival rates were 52.5% and 44.2%, respectively, similar to the
outcomes for patients with chemosensitive relapsed disease. No differences were observed between
the IPR and IF groups, and there were no transplantation-related deaths. More than one extranodal
site of disease and a second-line age-adjusted International Prognostic Index of 3 or 4 before ICE
chemotherapy were predictive of poor survival. These results suggest that patients with primary
refractory aggressive NHL should receive second-line chemotherapy, with the intent of
administering HDT/ASCT to those with chemosensitive disease. Newer therapies are needed to
improve the outcomes of patients with poor-risk primary refractory disease.
© 2000 by The American Society of Hematology.
[Full Text of Kewalramani et al.] [Reprint (PDF) Version of Kewalramani et al.]
-------------------------------------------------------------------------------Abstract 2 of 5
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During
Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and
High-Intermediate Risk Group
Auayporn Nademanee, Arturo Molina, Margaret R. O'Donnell, Andrew Dagis, David S. Snyder,
Pablo Parker, Anthony Stein, Eileen Smith, Ina Planás, Ashwin Kashyap, Ricardo Spielberger,
Henry Fung, K.K. Wong, George Somlo, Kim Margolin, Warren Chow, Irena Sniecinski, Nayana
Vora, Karl G. Blume, Joyce Niland, and Stephen J. Forman
From the Department of Hematology and Bone Marrow Transplantation, City of Hope National
Medical Center, Duarte, CA; and the Bone Marrow Transplant Program, Stanford University
Medical Center, Stanford, CA
We have conducted a pilot study to investigate the role of high-dose therapy and autologous bone
marrow/stem cell transplantation (ASCT) during first complete or partial remission in 52 patients
with poor-risk aggressive lymphoma. There were 42 patients with intermediate-grade or
immunoblastic lymphoma who were considered to be high (60%) and high-intermediate risk (40%)
groups at diagnosis based on the age-adjusted International Prognostic Index (IPI) and 10 patients
with high-grade, SNCCL (small non-cleaved cell, Burkitt's, and non-Burkitt's), who at presentation
had poor-risk features defined as elevated serum lactate dehydrogenase level, stage IV, and bulky
mass 10 cm. The median age was 34 years (range, 16 to 56 years). Thirty-nine were transplanted in
first complete remission and 13 in first partial remission after conventional therapy. Conditioning
regimens consisted of total body irradiation (TBI) administered as a single fraction 750 cGy in 3
patients and in fractionated doses for a total of 1,200 cGy in 44 patients, in combination with 60
mg/kg etoposide and 100 mg/kg cyclophosphamide. Five patients with prior radiotherapy received
450 mg/m2 carmustine instead of TBI. Stem cell sources were either bone marrow and/or peripheral
blood. No in vitro purging was used. All patients engrafted. Two SNCCL patients died of
venoocclusive disease at 25 days and acute leukemia at 27 months posttransplantation. There were
six relapses at 1.5 to 12.8 months posttransplantation. At a median follow-up of 44 months (range, 1
to 113 months), the estimated 3-year overall survival (OS) and disease-free survival (DFS) for all
patients was 84% (95% confidence interval [CI], 70% to 92%) and 82% (95% CI, 68% to 91%),
respectively. In the subset of patients with intermediate-grade and immunoblastic lymphoma, the 3year DFS was 89% (95% CI, 74% to 96%) for all patients, 87% (95% CI, 67% to 96%) for highrisk patients, and 92% (95 CI, 61% to 99%) for high-intermediate risk patients. The 3-year OS and
DFS for SNCCL patients were identical at 60% (95% CI, 30% to 84%). These results suggest that
high-dose therapy and ASCT during first remission may improve the survival and prognosis of
patients with poor-risk intermediate- and high-grade lymphoma. A prospective randomized study
comparing high-dose therapy and ASCT with conventional chemotherapy in IPI high-risk patients
with aggressive non-Hodgkin's lymphoma should be undertaken.
Blood, Vol. 90 No. 10 (November 15), 1997: pp. 3844-3852
© 1997 by The American Society of Hematology.
[Full Text of Nademanee et al.] [Reprint (PDF) Version of Nademanee et al.]
-------------------------------------------------------------------------------Abstract 3 of 5
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose
Chemotherapy and Autologous Hematopoietic Cell Transplantation
Laurie H. Sehn, Joseph H. Antin, Lawrence N. Shulman, Peter Mauch, Anthony Elias, Marshall E.
Kadin, and Catherine Wheeler
From the Hematology-Oncology Division, Brigham and Women's Hospital; Hematology-Oncology
Division and Department of Pathology, Beth Israel Hospital; Joint Center for Radiation Therapy,
Division of Medical Oncology, Dana-Farber Cancer Institute; and Harvard Medical School, Boston,
MA.
We performed a retrospective analysis of 35 patients with primary diffuse large B-cell lymphoma of
the mediastinum treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus
autologous hematopoietic cell transplantation to determine outcome and prognostic features for
progression-free survival (PFS). Thirty-five patients with primary diffuse large B-cell lymphoma of
the mediastinum in first response (complete remission [CR] or partial remission [PR]) with poor
prognostic features, with primarily refractory disease, or with relapsed disease following
conventional chemotherapy, were treated with CBV and autologous hematopoietic cell
transplantation. PFS and overall survival were assessed by the Kaplan-Meier method. Patient
characteristics before transplantation were examined by univariate analysis using the log-rank test
and by Cox's proportional hazards regression analysis to determine predictors of PFS. Estimated 5year PFS varied significantly with patient disease status at transplantation. Patients transplanted in
first response had an estimated 5-year PFS rate of 83%, compared with 58% and 27% for primarily
refractory and relapsed patients, respectively (P = .02). The strongest predictor of PFS was
chemotherapy responsiveness immediately before transplantation. Patients with chemotherapyresponsive disease had a significantly greater PFS rate than patients with chemotherapynonresponsive disease (risk ratio, 3.60; 95% confidence interval [CI], 1.14 to 11.4). No other factors
were found to be significant on univariate or multivariate analysis. Patients with primary diffuse
large B-cell lymphoma of the mediastinum can achieve prolonged PFS following high-dose
chemotherapy and autologous hematopoietic cell transplantation. Outcomes are strongly correlated
with disease status (first response v refractory v relapsed) at transplantation and chemotherapy
responsiveness immediately before transplantation.
Blood, Vol. 91 No. 2 (January 15), 1998: pp. 717-723
© 1998 by The American Society of Hematology.
[Full Text of Sehn et al.] [Reprint (PDF) Version of Sehn et al.]
-------------------------------------------------------------------------------Abstract 4 of 5
Submitted December 19, 2002
Accepted March 20, 2003
The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT)
outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, Jing Qin, Jaya M Satagopan, David
Verbel, Ariela Noy, Carol S Portlock, David J Straus, Joachim Yahalom, Stephen D Nimer, and
Craig H Moskowitz*
Department of Medicine - Lymphoma Service, Memorial Hospital, Memorial Sloan-Kettering
Cancer Center, New York, NY, USA; Department of Medicine - Hematology Service, Memorial
Hospital, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Department of Radiation Oncology, Memorial Hospital, Memorial Sloan-Kettering Cancer Center,
New York, NY, USA
Department of Biostatistics, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New
York, NY, USA
* Corresponding author; email: moskowic@mskcc.org.
Second-line chemotherapy followed by high dose therapy (HDT) with autologous stem cell
transplantation (ASCT) cures less than half of patients with relapsed or refractory diffuse large B
cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In three
sequential clinical trials, conducted from 1/93 to 8/00, we treated 150 patients with relapsed or
primary refractory DLBCL with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy
followed by HDT/ASCT for patients with chemosensitive disease. We evaluated the age-adjusted
international prognostic index at the initiation of second-line therapy (sAAIPI) as a predictor of
progression free survival (PFS) and overall survival (OS). At a median followup of 4 years, the PFS
and OS are 28% and 34% by intention to treat and 39% and 45% for only those patients with
chemosensitive disease. Three risk groups with different PFS and OS were identified by the
sAAIPI: low risk (0 factors) 70% and 74%; intermediate risk (1 factor) 39% and 49%; and high risk
(2 or 3 factors) 16% and 18% (p<0.001 for both PFS and OS). The sAAIPI also predicts the PFS
and OS for patients with ICE chemosensitive disease: low risk 69% and 83%; intermediate risk
46% and 55%; and high risk 25% and 26% (p<0.001 PFS and OS). The sAAIPI predicts outcome
for patients with relapsed or primary refractory DLBCL in both intent-to-treat and chemosensitive
populations. This powerful prognostic instrument should be used to evaluate new treatment
approaches and to compare results of different regimens.
[Reprint (PDF) Version of Hamlin et al.]
-------------------------------------------------------------------------------Abstract 5 of 5
Blood, Vol. 95 No. 12 (June 15), 2000: pp. 3687-3692
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission
Nicolas Mounier, Corinne Haioun, Bernard F. Cole, Christian Gisselbrecht, Catherine Sebban,
Pierre Morel, Gerald Marit, Reda Bouabdallah, Christophe Ravoet, Gilles Salles, Felix Reyes, and
Eric Lepage for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
From the Département d'information hospitalier and Service d'hématologie clinique Hôpital Henri
Mondor, AP-HP, Créteil, France; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Institut
d'hématologie, Hôpital Saint Louis, AP-HP, Paris, France; Service d'hématologie, Centre Léon
Bérard, Lyon, France; Service d'hématologie, Centre Hospitalier du Dr Schaffner, Lens, France;
Service d'hématologie, CHU de Bordeaux, Pessac, France; Service d'hématologie, Institut Paoli
Calmette, Marseille, France; Service d'hématologie, Centre Jolimont, La Louvière, Belgium; and
Service d'hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of
both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin
lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was
applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541
patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS)
curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1), secondary
toxicity (Tox2), time without symptom and toxicity (TWiST), and relapse (Rel). Areas under
survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT
increased, but not significantly, TWiST (+2.4 months in AUC, P = .17) and decreased Rel (3
months, P < .01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for
OS, 39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a
significant benefit in DFS (AUC 28.8 versus 24.9 months, P < .01) but not in OS (AUC 37.3 versus
36 months, P = .27). Sensitivity analysis, performed by varying QOL coefficients, demonstrated
significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients,
a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in
these patients with adverse prognostic factors in the first CR, even after adjusting for QOL using the
Q-TWiST method.
[Full Text of Mounier et al.] [Reprint (PDF) Version of Mounier et al.]
--------------------------------------------------------------------------------
-------------------------------------------------------------------------------Blood Online is sponsored by an
unrestricted grant from Shire
Copyright © 2003 by American Society of Hematology. HOME HELP FEEDBACK
SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
QUICK SEARCH: [advanced]
Author:
Keyword(s):
Year: Vol: Page:
-------------------------------------------------------------------------------Download ALL Selected Citations
to Citation Manager
Selected Abstracts
Returned: 6 citations and abstracts. Click on down arrow or scroll to see abstracts.
Maurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, Pier Luigi Zinzani, Antonio De Vivo,
Maria Cantonetti, Brunangelo Falini, Sergio Storti, Giovanna Meloni, Manuela Rizzo, Anna Lia
Molinari, Francesco Lauria, Luciano Moretti, Vito Michele Lauta, Patrizio Mazza, Luciano
Guardigni, E. Pescarmona, S.A. Pileri, Franco Mandelli, and Sante Tura
Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line
Therapy in High-Risk, Aggressive Non-Hodgkin’s Lymphoma: An Italian Multicenter Randomized
Trial
J Clin Oncol 21: 1255-1262.
Christian Gisselbrecht, Eric Lepage, Thierry Molina, Bruno Quesnel, Georges Fillet, Pierre
Lederlin, Bertrand Coiffier, Hervé Tilly, Jean Gabarre, Francoise Guilmin, Olivier Hermine, and
Félix Reyes
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive
Lymphoma
J Clin Oncol 20: 2472-2479.
Julie M. Vose, Mei-Jie Zhang, Philip A. Rowlings, Hillard M. Lazarus, Brian J. Bolwell, Cesar O.
Freytes, Santiago Pavlovsky, Armand Keating, Burhan Yanes, Koen van Besien, James O.
Armitage, and Mary M. Horowitz
Autologous Transplantation for Diffuse Aggressive Non-Hodgkin’s Lymphoma in Patients Never
Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry
J Clin Oncol 19: 406-413.
Corinne Haioun, Eric Lepage, Christian Gisselbrecht, Gilles Salles, Bertrand Coiffier, Pauline
Brice, André Bosly, Pierre Morel, Christiane Nouvel, Hervé Tilly, Pierre Lederlin, Catherine
Sebban, Josette Brière, Philippe Gaulard, and Félix Reyes
Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final
Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte
Study
J Clin Oncol 18: 3025-3030.
Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel, Josef Birkmann, Lorenz Trumper, Harald
Schmalenberg, Tunca Karakas, Bernd Metzner, Dieter K. Hossfeld, Helge G. Bischoff, Astrid
Franke, Marcel Reiser, Peter Muller, Luisa Mantovani, Marc Grundeis, Frank Rothmann, Cay-Uwe
von Seydewitz, Rolf M. Mesters, Ernst U. Steinhauer, Dorothea Krahl, Kurt Schumacher, Michael
Kneba, Michael Baudis, Norbert Schmitz, Rudiger Pfab, Hubert Koppler, Reza Parwaresch,
Michael Pfreundschuh, and Klaus Havemann
Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for
"Aggressive" Lymphoma
J Clin Oncol 20: 4413-4419.
Julie M. Vose, Graham Sharp, Wing C. Chan, Craig Nichols, Kevin Loh, David Inwards, Robert
Rifkin, Philip J. Bierman, James C. Lynch, Dennis D. Weisenburger, Anne Kessinger, and James O.
Armitage
Autologous Transplantation for Aggressive Non-Hodgkin’s Lymphoma: Results of a Randomized
Trial Evaluating Graft Source and Minimal Residual Disease
J Clin Oncol 20: 2344-2352.
-------------------------------------------------------------------------------Abstract 1 of 6 Journal of Clinical Oncology, Vol 21, Issue 7 (April), 2003: 1255-1262
© 2003 American Society for Clinical Oncology
Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line
Therapy in High-Risk, Aggressive Non-Hodgkin’s Lymphoma: An Italian Multicenter Randomized
Trial
Maurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, Pier Luigi Zinzani, Antonio De Vivo,
Maria Cantonetti, Brunangelo Falini, Sergio Storti, Giovanna Meloni, Manuela Rizzo, Anna Lia
Molinari, Francesco Lauria, Luciano Moretti, Vito Michele Lauta, Patrizio Mazza, Luciano
Guardigni, E. Pescarmona, S.A. Pileri, Franco Mandelli, Sante Tura
From the Departments of Cellular Biotechnology and Hematology and Experimental Medicine and
Pathology, University "La Sapienza" of Rome, Hematology University "Tor Vergata" Rome, and
Division of Hematology "La Cattolica" University of Rome, Rome; Institute of Hematology and
Medical Oncology, University of Bologna, Bologna; Division of Hematology, University of Napoli,
Napoli; Hematology University of Perugia, Perugia; Division of Hematology, Ravenna Hospital,
Ravenna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Internal Medicine,
University of Bari, Bari; Division of Hematology, Taranto Hospital, Taranto; and Division of
Hematology, Cesena Hospital, Cesena; Italy.
Address reprint requests to Maurizio Martelli, MD, Dipartimento Biotecnologie Cellulari ed
Ematologia, University "La Sapienza" via Benevento, 6 00161 Roma, Italy; email:
martelli@bce.med.uniroma1.it.
Purpose: To evaluate the role of early intensification with high-dose therapy (HDT) and autologous
stem-cell transplantation (ASCT) as front-line chemotherapy for patients with high-risk,
histologically aggressive non-Hodgkin’s lymphoma (NHL).
Patients and Methods: We planned a multicenter, randomized trial to compare a conventional
chemotherapy regimen of methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide,
vincristine, prednisone, and bleomycin (MACOP-B; arm A) with an abbreviated regimen of
MACOP-B (8 weeks) followed by HDT and ASCT (arm B) for intermediate-high-risk/high-risk
patients (according to the age-adjusted International Prognostic Index). From September 1994 to
April 1998, 150 patients with aggressive lymphoma were enrolled onto the trial. Seventy-five
patients were randomly assigned to arm A and 75 patients were randomly assigned to arm B. In
both arms, involved-field radiation therapy (36 Gy) was delivered to the site of bulky disease.
Results: The rate of complete response was 68% in arm A and 76% in arm B (P = not significant
[NS]). Three toxic deaths (4%) occurred in arm B and one (1%) occurred in arm A (P = NS). In arm
B, 30 patients (40%) did not undergo HDT and ASCT. According to the intention-to-treat analysis
at a median follow-up of 24 months, 5-year overall survival probability in arms A and B was 65%
and 64% (P = .95), 5-year progression-free survival was 49% and 61% (P = .21), and 5-year
relapse-free survival was 65% and 77% (P = .22), respectively.
Conclusion: Abbreviated chemotherapy followed by intensification with HDT-ASCT is not
superior to conventional chemotherapy in patients with high-risk, aggressive NHL. Additional
randomized trials will clarify whether HDT-ASCT as front-line therapy after a complete course of
conventional chemotherapy improves survival in this group of patients.
Supported by Ministero dell’ Università e Ricerca Scientifica (MURST) 40%.
[Full Text of Martelli et al.] [Reprint (PDF) Version of Martelli et al.]
-------------------------------------------------------------------------------Abstract 2 of 6 Journal of Clinical Oncology, Vol 20, Issue 10 (May), 2002: 2472-2479
© 2002 American Society for Clinical Oncology
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive
Lymphoma
By Christian Gisselbrecht, Eric Lepage, Thierry Molina, Bruno Quesnel, Georges Fillet, Pierre
Lederlin, Bertrand Coiffier, Hervé Tilly, Jean Gabarre, Francoise Guilmin, Olivier Hermine, Félix
Reyes for the Groupe d’Etude des Lymphomes de l’Adulte
From the Institut d’Hématologie, GELA Hôpital Saint Louis; Service d’Anatomie Pathologique,
Hôtel Dieu; Service d’Hématologie, Hôpital Pitié Salpétrière; Service d’Hématologie, Hôpital
Necker, Paris; Departement d’Information Hospitalier, Hôpital Henri Mondor; Service
d’Hématologie, Hôpital Henri Mondor, Créteil; Centre Hospitalier Universitaire de Lille, Lille;
Service d’Hématologie et Medecine interne, Centre Hospitalier Universitaire Brabois, Vandoeuvre
les Nancy; Centre Hospitalier Lyon Sud, Pierre Bénite; Centre Henri Becquerel, Rouen; Service
d’Hématologie, Hôpital Beaujon, Clichy, France; and Centre Hospitalier Universitaire de Liège,
Domaine Universitaire de Sart Tilman, Liège, Belgium.
Address reprint requests to Christian Gisselbrecht, MD, Institut d’Hématologie, Hôpital SaintLouis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, France; email:
christian.gisselbrecht@sls.ap-hop-paris.fr.
PURPOSE: Randomized trial LNH93-3 was conducted on patients who had poor-prognosis
aggressive lymphoma and were younger than 60 years with two to three factors of the age-adjusted
International Prognostic Index to evaluate the benefit of early high-dose therapy (HDT) with
autologous stem-cell transplantation (ASCT).
PATIENTS AND METHODS: Patients were randomized between doxorubicin, cyclophosphamide,
vindesine, bleomycin, and prednisone (ACVBP) chemotherapy followed by sequential
consolidation and an experimental shortened treatment consisting of three cycles with escalated
doses of cyclophosphamide, epirubicin, vindesine, bleomycin, and prednisone and collection of
peripheral-blood stem cells. On day 60, HDT was administered with 1,3-bis(2-chloroethyl)-1nitrosourea, etoposide, cytarabine, and melphalan followed by ASCT.
RESULTS: Eligible patients (n = 370) with aggressive lymphoma were analyzed. For ACVBP (181
patients) and HDT (189 patients), respective complete remission rates were 64% and 63%. With a
median follow-up of 60 months, 5-year overall survival and event-free survival for ACVBP and
HDT were 60% ± 8% and 46% ± 8% (P = .007) and 52 ± 8% and 39 ± 8% (P = .01), respectively.
Survival was independently affected by age greater than 40 years (P = .0003), T-cell phenotype (P =
.009), bone marrow involvement (P = .003), and HDT treatment group (P = .04).
CONCLUSION: Early HDT with ASCT in high-risk patients was inferior to the ACVBP
chemotherapy regimen. These results indicate that the received dose-intensity before HDT was too
low when compared with ACVBP and HDT and was given too early.
[Full Text of Gisselbrecht et al.] [Reprint (PDF) Version of Gisselbrecht et al.]
-------------------------------------------------------------------------------Abstract 3 of 6 Journal of Clinical Oncology, Vol 19, Issue 2 (January), 2001: 406-413
© 2001 American Society for Clinical Oncology
Autologous Transplantation for Diffuse Aggressive Non-Hodgkin’s Lymphoma in Patients Never
Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry
By Julie M. Vose, Mei-Jie Zhang, Philip A. Rowlings, Hillard M. Lazarus, Brian J. Bolwell, Cesar
O. Freytes, Santiago Pavlovsky, Armand Keating, Burhan Yanes, Koen van Besien, James O.
Armitage, Mary M. Horowitz, Others of the Autologous Blood and Marrow Transplant Registry
Lymphoma Working Committee
From the Lymphoma Working Committee of the Autologous Blood and Marrow Transplant
Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI; University of
Nebraska Medical Center, Omaha, NE; Ireland Cancer Center, University Hospitals of Cleveland,
Case Western Reserve University, Cleveland, The Cleveland Clinic Foundation, Cleveland, and
Miami Valley Hospital, Dayton, OH; University of Texas Health Science Center at San Antonio,
San Antonio, TX; Fundaleu Hospital, Buenos Aires, Argentina; Princess Margaret Hospital,
Toronto, Ontario, Canada; and University of Illinois, Chicago, IL.
Address reprint requests to Julie M. Vose, MD, Department of Internal Medicine, University of
Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680; email
jmvose@unmc.edu.
PURPOSE: To evaluate the results of high-dose chemotherapy and autologous hematopoietic stemcell transplantation (autotransplants) in patients with diffuse aggressive non-Hodgkin’s lymphoma
(NHL) who never achieve a complete remission with conventional chemotherapy.
PATIENTS AND METHODS: Detailed records from the Autologous Blood and Marrow
Transplant Registry (ABMTR) on 184 patients with diffuse aggressive NHL who never achieved a
complete remission with conventional chemotherapy and subsequently received an autotransplant
were evaluated. Transplants were performed between 1989 and 1995 and were reported to the
ABMTR by 48 centers in North and South America.
RESULTS: Seventy-nine (44%) of 184 patients achieved a complete remission or a complete
remission with residual imaging abnormalities of unknown significance after autotransplantation.
Thirty-four (19%) of 184 had a partial remission and 55 (31%) of 184 had no response or
progressive disease. Eleven patients (6%) were not assessable for response because of early death.
The probabilities of progression-free and overall survival at 5 years after transplantation were 31%
(95% confidence interval [CI], 24% to 38%) and 37% (95% CI, 30% to 45%), respectively. In
multivariate analysis, chemotherapy resistance, Karnofsky performance status score less than 80 at
transplantation, age 55 years at transplantation, receiving three or more prior chemotherapy
regimens, and not receiving pre- or posttransplant involved-field irradiation therapy were adverse
prognostic factors for overall survival.
CONCLUSION: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation
should be considered for patients with diffuse aggressive NHL who never achieve a complete
remission but who are still chemotherapy-sensitive and are otherwise transplant candidates.
The contents of this article are solely the responsibility of the authors and do not necessarily
represent the official views of the National Cancer Institute.
For the names of the other authors on the ABMTR Lymphoma Working Committee, see the
Appendix.
[Full Text of Vose et al.] [Reprint (PDF) Version of Vose et al.]
-------------------------------------------------------------------------------Abstract 4 of 6 Journal of Clinical Oncology, Vol 18, Issue 16 (August), 2000: 3025-3030
© 2000 American Society for Clinical Oncology
Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final
Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte
Study
By Corinne Haioun, Eric Lepage, Christian Gisselbrecht, Gilles Salles, Bertrand Coiffier, Pauline
Brice, André Bosly, Pierre Morel, Christiane Nouvel, Hervé Tilly, Pierre Lederlin, Catherine
Sebban, Josette Brière, Philippe Gaulard, Félix Reyes
From the Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil; Hôpital
Saint-Louis, AP-HP, Paris; Centre Hospitalier Lyon-Sud, Pierre Bénite; Centre Henri Becquerel,
Rouen; Centre Hospitalier Huriez, Lille; Hôpital Purpan, Toulouse; Hôpitaux de Brabois, Nancy;
Centre Léon Bérard, Lyon, France; and Cliniques Universitaires de Mont Godinne, Yvoir, Belgium.
Address reprint requests to Corinne Haioun, MD, Service d’Hématologie Clinique, Hôpital Henri
Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; email corinne
.haioun@hmn.ap-hop-paris.fr.
PURPOSE: To present the final analysis, with a median follow-up of 8 years, of the LNH87–2
randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus
etoposide, asparaginase, and cytarabine) with high-dose therapy (HDT) using cyclophosphamide,
carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation in patients with
aggressive non-Hodgkin’s lymphoma in first complete remission after induction, focusing on
high/intermediate- and high-risk patients identified by the age-adjusted international prognostic
index.
PATIENTS AND METHODS: Among the 916 eligible patients, 451 presented with two (n = 318)
or three (n = 133) risk factors. After reaching complete remission to induction therapy, 236 of these
higher risk patients were assessable for the consolidation phase, with 125 patients in the HDT arm
and 111 in the sequential chemotherapy arm.
RESULTS: Among these 451 higher risk patients, 277 (61%) achieved complete remission after
induction treatment. In the population of 236 randomized patients, HDT was superior to sequential
chemotherapy, with 8-year disease-free survival rates of 55% (95% confidence interval [CI], 46%
to 64%) and 39% (95% CI, 30% to 48%), respectively (P = .02; relative risk, 1.56). The 8-year
survival rate was significantly superior in the HDT arm (64%; 95% CI, 55% to 73%) compared
with the sequential chemotherapy arm (49%; 95% CI, 39% to 59%) (P = .04; relative risk, 1.51).
CONCLUSION: On the basis of the final analysis of this prospectively treated series of patients,
retrospectively analyzed on the basis of the International Prognostic Index, we hypothesize that
HDT benefits patients at higher risk who achieve complete remission after induction treatment.
[Full Text of Haioun et al.] [Reprint (PDF) Version of Haioun et al.]
-------------------------------------------------------------------------------Abstract 5 of 6 Journal of Clinical Oncology, Vol 20, Issue 22 (November), 2002: 4413-4419
© 2002 American Society for Clinical Oncology
Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for
"Aggressive" Lymphoma
Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel, Josef Birkmann, Lorenz Trumper, Harald
Schmalenberg, Tunca Karakas, Bernd Metzner, Dieter K. Hossfeld, Helge G. Bischoff, Astrid
Franke, Marcel Reiser, Peter Muller, Luisa Mantovani, Marc Grundeis, Frank Rothmann, Cay-Uwe
von Seydewitz, Rolf M. Mesters, Ernst U. Steinhauer, Dorothea Krahl, Kurt Schumacher, Michael
Kneba, Michael Baudis, Norbert Schmitz, Rudiger Pfab, Hubert Koppler, Reza Parwaresch,
Michael Pfreundschuh, Klaus Havemann
From the Departments of Hematology and Oncology, Universitätsklinikum Marburg, Klinikum
Nürnberg, Universitätsklinikum Homburg, Universitätsklinikum Jena, Universitätsklinikum Ulm,
Klinikum Oldenburg, Universitätsklinikum Hamburg, Thoraxklinik Heidelberg-Rohrbach,
Universitätsklinikum Magdeburg, Universitätsklinikum Köln, Zentralklinikum Augsburg,
Universitätsklinikum Leipzig, Universitätsklinikum Leipzig, Klinikum Chemnitz, Klinikum
Potsdam, Krankenhaus Hamburg-Altona, Universitätsklinikum Münster, Klinikum Kassel,
Humboldt-Universität Berlin, Robert-Bosch Krankenhaus Stuttgart, Universitätsklinikum
Göttingen, Universitätsklinikum Heidelberg, Universitätsklinikum Kiel, Klinikum Minden,
Universitätsklinikum Rostock, Universitätsklinikum Zürich, Klinikum Karlsruhe, Klinikum Hagen,
Klinikum Herford, Klinikum Lemgo, Universitätsklinikum Lund, Klinikum Mönchengladbach,
Universitätsklinikum Uppsala, Universitätsklinikum Aachen, Diakonissenkrankenhaus Bremen,
Klinikum Cottbus, Klinikum Darmstadt, Klinikum Eschweiler, Diakoniekrankenhaus Freiburg,
Klinikum Münchberg, Klinikum Schwenningen, Klinikum Schweinfurt, Klinikum Trier, and
Klinikum Wolfsburg; the Institute of Medical Statistics, Universität Heidelberg; and the Institute of
Hematopathology, Universität Kiel, Germany.
Address reprint requests to Ulrich Kaiser, MD, St Bernward Krankenhaus, Klinik für Hämatologie,
Onkologie und Immunologie, Treibestrasse 9, D-31134 Hildesheim, Germany; email:
pd.dr.u.kaiser@bernward-khs.de.
PURPOSE: This trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group
compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF)
radiotherapy in a randomized, multicenter, phase III study.
PATIENTS AND METHODS: Three hundred twelve patients with "aggressive" non-Hodgkin’s
lymphoma aged 60 years with elevated serum lactate dehydrogenase levels were included from
1990 to 1997. Patients with at least a minor response after two cycles of CHOEP (CHOP +
etoposide 3 x 100 mg/m2) were to receive three further cycles of CHOEP followed by IF
radiotherapy (arm A) or one further cycle of CHOEP followed by autologous stem-cell
transplantation and IF radiotherapy (arm B).
RESULTS: Among 158 patients randomized to arm B, 103 (65%) received HDT. The complete
remission rate at the end of treatment was 62.9% in arm A and 69.9% in arm B. With a median
observation time of 45.5 months, overall survival for all 312 patients was 63% after 3 years (63%
for arm A, 62% for arm B; P = .68). Event-free survival was 49% for arm A versus 59% for arm B
(P = .22). Relapse in arm B was associated with a significantly worse survival rate than relapse in
arm A (P < .05). Relapse after HDT occurred early (median interval, 3 months). Six patients
developed secondary neoplasia, three in arm A and three in arm B.
CONCLUSION: Results of the randomized trial comparing CHOP-like chemotherapy with early
HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan
following shortened standard chemotherapy.
[Full Text of Kaiser et al.] [Reprint (PDF) Version of Kaiser et al.]
-------------------------------------------------------------------------------Abstract 6 of 6 Journal of Clinical Oncology, Vol 20, Issue 9 (May), 2002: 2344-2352
© 2002 American Society for Clinical Oncology
Autologous Transplantation for Aggressive Non-Hodgkin’s Lymphoma: Results of a Randomized
Trial Evaluating Graft Source and Minimal Residual Disease
By Julie M. Vose, Graham Sharp, Wing C. Chan, Craig Nichols, Kevin Loh, David Inwards, Robert
Rifkin, Philip J. Bierman, James C. Lynch, Dennis D. Weisenburger, Anne Kessinger, James O.
Armitage
From the Departments of Internal Medicine, Anatomy and Cell Biology, Pathology and
Microbiology, and Preventive and Societal Medicine, University of Nebraska Medical Center,
Omaha, NE; Indiana University Medical Center, Indianapolis, IN; Queens Medical Center,
Honolulu, HI; Mayo Clinic, Rochester, MN; and Rocky Mountain Cancer Center, Denver, CO.
Address reprint requests to Julie M. Vose, MD, Department of Internal Medicine, Section of
Hematology/Oncology, University of Nebraska Medical Center, 600 S 42nd St, Omaha, NE 69198;
email: jmvose@unmc.edu.
PURPOSE: To determine whether the source of autologous hematopoietic stem cells altered the
clinical outcomes of patients undergoing high-dose chemotherapy and hematopoietic stem-cell
transplantation (HSCT) for aggressive non-Hodgkin’s lymphoma (NHL).
PATIENTS AND METHODS: Of 105 high-risk, persistent, or relapsed NHL patients slated for an
autologous HSCT entered onto this trial, 93 eligible patients were randomized to receive cytokinenaive autologous bone marrow transplantation (ABMT) (n = 46) or mobilized peripheral-blood
stem-cell transplantation (PBSCT) (n = 47). All patients received carmustine, etoposide, cytarabine,
and cyclophosphamide as the conditioning regimen. PBSCT patients also received identical
mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/d, and both groups
received G-CSF 5 µg/kg/d after the infusion of the stem-cell product until neutrophil engraftment.
RESULTS: PBSCT patients had significantly faster engraftment of all cell lineages: median time to
absolute neutrophil count 500/µL, 10 days versus 13 days on the ABMT arm; median time to
platelet count greater than 20,000/µL untransfused, 11 days versus 15 days on the ABMT arm; and
median time to RBC transfusion independence, 8 days versus 16 days on the ABMT arm. The
complete response rate was 72% for PBSCT and 54% for ABMT. The death rate before
posttransplant day 100 was 2% on the ABMT arm and 6% on PBSCT arm. Event-free survival was
37% for PBSCT and 37% for ABMT. However, overall survival for PBSCT was 61% compared
with 43% for ABMT.
CONCLUSION: Patients with aggressive NHL receiving HSCT randomized to PBSCT
demonstrated improved neutrophil engraftment and platelet and RBC transfusion independence.
The complete response rate and EFS were not statistically different by randomization arm. Patients
whose harvests were positive for minimal residual disease by molecular analysis had poorer EFS.
[Full Text of Vose et al.] [Reprint (PDF) Version of Vose et al.]
-------------------------------------------------------------------------------HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
© 2003 American Society of Clinical Oncology.
International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell
Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury
M.A. Shipp, M.D. Abeloff, K.H. Antman, G. Carroll, A. Hagenbeek, M. Loeffler, E.
Montserrat, J.A. Radford, G. Salles, N. Schmitz, M. Symann, J.O. Armitage, T. Philip, and B.
Coiffier
JCO Jan 1 1999: 423. [Full Text] [PDF]
High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional-Dose
Consolidation/Maintenance Therapy as Postremission Therapy for Adult Patients With
Lymphoblastic Lymphoma: Results of a Randomized Trial of the European Group for Blood
and Marrow Transplantation and the United Kingdom Lymphoma Group
John W. Sweetenham, Gino Santini, Wendi Qian, Monica Guelfi, Norbert Schmitz, Sarah
Simnett, Arnon Nagler, Harald Holte, Stein Kvaloy, Paulo Bruzzi, and Anthony H. Goldstone
JCO Jun 1 2001: 2927-2936. [Abstract] [Full Text] [PDF]
Survival Benefit of High-Dose Therapy in Poor-Risk
Aggressive Non-Hodgkin’s Lymphoma: Concerns About
Omissions in the Data Presented
R.D. Kennedy, R.G. Cuthbert, P.J. Kettle, T.C.M. Morris
Queens University of BelfastBelfast City HospitalBelfast, Northern Ireland
To the Editor:We find the results from the LNH87-2 study published in the August 2000 issue of
the Journal of Clinical Oncology1 interesting, but we have some concerns regarding the data.
First, we noted that two different induction regimens were used until 4 years into enrollment. One
regimen used mitoxantrone and this was believed to be inferior to a doxorubicin-containing
regimen. In the patients who proceeded to consolidation therapy, the authors have not demonstrated
that the high-dose group and sequential chemotherapy groups were balanced with regard to
induction. Our concern is that one group may have received a significantly inferior induction
treatment.
Second, the authors do not explain why 31% of the group randomized to receive high-dose
treatment did not receive it. Although this would not influence the survival and relapse figures,
since the data were analyzed on an intent-to-treat basis, it would influence the toxicity figures.
Perhaps patients who would have suffered toxicity from the high-dose procedure were removed
from the trial at this stage. The article also does not state the time between induction and
transplantation in the high-dose arm. This could have a bearing on the outcome, as the 69% who
proceeded to treatment may have been a self-selecting, good-prognosis group.
Third, we would like to have seen the overall survival figure for the 41 patients who did not receive
consolidation treatment. There is a suggestion from the disease-free survival figure of 51% that this
group may have had as good an outcome as the consolidative chemotherapy groups (although we
accept that the numbers in the no-consolidation group were low).
We find this trial encouraging and believe it highlights the need for further randomized clinical
trials designed to identify the subgroups of high-grade non-Hodgkin’s lymphoma that may benefit
from high-dose chemotherapy and autologous transplantation.
REFERENCES
1. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poorrisk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2
protocol—A Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 18: 30253030, 2000[Abstract/Free Full Text]
High-dose chemotherapy followed by autologous bone marrow transplantation versus
dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial
response to front-line chemotherapy: a prospective randomized italian multicenter study
M Martelli, M Vignetti, PL Zinzani, F Gherlinzoni, G Meloni, M Fiacchini, V De Sanctis, G
Papa, MF Martelli, F Calabresi, S Tura, and F Mandelli
JCO Feb 1 1996: 534-542.
Benefit of autologous bone marrow transplantation over
sequential chemotherapy in poor-risk aggressive nonHodgkin's lymphoma: updated results of the prospective study
LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte
C Haioun, E Lepage, C Gisselbrecht, Y Bastion, B Coiffier, P Brice, A Bosly, B Dupriez, C
Nouvel, H Tilly, P Lederlin, P Biron, J Briere, P Gaulard and F Reyes
Hopital Henri Mondor, Creteil, France. corinne.haioun@hmn.ap-hop- paris.fr
PURPOSE: To update the randomized study that compared consolidative sequential treatment
(ifosfamide, etoposide, asporaginase, and cytarabine) versus the high-dose regimen of
cyclophosphamide, carmustine, and etoposide (CBV) followed by autotransplantation in patients
with aggressive non-Hodgkin's lymphoma in first complete remission and to focus on highintermediate and high-risk patients identified by the international prognostic index. PATIENTS
AND METHODS: Nine hundred sixteen patients received induction treatment on the LNH84
protocol with open randomization for the anthracycline. In a subsequent randomization, 541 patients
in complete remission were assigned to receive consolidation by either sequential chemotherapy (n
= 273) or autotransplant (n = 268). Among the higher risk population (two or three risk factors), 236
patients in complete remission were assessable for the consolidation phase, with 111 in the
sequential chemotherapy arm and 125 in the autotransplant arm. RESULTS: Among 541
randomized patients, disease-free survival and survival did not differ significantly between the two
consolidative treatment arms. In the higher risk population, CBV was superior to sequential
chemotherapy, with 5-year disease-free survival rates of 59% (95% confidence interval, 49% to
69%) and 39% (95% confidence interval, 28% to 50%), respectively (P = .01, relative risk = 1.19).
The 5-year survival rate was superior in the CBV group at 65% (95% confidence interval, 56% to
74%) compared with 52% in the sequential chemotherapy group (95% confidence interval, 42% to
62%) (P = .06, relative risk = 1.49). CONCLUSION: This study shows a superior disease-free
survival for higher risk patients in complete remission. Dose-intensive consolidation therapy should
be considered for patients at higher risk who achieve complete remission after induction treatment.
Comparison of autologous bone marrow transplantation with
sequential chemotherapy for intermediate-grade and highgrade non-Hodgkin's lymphoma in first complete remission: a
study of 464 patients. Groupe d'Etude des Lymphomes de
l'Adulte
C Haioun, E Lepage, C Gisselbrecht, B Coiffier, A Bosly, H Tilly, P Morel, C Nouvel, R
Herbrecht and MF D'Agay
Hopital Henri Mondor, Creteil, France.
PURPOSE: Intensive chemotherapy followed by autotransplantation has given promising results in
partially responding or sensitive relapsed patients with aggressive non-Hodgkin's lymphoma. In
1987, we designed a randomized study to evaluate the potential benefit of a high-dose regimen
containing cyclophosphamide, carmustine, and etoposide (CBV) followed by autotransplantation
over a consolidative sequential chemotherapy (ifosfamide, etoposide, asparaginase, and cytarabine)
in patients in first complete remission with intermediate- and high-grade non-Hodgkin's lymphoma.
PATIENTS AND METHODS: Patients were younger than 55 years and had at least one adverse
prognostic factor. Induction treatment was that of the LNH84 protocol with an open randomization
on the anthracycline. Patients in complete remission were further randomly assigned to receive
either consolidation procedure. RESULTS: After induction treatment, 464 patients were assessable
for the consolidation phase. With a median follow-up duration of 28 months, the 3-year disease-free
survival rate was 52% (95% confidence interval, 45% to 59%) in the sequential chemotherapy arm
and 59% (95% confidence interval, 52% to 66%) in the autologous transplant arm (P = .46, relative
risk = 0.90). The 3-year survival rate did not differ between sequential chemotherapy and
autotransplantation, at 71% (95% confidence interval, 64% to 78%) and 69% (95% confidence
interval, 62% to 76%), respectively (P = .60, relative risk = 1.11). CONCLUSION: For such a
subset of patients, consolidation with the CBV regimen followed by autologous bone marrow
transplantation is not superior to sequential chemotherapy.
1: Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Related
Articles, Links
Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients
with high-risk aggressive non-Hodgkin's lymphoma.
Br J Haematol. 2003 Aug;122(3):457-64.
PMID: 12877674 [PubMed - in process]
2: Mangel J, Duncan A, Lachance S. Related Articles, Links
Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high
dose VP-16 and cyclophosphamide salvage regimen.
Leuk Lymphoma. 2003 Jun;44(6):1001-9.
PMID: 12854902 [PubMed - in process]
3: Tanimoto TE, Kusumi E, Hamaki T, Yuji K, Ueyama J, Miyakoshi S, Morinaga S, Kami M,
Kanda Y, Ando T, Yoshihara S, Masuo S, Kim SW, Nakai K, Tobinai K, Tanosaki R, Mineishi S,
Takaue Y, Muto Y. Related Articles, Links
High complete response rate after allogeneic hematopoietic stem cell transplantation with reducedintensity conditioning regimens in advanced malignant lymphoma.
Bone Marrow Transplant. 2003 Jul;32(2):131-7.
PMID: 12838276 [PubMed - in process]
4: Mollee P, Lazarus HM, Lipton J. Related Articles, Links
Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?
Bone Marrow Transplant. 2003 Jun;31(11):953-60.
PMID: 12774044 [PubMed - in process]
5: Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ,
Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH.
Related Articles, Links
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with
relapsed/refractory non-Hodgkin's lymphoma following CD34-selected hematopoietic cell
transplantation.
Blood. 2003 May 22 [Epub ahead of print]
PMID: 12763934 [PubMed - as supplied by publisher]
6: Mukai HY, Okoshi Y, Shimizu S, Katsura Y, Takei N, Hasegawa Y, Kojima H, Mori N,
Nagasawa T. Related Articles, Links
Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with highdose chemotherapy and total body irradiation.
Eur J Haematol. 2003 Jun;70(6):413-6.
PMID: 12756026 [PubMed - indexed for MEDLINE]
7: Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithauser
F, Wawra E, Munzert G, Reske SN. Related Articles, Links
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging
proliferation in a murine B-Cell lymphoma model and in the human disease.
Cancer Res. 2003 May 15;63(10):2681-7.
PMID: 12750297 [PubMed - indexed for MEDLINE]
8: M'kacher R, Farace F, Bennaceur-Griscelli A, Violot D, Clausse B, Dossou J, Valent A,
Parmentier C, Ribrag V, Bosq J, Carde P, Turhan AG, Bernheim A. Related Articles, Links
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to
t(11;14) and generation of a mouse model.
Cancer Genet Cytogenet. 2003 May;143(1):32-8.
PMID: 12742154 [PubMed - indexed for MEDLINE]
9: Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Related Articles,
Links
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of
relapsed and refractory aggressive non-Hodgkin's lymphoma.
Ann Oncol. 2003;14 Suppl 1:i5-10.
PMID: 12736224 [PubMed - in process]
10: Nakagawa Y, Sawanobori M, Amaya H, Matsuda I, Inoue Y, Suzuki K, Hashimoto S, Kanno
K. Related Articles, Links
Clinical implications of abnormalities of chromosomes 1 and 13 in multiple myeloma.
Acta Haematol. 2003;109(3):129-36.
PMID: 12714822 [PubMed - indexed for MEDLINE]
11: Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL. Related Articles, Links
Aggressive lymphoma: improving treatment outcome with rituximab.
Anticancer Drugs. 2002 Nov;13 Suppl 2:S43-50.
PMID: 12710590 [PubMed - in process]
12: Gianni AM, Berinstein NL, Evans PA, Lopez-Guillermo A, Solano C. Related Articles, Links
Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome.
Anticancer Drugs. 2002 Nov;13 Suppl 2:S35-42.
PMID: 12710589 [PubMed - in process]
13: Imrie KR, Linch DC, Czuczman MS. Related Articles, Links
Debate on the conservative and aggressive treatment options for the optimal management of
indolent non-Hodgkin's lymphoma.
Anticancer Drugs. 2002 Nov;13 Suppl 2:S19-24.
PMID: 12710587 [PubMed - in process]
14: Yokoyama J, Fujimiya Y, Yamaguchi T, Shiga K, Saijo Y, Groveman DS, McBain JA, Suzuki
Y, Ebina T. Related Articles, Links
Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
Am J Hematol. 2003 May;73(1):1-11.
PMID: 12701113 [PubMed - indexed for MEDLINE]
15: Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Related Articles, Links
Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive
non-Hodgkin's lymphoma.
Leuk Lymphoma. 2003 Feb;44(2):251-5.
PMID: 12688341 [PubMed - in process]
16: Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF, St-Pierre Y. Related Articles,
Links
Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an
aggressive phenotype.
Leukemia. 2003 Apr;17(4):751-9.
PMID: 12682633 [PubMed - indexed for MEDLINE]
17: Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti
S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L,
Pescarmona E, Pileri SA, Mandelli F, Tura S. Related Articles, Links
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy
in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
J Clin Oncol. 2003 Apr 1;21(7):1255-62.
PMID: 12663712 [PubMed - indexed for MEDLINE]
18: Gisselbrecht C, Mounier N. Related Articles, Links
Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's
lymphoma.
Semin Oncol. 2003 Feb;30(1 Suppl 2):28-33. Review.
PMID: 12652462 [PubMed - indexed for MEDLINE]
19: Warland V, Jerusalem G, Hustinx R, Beguin Y, Silvestre RM, Fassotte MF, Foidart-Willems J,
Fillet G. Related Articles, Links
[End of treatment evaluation in patients with aggressive non-Hodgkin's lymphoma]
Rev Med Liege. 2002 Dec;57(12):779-84. Review. French.
PMID: 12632835 [PubMed - indexed for MEDLINE]
20: Howden BP, Slavin MA, Schwarer AP, Mijch AM. Related Articles, Links
Successful control of disseminated Scedosporium prolificans infection with a combination of
voriconazole and terbinafine.
Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):111-3. Epub 2003 Feb 14.
PMID: 12627286 [PubMed - indexed for MEDLINE]
21: Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H, Yagita M, Hosoi
G, Sako M, Yasui M, Yagi K, Kawa K. Related Articles, Links
Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell
lymphoproliferative disease.
Bone Marrow Transplant. 2003 Jan;31(2):105-11.
PMID: 12621491 [PubMed - in process]
22: Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis
CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF,
Caligiuri MA. Related Articles, Links
Experimental treatment of Epstein-Barr virus-associated primary central nervous system
lymphoma.
Cancer Res. 2003 Mar 1;63(5):965-71.
PMID: 12615710 [PubMed - indexed for MEDLINE]
23: Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht
C, Guilhot F, Vose JM, van Biesen K, Rizzo JD, Weisenburger DD, Isaacson P, Horowitz MM,
Goldstone AH, Lazarus HM, Schmitz N. Related Articles, Links
Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood
and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
Br J Haematol. 2003 Mar;120(5):793-800.
PMID: 12614212 [PubMed - indexed for MEDLINE]
24: Bobey NA, Stewart DA, Woodman RC. Related Articles, Links
Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by
autologous peripheral blood stem cell transplantation.
Leuk Lymphoma. 2002 Dec;43(12):2421-3.
PMID: 12613536 [PubMed - in process]
25: Andersson PO, Braide I, Nilsson-Ehle H. Related Articles, Links
Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose
chemotherapy.
Leuk Lymphoma. 2002 Dec;43(12):2351-3.
PMID: 12613523 [PubMed - in process]
26: Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J,
Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Related Articles, Links
Prognostic value of pretransplantation positron emission tomography using fluorine 18fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and
stem cell transplantation.
Blood. 2003 Jul 1;102(1):53-9. Epub 2003 Feb 27.
PMID: 12609836 [PubMed - in process]
27: Breccia M, D'Andrea M, Mengarelli A, Morano SG, D'Elia GM, Alimena G. Related Articles,
Links
Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem
cell transplantation.
Eur J Haematol. 2003 Mar;70(3):190-2.
PMID: 12605665 [PubMed - indexed for MEDLINE]
28: Nador RG, Chadburn A, Gundappa G, Cesarman E, Said JW, Knowles DM. Related Articles,
Links
Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders.
Am J Surg Pathol. 2003 Mar;27(3):293-302.
PMID: 12604885 [PubMed - indexed for MEDLINE]
29: Kroschinsky F, Friedrich K, Hanel M, Mohr B, Langer T, Meinhardt M, Thiede C, Bornhauser
M, Baretton G, Ehninger G. Related Articles, Links
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell
transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.
Ann Hematol. 2003 Jan;82(1):47-52. Epub 2002 Nov 29.
PMID: 12574966 [PubMed - indexed for MEDLINE]
30: Maniyur R, Anant K, Aneesh S, Vinita E, Manoj J, Rakesh P. Related Articles, Links
Posttransplant epididymal lymphoma: an aggressive variant.
Transplantation. 2003 Jan 27;75(2):246-7. No abstract available.
PMID: 12548134 [PubMed - indexed for MEDLINE]
31: Aull MJ, Buell JF, Peddi VR, Trofe J, Beebe TM, Hanaway MJ, Roy-Chaudhury P, Alloway
RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry. Related Articles,
Links
MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the
Israel Penn International Transplant Tumor Registry with a review of published literature.
Transplantation. 2003 Jan 27;75(2):225-8.
PMID: 12548128 [PubMed - indexed for MEDLINE]
32: Yamazaki T, Sawada U, Kura Y, Ito T, Kaneita Y, Yasukawa K, Horie T. Related Articles,
Links
Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy
for high and high-intermediate risk aggressive non-Hodgkin's lymphomas.
Leuk Lymphoma. 2002 Nov;43(11):2117-23.
PMID: 12533036 [PubMed - indexed for MEDLINE]
33: Aul C, Schroeder M, Giagounidis A. Related Articles, Links
[Medicinal therapy of malignant lymphomas]
Radiologe. 2002 Dec;42(12):943-53. German.
PMID: 12486548 [PubMed - in process]
34: Jadvar H, Conti PS. Related Articles, Links
Diagnostic utility of FDG PET in multiple myeloma.
Skeletal Radiol. 2002 Dec;31(12):690-4. Epub 2002 Sep 26.
PMID: 12483429 [PubMed - indexed for MEDLINE]
35: Schriber J. Related Articles, Links
Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with
filgrastim.
Drugs. 2002;62 Suppl 1:33-46. Review.
PMID: 12479593 [PubMed - indexed for MEDLINE]
36: Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M. Related Articles, Links
'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous
stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Bone Marrow Transplant. 2002 Dec;30(12):885-91.
PMID: 12476281 [PubMed - in process]
37: Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM,
Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J,
Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S,
Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ; Lymphoma Study Writing Committee,
International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant
Registry. Related Articles, Links
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic
lymphoma.
Blood. 2003 Apr 1;101(7):2476-82. Epub 2002 Nov 27.
PMID: 12456505 [PubMed - indexed for MEDLINE]
38: Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, Karakas T, Metzner
B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Muller P, Mantovani L, Grundeis M,
Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M,
Baudis M, Schmitz N, Pfab R, Koppler H, Parwaresch R, Pfreundschuh M, Havemann K. Related
Articles, Links
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for
"aggressive" lymphoma.
J Clin Oncol. 2002 Nov 15;20(22):4413-9.
PMID: 12431962 [PubMed - indexed for MEDLINE]
39: Fisher RI. Related Articles, Links
Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with
aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.
J Clin Oncol. 2002 Nov 15;20(22):4411-2. No abstract available.
PMID: 12431961 [PubMed - indexed for MEDLINE]
40: Krishnan A, Zaia J, Molina A. Related Articles, Links
Stem cell transplantation and gene therapy for HIV-related lymphomas.
J Hematother Stem Cell Res. 2002 Oct;11(5):765-75. Review.
PMID: 12427283 [PubMed - indexed for MEDLINE]
41: De Rosa L, Lalle M, Pandolfi A, Ruscio C, Amodeo R. Related Articles, Links
Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive Bcell non-Hodgkin's lymphoma in first complete remission.
Ann Hematol. 2002 Oct;81(10):575-81. Epub 2002 Sep 24.
PMID: 12424539 [PubMed - indexed for MEDLINE]
42: Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, TeruyaFeldstein J, Portlock CS. Related Articles, Links
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous
stem cell transplantation.
Cancer J. 2002 Sep-Oct;8(5):371-6.
PMID: 12416894 [PubMed - indexed for MEDLINE]
43: Labar B, Bogdanic V, Nemet D, Mrsic M, Serventi-Seiwerth R, Sertic D, Golubic-Cepulic B,
Vrtar M, Santek F, Batinic D, Mikulic M, Pulanic D. Related Articles, Links
Allogeneic stem cell transplantation in treatment of aggressive lymphomas: case series.
Croat Med J. 2002 Oct;43(5):565-8.
PMID: 12402397 [PubMed - indexed for MEDLINE]
44: Kluin-Nelemans HC. Related Articles, Links
Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma.
Croat Med J. 2002 Oct;43(5):561-4.
PMID: 12402396 [PubMed - indexed for MEDLINE]
45: Costes-Martineau V, Delfour C, Obled S, Lamant L, Pageaux GP, Baldet P, Blanc P, Delsol G.
Related Articles, Links
Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case
report and literature review.
J Clin Pathol. 2002 Nov;55(11):868-71. Review.
PMID: 12401829 [PubMed - indexed for MEDLINE]
46: Ripp JA, Loiue DC, Chan W, Nawaz H, Portlock CS. Related Articles, Links
T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients.
Leuk Lymphoma. 2002 Aug;43(8):1573-80.
PMID: 12400599 [PubMed - indexed for MEDLINE]
47: Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G,
Schmitz N; Lymphoma Working Party of the European Group for Blood and Bone Marrow
Transplantation. Related Articles, Links
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity
allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the
European Group for Blood and Bone Marrow Transplantation.
Blood. 2002 Dec 15;100(13):4310-6. Epub 2002 Aug 15.
PMID: 12393626 [PubMed - indexed for MEDLINE]
48: Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK,
Diehl V, Engert A; Participating Centers. Related Articles, Links
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low
toxicity in patients with relapsed and refractory Hodgkin's disease.
Ann Oncol. 2002 Oct;13(10):1628-35.
PMID: 12377653 [PubMed - indexed for MEDLINE]
49: Salar A, Martino R, Perea G, Ribera JM, Lopez-Guillermo A, Guardia R, Escoda L, Altes A,
Sierra J, Montserrat E. Related Articles, Links
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone,
high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed
aggressive non-Hodgkin's lymphoma.
Haematologica. 2002 Oct;87(10):1028-35.
PMID: 12368156 [PubMed - indexed for MEDLINE]
50: Blokx WA, Andriessen MP, van Hamersvelt HW, van Krieken JH. Related Articles, Links
Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell
lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the
literature on cutaneous B-cell posttransplantation lymphoproliferative disease.
Am J Dermatopathol. 2002 Oct;24(5):414-22.
PMID: 12357204 [PubMed - indexed for MEDLINE]
51: Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S,
Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H. Related Articles, Links
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with
aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line
chemotherapy.
Eur J Haematol. 2002 Jun;68(6):354-61.
PMID: 12225393 [PubMed - indexed for MEDLINE]
52: Smith SM, Grinblatt D, van Besien K. Related Articles, Links
Autologous and allogeneic transplantation for aggressive NHL.
Cytotherapy. 2002;4(3):223-40. Review.
PMID: 12194719 [PubMed - indexed for MEDLINE]
53: Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J,
Cabanillas F, Sarris AH. Related Articles, Links
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is
associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of
cutaneous involvement.
Ann Oncol. 2002 Aug;13(8):1290-9.
PMID: 12181254 [PubMed - indexed for MEDLINE]
54: Dearden CE, Matutes E, Catovsky D. Related Articles, Links
Alemtuzumab in T-cell malignancies.
Med Oncol. 2002;19 Suppl:S27-32. Review.
PMID: 12180489 [PubMed - indexed for MEDLINE]
55: Pasquale MA, Weppler D, Smith J, Icardi M, Amador A, Gonzalez M, Kato T, Tzakis A, Ruiz
P. Related Articles, Links
Burkitt s lymphoma variant of post-transplant lymphoproliferative disease (PTLD).
Pathol Oncol Res. 2002;8(2):105-8.
PMID: 12172573 [PubMed - indexed for MEDLINE]
56: Au WY, Liang R. Related Articles, Links
Peripheral T-cell lymphoma.
Curr Oncol Rep. 2002 Sep;4(5):434-42. Review.
PMID: 12162919 [PubMed - indexed for MEDLINE]
57: Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F,
Salvucci M, Tura S, Baccarani M. Related Articles, Links
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for
relapsed/refractory lymphoma patients.
Haematologica. 2002 Aug;87(8):816-21.
PMID: 12161357 [PubMed - indexed for MEDLINE]
58: Porcar Ramells C, Clemente Gonzalez C, Garcia Pares D, Guardia Sanchez R, Perez Ayuso
MJ, Garcia-Bragado Dalmau F. Related Articles, Links
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to
polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of
the literature]
An Med Interna. 2002 Jun;19(6):305-9. Review. Spanish.
PMID: 12152391 [PubMed - indexed for MEDLINE]
59: Brice P, Haioun C, Andre M, Gisselbrecht C; Groupe d'Etude des Lymphomes de l'Adulte.
Related Articles, Links
Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive
lymphomas.
Blood. 2002 Jul 15;100(2):736. No abstract available.
PMID: 12123236 [PubMed - indexed for MEDLINE]
60: Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R,
Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V;
German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for
Blood and Marrow Transplantation. Related Articles, Links
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous
haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a
randomised trial.
Lancet. 2002 Jun 15;359(9323):2065-71.
PMID: 12086759 [PubMed - indexed for MEDLINE]
61: Vonderheid EC. Related Articles, Links
Treatment of cutaneous T cell lymphoma: 2001.
Recent Results Cancer Res. 2002;160:309-20.
PMID: 12079229 [PubMed - indexed for MEDLINE]
62: Stockfleth E, Ulrich C, Meyer T, Christophers E. Related Articles, Links
Epithelial malignancies in organ transplant patients: clinical presentation and new methods of
treatment.
Recent Results Cancer Res. 2002;160:251-8.
PMID: 12079221 [PubMed - indexed for MEDLINE]
63: Evens AM, Gordon LI. Related Articles, Links
Burkitt's and Burkitt-like lymphoma.
Curr Treat Options Oncol. 2002 Aug;3(4):291-305. Review.
PMID: 12074766 [PubMed - indexed for MEDLINE]
64: Haioun C, Reyes F. Related Articles, Links
[Aggressive lymphomas]
Rev Prat. 2002 May 1;52(9):972-7. Review. French.
PMID: 12063763 [PubMed - indexed for MEDLINE]
65: Densmore JJ, Williams ME. Related Articles, Links
Mantle cell lymphoma.
Curr Treat Options Oncol. 2000 Aug;1(3):281-5. Review.
PMID: 12057172 [PubMed - indexed for MEDLINE]
66: Hayman SR, Fonseca R. Related Articles, Links
Plasma cell leukemia.
Curr Treat Options Oncol. 2001 Jun;2(3):205-16. Review.
PMID: 12057120 [PubMed - indexed for MEDLINE]
67: Varga F, Demeter J. Related Articles, Links
[Progress in the treatment of non-Hodgkin's lymphomas]
Magy Onkol. 2001;45(1):45-50. Hungarian.
PMID: 12050728 [PubMed - as supplied by publisher]
68: Hagemeister FB. Related Articles, Links
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and
stem cell rescue.
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.
PMID: 12042984 [PubMed - indexed for MEDLINE]
69: Moskowitz C. Related Articles, Links
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S9-12. Epub 2002 Apr 12.
PMID: 12042983 [PubMed - indexed for MEDLINE]
70: Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, Huber C, Derigs HG. Related
Articles, Links
Rituximab in vivo purging is safe and effective in combination with CD34-positive selected
autologous stem cell transplantation for salvage therapy in B-NHL.
Bone Marrow Transplant. 2002 May;29(9):769-75.
PMID: 12040475 [PubMed - indexed for MEDLINE]
71: Armitage JO. Related Articles, Links
The role of mitoxantrone in non-Hodgkin's lymphoma.
Oncology (Huntingt). 2002 Apr;16(4):490-502, 507-8; discussion 511-2, 514. Review.
PMID: 12017536 [PubMed - indexed for MEDLINE]
72: Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H,
Gabarre J, Guilmin F, Hermine O, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Related
Articles, Links
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive
lymphoma.
J Clin Oncol. 2002 May 15;20(10):2472-9.
PMID: 12011124 [PubMed - indexed for MEDLINE]
73: Rossbach HC, Chamizo W, Dumont DP, Barbosa JL, Sutcliffe MJ. Related Articles, Links
Hepatosplenic gamma/delta T-cell lymphoma with isochromosome 7q, translocation t(7;21), and
tetrasomy 8 in a 9-year-old girl.
J Pediatr Hematol Oncol. 2002 Feb;24(2):154-7. Review.
PMID: 11990705 [PubMed - indexed for MEDLINE]
74: Harris E, Paneesha S, Jackson N, Jones L, Mahendra P. Related Articles, Links
Burkitt's lymphoma: single-centre experience with modified BFM protocol.
Clin Lab Haematol. 2002 Apr;24(2):111-4.
PMID: 11985557 [PubMed - indexed for MEDLINE]
75: Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC,
Weisenburger DD, Kessinger A, Armitage JO. Related Articles, Links
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial
evaluating graft source and minimal residual disease.
J Clin Oncol. 2002 May 1;20(9):2344-52.
PMID: 11981006 [PubMed - indexed for MEDLINE]
76: Apisarnthanarax N, Talpur R, Duvic M. Related Articles, Links
Treatment of cutaneous T cell lymphoma: current status and future directions.
Am J Clin Dermatol. 2002;3(3):193-215. Review.
PMID: 11978140 [PubMed - indexed for MEDLINE]
77: Kvell K, Balogh P, Nemeth P. Related Articles, Links
[Clinical aspects of Epstein-Barr-virus-associated lymphoproliferative disease]
Orv Hetil. 2002 Apr 7;143(14):713-9. Review. Hungarian.
PMID: 11975391 [PubMed - indexed for MEDLINE]
78: Hussein MA. Related Articles, Links
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Oncologist. 2002;7 Suppl 1:20-9. Review.
PMID: 11961206 [PubMed - indexed for MEDLINE]
79: Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard
N, Ribrag V, Janvier M, Sebban C, Casasnovas RO, Bouabdallah R, Dreyfus F, Verkarre V,
Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B, Hermine O. Related Articles, Links
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem
cell transplantation induces a high rate of complete response and improves event-free survival in
mantle cell lymphoma: a prospective study.
Leukemia. 2002 Apr;16(4):587-93.
PMID: 11960337 [PubMed - indexed for MEDLINE]
80: Sanda T, Lida S, Ito M, Tsuboi K, Miura K, Harada S, Komatsu H, Wakita A, Inagaki H, Ueda
R. Related Articles, Links
Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and highdose chemotherapy.
Int J Hematol. 2002 Feb;75(2):195-200.
PMID: 11939269 [PubMed - indexed for MEDLINE]
81: Macdonald D, Reiter A, Cross NC. Related Articles, Links
The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation
of FGFR1.
Acta Haematol. 2002;107(2):101-7. Review.
PMID: 11919391 [PubMed - indexed for MEDLINE]
82: Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R,
Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A,
Harik S, Barlogie B, Tricot G. Related Articles, Links
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities,
plasmablastic morphology and extramedullary manifestations.
Br J Haematol. 2002 Apr;117(1):103-8. Review.
PMID: 11918539 [PubMed - indexed for MEDLINE]
83: Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, Yamamoto K, Fujii N,
Nawa Y, Hiramatsu Y, Sunami K, Ishimaru F, Yoshimo T, Kiura K, Harada M. Related Articles,
Links
High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and
nasal-type CD56+ natural killer cell lymphomas.
Leuk Lymphoma. 2001 Nov-Dec;42(6):1297-303.
PMID: 11911411 [PubMed - indexed for MEDLINE]
84: Murdock J, Morris TC, Alexander HD, McNamee P. Related Articles, Links
Red cell aplasia due to erythrovirus parvovirus B19 infection in a Jehovah's witness with posttransplant EBV-induced aggressive lymphoma: management considerations.
Leuk Lymphoma. 2002 Jan;43(1):211-3.
PMID: 11911105 [PubMed - indexed for MEDLINE]
85: Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe
N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L,
Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Related Articles, Links
Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant
rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Bone Marrow Transplant. 2002 Feb;29(4):303-12.
PMID: 11896427 [PubMed - indexed for MEDLINE]
86: Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, Wormann B, Brittinger G,
Becker W. Related Articles, Links
High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the
iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of
a pilot study.
Cancer. 2002 Feb 15;94(4 Suppl):1363-72.
PMID: 11877767 [PubMed - indexed for MEDLINE]
87: Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J,
Glabbeke M, Henry-Amar M, Carde P. Related Articles, Links
The achievements of the EORTC Lymphoma Group. European Organisation for Research and
Treatment of Cancer.
Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13.
PMID: 11858975 [PubMed - indexed for MEDLINE]
88: Seymour JF, Grigg AP, Szer J, Fox RM. Related Articles, Links
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for
patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Cancer. 2002 Feb 1;94(3):585-93.
PMID: 11857288 [PubMed - indexed for MEDLINE]
89: Mounier N, Socie G, Gisselbrecht C. Related Articles, Links
High-dose therapy for indolent lymphoma.
Crit Rev Oncol Hematol. 2002 Feb;41(2):225-39. Review.
PMID: 11856598 [PubMed - indexed for MEDLINE]
90: Au WY, Lie AK, Liang R, Liu CL, Shek TW, Lau GK. Related Articles, Links
Aggressive hepatocellular carcinoma complicating pregnancy after autologous bone marrow
transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant. 2002 Jan;29(2):177-9.
PMID: 11850714 [PubMed - indexed for MEDLINE]
91: Ugo V, Legrand O, Delmer A, Rio B, Casadevall N, Marie JP. Related Articles, Links
[Update on malignant hemopathies]
Bull Cancer. 2002 Jan;89(1):75-88. Review. French.
PMID: 11847029 [PubMed - indexed for MEDLINE]
92: Haioun C, Mounier N, Quesnel B, Morel P, Rieux C, Beaujean F, Marolleau JP, Belhadj K,
Simon D, Gaulard PH, Lepage E, Gisselbrecht CH, Reyes F. Related Articles, Links
Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a
pilot study of 36 patients.
Ann Oncol. 2001 Dec;12(12):1749-55.
PMID: 11843254 [PubMed - indexed for MEDLINE]
93: Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B,
Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P,
Berinstein NL. Related Articles, Links
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell
transplantation for mantle cell lymphoma.
Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.
PMID: 11842390 [PubMed - indexed for MEDLINE]
94: Fend F, Martinez A, Quintanilla-Martinez L, Sanz L, Combalia N, Raffeld M, Jaffe ES,
Montserrat E, Campo E. Related Articles, Links
Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell
lymphoma.
Br J Haematol. 2002 Feb;116(2):329-33.
PMID: 11841433 [PubMed - indexed for MEDLINE]
95: Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Potzi C, Raderer M,
Dudczak R, Kletter K. Related Articles, Links
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse
of malignant lymphoma after high-dose therapy with stem cell transplantation.
Leukemia. 2002 Feb;16(2):260-7.
PMID: 11840293 [PubMed - indexed for MEDLINE]
96: Pettengell R. Related Articles, Links
Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S1-4. Review.
PMID: 11840153 [PubMed - indexed for MEDLINE]
97: Ornstein DL, Ririe DW, Shaughnessy PJ, Neuhauser T, Bee C. Related Articles, Links
Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal
extramedullary plasmacytomas progressing after autologous transplantation.
Bone Marrow Transplant. 2002 Jan;29(1):71-4.
PMID: 11840148 [PubMed - indexed for MEDLINE]
98: Jassal DS, Kasper K, Morales C, Rubinger M. Related Articles, Links
Autologous peripheral stem cell transplantation for aggressive hemophagocytic syndrome
associated with T-cell lymphoma: case study and review.
Am J Hematol. 2002 Jan;69(1):64-6.
PMID: 11835334 [PubMed - indexed for MEDLINE]
99: Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Related Articles, Links
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma
growth.
J Biol Chem. 2002 Apr 19;277(16):14153-8. Epub 2002 Jan 23.
PMID: 11809760 [PubMed - indexed for MEDLINE]
100: Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F,
Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs. Related Articles, Links
Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically
tailored treatment.
Haematologica. 2002 Jan;87(1):67-77.
PMID: 11801467 [PubMed - indexed for MEDLINE]
101: Reyes F. Related Articles, Links
[First-line treatment of lymphomas of "high grade malignancy" or "aggressive lymphomas"]
Cancer Radiother. 2001 Nov;5 Suppl 1:142s-148s. Review. French.
PMID: 11797274 [PubMed - indexed for MEDLINE]
102: Khassawneh BY, White P Jr, Anaissie EJ, Barlogie B, Hiller FC. Related Articles, Links
Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation.
Chest. 2002 Jan;121(1):185-8.
PMID: 11796449 [PubMed - indexed for MEDLINE]
103: Nagafuji K, Fujisaki T, Arima F, Ohshima K. Related Articles, Links
L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous
peripheral blood stem cell transplantation.
Int J Hematol. 2001 Dec;74(4):447-50.
PMID: 11794702 [PubMed - indexed for MEDLINE]
104: Gross TG. Related Articles, Links
Low-dose chemotherapy for children with post-transplant lymphoproliferative disease.
Recent Results Cancer Res. 2002;159:96-103. Review.
PMID: 11785850 [PubMed - indexed for MEDLINE]
105: Cornely OA, Pels H, Bethe U, Seibold M, Toepelt K, Soehngen D, Ritzkowsky A. Related
Articles, Links
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions
following allogeneic stem cell transplantation.
Bone Marrow Transplant. 2001 Nov;28(9):899-901.
PMID: 11781653 [PubMed - indexed for MEDLINE]
106: Schmitz N. Related Articles, Links
6. Report on workshop: EBMT workshop "High dose therapy in aggressive NHL".
Ann Hematol. 2001;80 Suppl 3:B24-5. No abstract available.
PMID: 11757700 [PubMed - indexed for MEDLINE]
107: Kluin-Nelemans HC. Related Articles, Links
Indications for early autologous stem cell transplantation in aggressive lymphoma.
Ann Hematol. 2001;80 Suppl 3:B121-2. Review. No abstract available.
PMID: 11757692 [PubMed - indexed for MEDLINE]
108: Pfreundschuh M. Related Articles, Links
Lymphoma 2000. The First International Symposium on Biology and Treatment of Aggressive
Lymphomas: The stagnation seems to be over.
Ann Hematol. 2001;80 Suppl 3:B1-2. No abstract available.
PMID: 11757687 [PubMed - indexed for MEDLINE]
109: Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L,
Tedeschi A, Magliano E, Morra E. Related Articles, Links
Invasive aspergillosis in haematological malignancies: clinical findings and management for
intensive chemotherapy completion.
Am J Hematol. 2001 Dec;68(4):231-6.
PMID: 11754411 [PubMed - indexed for MEDLINE]
110: Baldissera RC, Aranha JF, Oliveira GB, Vigorito AC, Eid KA, Miranda EC, De Souza CA.
Related Articles, Links
High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell
transplantation improves the salvage treatment for persistent or sensitive relapsed malignant
lymphoma.
Braz J Med Biol Res. 2002 Jan;35(1):49-57.
PMID: 11743614 [PubMed - indexed for MEDLINE]
111: Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Related Articles, Links
Immunotherapy of Non-Hodgkin's lymphomas.
Hematology (Am Soc Hematol Educ Program). 2001;:221-40. Review.
PMID: 11722986 [PubMed - indexed for MEDLINE]
112: Bertini M, Boccomini C, Calvi R. Related Articles, Links
The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma
(DLCL).
Clin Lymphoma. 2001 Mar;1(4):278-84. Review.
PMID: 11707842 [PubMed - indexed for MEDLINE]
113: Intragumtornchai T, Prayoonwiwat W, Numbenjapon T, Assawametha N, O'Charoen R,
Swasdikul D. Related Articles, Links
CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood
progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's
lymphoma.
Clin Lymphoma. 2000 Dec;1(3):219-25.
PMID: 11707834 [PubMed - indexed for MEDLINE]
114: Schiffer CA. Related Articles, Links
Treatment of high-grade lymphoid malignancies in adults.
Semin Hematol. 2001 Oct;38(4 Suppl 10):22-6. Review.
PMID: 11694948 [PubMed - indexed for MEDLINE]
115: Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Tass P, Brousse
N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L,
Hermine O, Lamy T. Related Articles, Links
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.
Leukemia. 2001 Nov;15(11):1785-91.
PMID: 11681422 [PubMed - indexed for MEDLINE]
116: Mongini C, Ruybal P, Gravisaco MJ, Croci M, Sanchez Lockhart M, Fabris V, Waldner AC.
Related Articles, Links
Characterization of the immunophenotype and the metastatic properties of a murine T-lymphoma
cell line. Unexpected expression of cytoplasmatic CD4.
In Vitro Cell Dev Biol Anim. 2001 Sep;37(8):499-504.
PMID: 11669283 [PubMed - indexed for MEDLINE]
117: Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS. Related Articles, Links
Tandem transplantation in lymphoma.
Bone Marrow Transplant. 2001 Sep;28(6):529-35. Review.
PMID: 11607764 [PubMed - indexed for MEDLINE]
118: Bosly A, Gisselbrecht C. Related Articles, Links
[Therapy intensification with autologous transplantation in non-Hodgkin's lymphomas]
Bull Cancer. 2001 Sep;88(9):877-87. Review. French.
PMID: 11604361 [PubMed - indexed for MEDLINE]
119: Zimonjic DB, Keck-Waggoner C, Popescu NC. Related Articles, Links
Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's
lymphoma.
Leukemia. 2001 Oct;15(10):1582-8.
PMID: 11587216 [PubMed - indexed for MEDLINE]
120: Ogura M. Related Articles, Links
[Recent progress in the treatment of malignant lymphoma]
Gan To Kagaku Ryoho. 2001 Sep;28(9):1213-35. Review. Japanese.
PMID: 11579632 [PubMed - indexed for MEDLINE]
121: Chou T. Related Articles, Links
[Multiple myeloma--advances in disease biology and implications for therapy]
Gan To Kagaku Ryoho. 2001 Sep;28(9):1206-12. Review. Japanese.
PMID: 11579631 [PubMed - indexed for MEDLINE]
122: Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS. Related Articles,
Links
The impact of external beam radiation therapy prior to autologous bone marrow transplantation in
patients with non-Hodgkin's lymphoma.
Biol Blood Marrow Transplant. 2001;7(8):446-53.
PMID: 11569890 [PubMed - indexed for MEDLINE]
123: Leonard JP, Schattner EJ, Coleman M. Related Articles, Links
Biology and management of mantle cell lymphoma.
Curr Opin Oncol. 2001 Sep;13(5):342-7. Review.
PMID: 11555710 [PubMed - indexed for MEDLINE]
124: Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, Chilcott S, Spittle
M, Grieve RJ, Stewart S, Apperley JF, Russell-Jones R. Related Articles, Links
T-cell depletion and autologous stem cell transplantation in the management of tumour stage
mycosis fungoides with peripheral blood involvement.
Br J Haematol. 2001 Sep;114(3):624-31.
PMID: 11552988 [PubMed - indexed for MEDLINE]
125: Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, Tarella C, Zaglio F,
Vitolo U, Di Nicola M, Pogliani E, Cavalli F, Gianni AM, Barbui T. Related Articles, Links
Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome
of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
Br J Haematol. 2001 Aug;114(2):333-41.
PMID: 11529852 [PubMed - indexed for MEDLINE]
126: Tutschka PJ, Bilgrami SA, Feingold JM, Edwards RL, Bona RD, Naqvi B, Clive J. Related
Articles, Links
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and
cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan,
etoposide and cyclophosphamide for patients with advanced lymphoma.
Acta Haematol. 2001;105(4):222-32.
PMID: 11528096 [PubMed - indexed for MEDLINE]
127: Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA,
Samuels BI, Palmer JL, Cabanillas F. Related Articles, Links
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive nonHodgkin's lymphoma.
Ann Oncol. 2001 Jul;12(7):923-7.
PMID: 11521796 [PubMed - indexed for MEDLINE]
128: Molina A, Popplewell L, Kashyap A, Nademanee A. Related Articles, Links
Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National
Medical Center.
Clin Transpl. 2000;:317-42. Review.
PMID: 11512326 [PubMed - indexed for MEDLINE]
129: Schafer H, Berger C, Aepinus C, Hebart H, Beck R, Kaiserling E, Kanz L, Einsele H, Knecht
H. Related Articles, Links
Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights
through latent membrane protein 1 fingerprinting.
Transplantation. 2001 Aug 15;72(3):492-6.
PMID: 11502981 [PubMed - indexed for MEDLINE]
130: Screpanti V, Wallin RP, Ljunggren HG, Grandien A. Related Articles, Links
A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells.
J Immunol. 2001 Aug 15;167(4):2068-73.
PMID: 11489989 [PubMed - indexed for MEDLINE]
131: Rakozy CK, Mohamed AN, Vo TD, Khatib G, Long PM, Eilender D, Palutke M. Related
Articles, Links
CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically,
cytogenetically, and clinically diverse.
Am J Clin Pathol. 2001 Aug;116(2):168-76.
PMID: 11488062 [PubMed - indexed for MEDLINE]
132: Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan
M, Hurley D, Uhl L, Avigan D. Related Articles, Links
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell nonHodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Eur J Haematol Suppl. 2001 Jul;(64):56-62.
PMID: 11486404 [PubMed - indexed for MEDLINE]
133: Reiser M, Bredenfeld H, Engert A, Diehl V. Related Articles, Links
The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
Eur J Haematol Suppl. 2001 Jul;(64):37-40. Review.
PMID: 11486400 [PubMed - indexed for MEDLINE]
134: Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. Related Articles, Links
4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required
for protective immunity against parental tumors.
Cell Immunol. 2001 May 25;210(1):56-65.
PMID: 11485353 [PubMed - indexed for MEDLINE]
135: Wu S, Lin X. Related Articles, Links
[A clinical study of six cases of Pneumocystis carinii pneumonia]
Zhonghua Jie He He Hu Xi Za Zhi. 1998 Oct;21(10):590-2. Chinese.
PMID: 11477873 [PubMed - indexed for MEDLINE]
136: Holyoake TL, Freshney MG, Samuel K, Ansell J, Watson GE, Wright EG, Graham GJ,
Pragnell IB. Related Articles, Links
In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone
marrow transplantation induces B-cell leukaemia in mice.
Br J Haematol. 2001 Jul;114(1):49-56.
PMID: 11472344 [PubMed - indexed for MEDLINE]
137: Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA,
Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Related Articles, Links
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell
transplantation in multiple myeloma or non-Hodgkin lymphoma.
Blood. 2001 Aug 1;98(3):579-85.
PMID: 11468153 [PubMed - indexed for MEDLINE]
138: Ohori NP, Whisnant RE, Nalesnik MA, Swerdlow SH. Related Articles, Links
Primary pleural effusion posttransplant lymphoproliferative disorder: Distinction from secondary
involvement and effusion lymphoma.
Diagn Cytopathol. 2001 Jul;25(1):50-3.
PMID: 11466813 [PubMed - indexed for MEDLINE]
139: Tabata M, Kodama K, Matsuo T. Related Articles, Links
Peripheral blood stem cell transplantation in patients over 65 years old with malignant lymphoma-possibility of early completion of chemotherapy and improvement of performance status.
Intern Med. 2001 Jun;40(6):471-4.
PMID: 11446668 [PubMed - indexed for MEDLINE]
140: Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P,
Jaburg N, Loliger C, Schafer P, Hinke A, Zander AR. Related Articles, Links
Patient cytomegalovirus seropositivity with or without reactivation is the most important
prognostic factor for survival and treatment-related mortality in stem cell transplantation from
unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Br J Haematol. 2001 Jun;113(4):1060-71.
PMID: 11442503 [PubMed - indexed for MEDLINE]
141: Kimby E, Brandt L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology
Assessment in Health Care. Related Articles, Links
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma.
Acta Oncol. 2001;40(2-3):198-212. Review.
PMID: 11441932 [PubMed - indexed for MEDLINE]
142: Ratei R, Matylis A, Krahl D, Arnold R, Stein H, Dorken B, Ludwig WD. Related Articles,
Links
Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related
donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.
Leuk Lymphoma. 2000 Dec;40(1-2):133-40.
PMID: 11426614 [PubMed - indexed for MEDLINE]
143: Langouet AM, Brice P, Simon D, Bocaccio C, Munck JN, Fillet G, Peny AM, Salles G,
Quesnel B, Lefrere F, Felix R, Gisselbrecht C. Related Articles, Links
Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell
transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients.
Hematol J. 2001 Mar;2(2):81-86.
PMID: 11423999 [PubMed - as supplied by publisher]
144: Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, Gridelli B, Barbui T. Related
Articles, Links
Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after
solid organ transplant.
Haematologica. 2001 Jun;86(6):618-23.
PMID: 11418370 [PubMed - indexed for MEDLINE]
145: Bouabdallah R, Stoppa AM, Coso D, Bardou VJ, Blaise D, Chabannon C, Gastaut JA,
Maraninchi D. Related Articles, Links
Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with
aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): final
analysis of survival in two consecutive ISC trials.
Ann Oncol. 2001 Apr;12(4):513-7.
PMID: 11398886 [PubMed - indexed for MEDLINE]
146: Vatazin AV, Prokopenko EI, Shcherbakova EO, Pasov SA, Ivanov IA, Kazantseva IA.
Related Articles, Links
[Malignant tumors in patients with kidney transplants ]
Urologiia. 2000 Sep-Oct;(5):11-5. Russian.
PMID: 11392215 [PubMed - indexed for MEDLINE]
147: Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Related
Articles, Links
Live attenuated measles virus induces regression of human lymphoma xenografts in
immunodeficient mice.
Blood. 2001 Jun 15;97(12):3746-54.
PMID: 11389012 [PubMed - indexed for MEDLINE]
148: Niitsu N, Okamoto M, Okabe-Kado J, Takagi T, Yoshida T, Aoki S, Honma Y, Hirano M.
Related Articles, Links
Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma.
Leukemia. 2001 May;15(5):832-9.
PMID: 11368446 [PubMed - indexed for MEDLINE]
149: Hamblin TJ. Related Articles, Links
Achieving optimal outcomes in chronic lymphocytic leukaemia.
Drugs. 2001;61(5):593-611. Review.
PMID: 11368285 [PubMed - indexed for MEDLINE]
150: Kitajima H, Nasu K, Tsudo M, Fujimoto M, Hayashi K, Ohno H, Konaka Y, Katsurada T,
Arima N, Doi S, Moriguchi T, Fukuhara S. Related Articles, Links
[High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive nonHodgkin's lymphoma remaining in initial remission: results of a feasibility study]
Rinsho Ketsueki. 2001 Mar;42(3):191-8. Japanese.
PMID: 11345781 [PubMed - indexed for MEDLINE]
151: Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C,
Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Related
Articles, Links
Infusional vinorelbine in relapsed or refractory lymphomas.
Leuk Lymphoma. 2000 Oct;39(3-4):291-9.
PMID: 11342309 [PubMed - indexed for MEDLINE]
152: Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Related Articles, Links
Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma.
Br J Haematol. 2001 Apr;113(1):202-8.
PMID: 11328303 [PubMed - indexed for MEDLINE]
153: Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, Appelbaum
FR, Press OW. Related Articles, Links
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for nonHodgkin's lymphoma in adults 60 years of age and older.
Bone Marrow Transplant. 2001 Mar;27(6):593-9.
PMID: 11319588 [PubMed - indexed for MEDLINE]
154: Nishii K, Katayama N, Chen F, Usui E, Kadowaki S, Mitani H, Masuya M, Kageyama SI,
Kita K, Shiku H. Related Articles, Links
Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy
with autologous stem cell support for multiple myeloma.
Bone Marrow Transplant. 2001 Mar;27(5):555-8.
PMID: 11313693 [PubMed - indexed for MEDLINE]
155: Vantelon JM, Munck JN, Bourhis JH, Pico JL, Fadel C, Ulusakarya A, Carde P, Fenaux P,
Ribrag V. Related Articles, Links
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy.
Bone Marrow Transplant. 2001 Mar;27(5):531-6.
PMID: 11313688 [PubMed - indexed for MEDLINE]
156: Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J, Lahuerta JJ, Garcia-Conde J, Arranz
R, Leon A, Zuazu J, Garcia-Larana J, Lopez-Guillermo A, Sanz MA, Granena A, Garcia JC, Conde
E; GEL/TAMO Spanish Cooperative Group. Related Articles, Links
Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of
preparative regimens.
Bone Marrow Transplant. 2001 Feb;27(4):405-12.
PMID: 11313670 [PubMed - indexed for MEDLINE]
157: van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R,
Andersson B, Gajewski J, Champlin R, Cabanillas F. Related Articles, Links
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in
recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term
survival.
Bone Marrow Transplant. 2001 Feb;27(4):397-404.
PMID: 11313669 [PubMed - indexed for MEDLINE]
158: Kewalramani T, Moskowitz CH. Related Articles, Links
Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease:
who benefits?
Curr Oncol Rep. 2001 May;3(3):271-8. Review.
PMID: 11296139 [PubMed - indexed for MEDLINE]
159: Claviez A, Tiemann M, Wagner HJ, Dreger P, Suttorp M. Related Articles, Links
Epstein-Barr virus-associated post-transplant lymphoproliferative disease after bone marrow
transplantation mimicking graft-versus-host disease.
Pediatr Transplant. 2000 May;4(2):151-5.
PMID: 11272609 [PubMed - indexed for MEDLINE]
160: Greinix HT. Related Articles, Links
[Autologous stem cell transplantation in lymphomas and Hodgkin's disease]
Acta Med Austriaca. 2000;27 Suppl 52:25-9. Review. German.
PMID: 11261274 [PubMed - indexed for MEDLINE]
161: Hinterberger W. Related Articles, Links
[Autologous transplantation of hematopoietic stem cells--therapeutic spectrum and future
developments]
Acta Med Austriaca. 2000;27 Suppl 52:1-7. Review. German.
PMID: 11261270 [PubMed - indexed for MEDLINE]
162: Pahl E, Naftel DC, Canter CE, Frazier EA, Kirklin JK, Morrow WR; Pediatric Heart
Transplant Study. Related Articles, Links
Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients:
a multi-institutional study.
J Heart Lung Transplant. 2001 Mar;20(3):279-87.
PMID: 11257553 [PubMed - indexed for MEDLINE]
163: Paulli M, Vallisa D, Viglio A, Boveri E, Kindl S, Vassallo G, Magrini U, Cavanna L. Related
Articles, Links
ALK positive lymphohistiocytic variant of anaplastic large cell lymphoma in an adult.
Haematologica. 2001 Mar;86(3):260-5.
PMID: 11255272 [PubMed - indexed for MEDLINE]
164: Bock HA. Related Articles, Links
Steroid-resistant kidney transplant rejection: diagnosis and treatment.
J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S48-52. Review.
PMID: 11251032 [PubMed - indexed for MEDLINE]
165: Kennedy RD, Cuthbert RG, Kettle PJ, Morris TC. Related Articles, Links
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: concerns
about omissions in the data presented.
J Clin Oncol. 2001 Mar 15;19(6):1884. No abstract available.
PMID: 11251023 [PubMed - indexed for MEDLINE]
166: van Besien K, Kelta M, Bahaguna P. Related Articles, Links
Primary mediastinal B-cell lymphoma: a review of pathology and management.
J Clin Oncol. 2001 Mar 15;19(6):1855-64. Review.
PMID: 11251018 [PubMed - indexed for MEDLINE]
167: Boullanger N, Renou P, Dugay J, Boyer J, de Yberlucea LR, Combe M, Coulon MA. Related
Articles, Links
[Palpable mantel cell lymphoma in the breast]
Presse Med. 2001 Feb 3;30(4):163-5. French.
PMID: 11229304 [PubMed - indexed for MEDLINE]
168: Lindahl J, Kimby E, Bjorkstrand B, Christensson B, Hellstrom-Lindberg E. Related Articles,
Links
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD.
Leuk Res. 2001 Mar;25(3):267-70.
PMID: 11226525 [PubMed - indexed for MEDLINE]
169: Fisher RI. Related Articles, Links
Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma.
Semin Oncol. 2000 Dec;27(6 Suppl 12):2-8. Review.
PMID: 11225996 [PubMed - indexed for MEDLINE]
170: Schwartz DL, Schechter GP, Seltzer S, Chauncey TR. Related Articles, Links
Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy
for non-Hodgkin's lymphoma.
Bone Marrow Transplant. 2000 Dec;26(12):1355-9.
PMID: 11223979 [PubMed - indexed for MEDLINE]
171: Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S,
Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM; Autologous Blood and Marrow
Transplant Registry Lymphoma Working Committee. Related Articles, Links
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never
achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
J Clin Oncol. 2001 Jan 15;19(2):406-13.
PMID: 11208832 [PubMed - indexed for MEDLINE]
172: Sakhuja V, Sud K, Kalra OP, D'Cruz S, Kohli HS, Jha V, Gupta K, Vasishta RK. Related
Articles, Links
Central nervous system complications in renal transplant recipients in a tropical environment.
J Neurol Sci. 2001 Jan 15;183(1):89-93.
PMID: 11166801 [PubMed - indexed for MEDLINE]
173: Baron PW, Heneghan MA, Suhocki PV, Nuckols JD, Tuttle-Newhall JE, Howell DN, Clavien
PA. Related Articles, Links
Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation.
Liver Transpl. 2001 Jan;7(1):62-7. Review.
PMID: 11150426 [PubMed - indexed for MEDLINE]
174: Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM,
Musson H, Teodorovic I, Maes B, Carbone A, Carde P, Thomas J. Related Articles, Links
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's
lymphoma: randomized phase III EORTC study.
J Natl Cancer Inst. 2001 Jan 3;93(1):22-30.
PMID: 11136838 [PubMed - indexed for MEDLINE]
175: Fisher RI. Related Articles, Links
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned
and challenges remaining.
J Natl Cancer Inst. 2001 Jan 3;93(1):4-5. No abstract available.
PMID: 11136829 [PubMed - indexed for MEDLINE]
176: Lalle M, Montuoro A. Related Articles, Links
Autologous bone marrow transplantation in relapses of chemotherapy-sensitive aggressive nonHodgkin's lymphoma: long-term outcome.
J Chemother. 2000 Oct;12(5):431-4.
PMID: 11128564 [PubMed - indexed for MEDLINE]
177: Muti G, De Gasperi A, Cantoni S, Oreste P, Gini G, Civati G, Busnach G, Brando B, Frigerio
M, Mangiavacchi M, Alberti A, Decarus L, Rondinara G, De Giuli E, Morra E. Related Articles,
Links
Incidence and clinical characteristics of posttransplant lymphoproliferative disorders: report from a
single center.
Transpl Int. 2000;13 Suppl 1:S382-7.
PMID: 11112038 [PubMed - indexed for MEDLINE]
178: Corato A, Ambrosetti A, Rossi B, Vincenzi C, Lambiase A, Perona G, Pizzolo G, de Wynter
E, Nadali G. Related Articles, Links
Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus
filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
J Hematother Stem Cell Res. 2000 Oct;9(5):673-82.
PMID: 11091491 [PubMed - indexed for MEDLINE]
179: Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Related Articles, Links
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient
mice.
J Immunol. 2000 Dec 1;165(11):6024-8.
PMID: 11086033 [PubMed - indexed for MEDLINE]
180: Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L, Walker I, Benger
A, Gluck S, Smith A. Related Articles, Links
Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma
(NHL): results of a provincial strategy. Ontario BMT Network, Canada.
Bone Marrow Transplant. 2000 Oct;26(8):859-64.
PMID: 11081385 [PubMed - indexed for MEDLINE]
181: Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson
WH. Related Articles, Links
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year followup study of EPOCH.
J Clin Oncol. 2000 Nov 1;18(21):3633-42.
PMID: 11054436 [PubMed - indexed for MEDLINE]
182: Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac
Intyre E, Brousse N, Kreis H, Hermine O. Related Articles, Links
Durable remission after aggressive chemotherapy for very late post-kidney transplant
lymphoproliferation: A report of 16 cases observed in a single center.
J Clin Oncol. 2000 Nov 1;18(21):3622-32.
PMID: 11054435 [PubMed - indexed for MEDLINE]
183: Tsujimura H, Takagi T, Tamaru J, Sakai C. Related Articles, Links
Involvement of the appendix in a relapsed case of primary nasal NK/T-cell lymphoma.
Leuk Lymphoma. 2000 May;37(5-6):633-4.
PMID: 11042526 [PubMed - indexed for MEDLINE]
184: Sperr WR, Horny HP, Lechner K, Valent P. Related Articles, Links
Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.
Leuk Lymphoma. 2000 May;37(5-6):473-86. Review.
PMID: 11042508 [PubMed - indexed for MEDLINE]
185: Reece DE, Brockington DA, Phillips GL, Barnett MJ, Klingemann HG, Nantel SH,
Sutherland HJ, Shepherd JD. Related Articles, Links
Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma.
Bone Marrow Transplant. 2000 Sep;26(6):621-6.
PMID: 11041567 [PubMed - indexed for MEDLINE]
186: Bogart JA, Zamkoff K, Chung CT. Related Articles, Links
Aggressive radiotherapy adjuvant to peripheral blood stem cell transplant for relapsed Hodgkin's
disease.
Am J Clin Oncol. 2000 Oct;23(5):516-20.
PMID: 11039515 [PubMed - indexed for MEDLINE]
187: Ferreri AJ, Reni M, Villa E. Related Articles, Links
Therapeutic management of primary central nervous system lymphoma: lessons from prospective
trials.
Ann Oncol. 2000 Aug;11(8):927-37. Review.
PMID: 11038028 [PubMed - indexed for MEDLINE]
188: Ballestrero A, Clavio M, Ferrando F, Gonella R, Garuti A, Sessarego M, Ghio R, Gobbi M,
Patrone F. Related Articles, Links
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for
aggressive non-Hodgkin's lymphoma.
Int J Oncol. 2000 Nov;17(5):1007-13.
PMID: 11029505 [PubMed - indexed for MEDLINE]
189: Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J,
Lyons NC, Yahalom J, Nimer SD, Moskowitz CH. Related Articles, Links
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary
refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Blood. 2000 Oct 1;96(7):2399-404.
PMID: 11001890 [PubMed - indexed for MEDLINE]
190: Salles G, Coiffier B. Related Articles, Links
Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun;12(1-2):151-69. Review.
PMID: 11000990 [PubMed - indexed for MEDLINE]
191: Montuoro A, Lalle M, Ingletto D. Related Articles, Links
Autologous bone marrow transplantation as consolidation therapy in newly diagnosed nonHodgkin's lymphoma: long-term outcome.
Int J Oncol. 2000 Oct;17(4):771-5.
PMID: 10995890 [PubMed - indexed for MEDLINE]
192: Fanin R, Sperotto A, Ruiz De Elvira C, Zaja F, Stocchi R, Geromin A, Cerno M, Patriarca F,
Fanni Canelles M, Damiani D, Baccarani M. Related Articles, Links
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of
autologous stem cell transplantation in first remission on outcome.
Haematologica. 2000 Sep;85(9):943-51.
PMID: 10980633 [PubMed - indexed for MEDLINE]
193: Imashuku S. Related Articles, Links
Advances in the management of hemophagocytic lymphohistiocytosis.
Int J Hematol. 2000 Jul;72(1):1-11. Review.
PMID: 10979202 [PubMed - indexed for MEDLINE]
194: Hauke RJ, Armitage JO. Related Articles, Links
Treatment of non-Hodgkin lymphoma.
Curr Opin Oncol. 2000 Sep;12(5):412-8. Review. Erratum in: Curr Opin Oncol 2000
Nov;12(6):598.
PMID: 10975547 [PubMed - indexed for MEDLINE]
195: Petrucci MT, La Verde G, Ribersani M, Avvisati G, Mandelli F. Related Articles, Links
Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher
risk multiple myeloma patients.
Leuk Lymphoma. 2000 Sep;39(1-2):131-8.
PMID: 10975391 [PubMed - indexed for MEDLINE]
196: Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P,
Sarris AH, Younes A, Rodriguez J, Cabanillas F. Related Articles, Links
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell
transplant in elderly patients.
Leuk Lymphoma. 2000 Sep;39(1-2):77-85.
PMID: 10975386 [PubMed - indexed for MEDLINE]
197: Enblad G, Carlson K, Bengtsson M, Hagberg H. Related Articles, Links
A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of
tumour heterogeneity?
Med Oncol. 2000 Aug;17(3):229-32.
PMID: 10962536 [PubMed - indexed for MEDLINE]
198: Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T,
Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K. Related Articles, Links
Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly
CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuGCSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
Leuk Lymphoma. 2000 Aug;38(5-6):521-32.
PMID: 10953973 [PubMed - indexed for MEDLINE]
199: Swinnen LJ. Related Articles, Links
Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virusrelated lymphomas.
Semin Oncol. 2000 Aug;27(4):402-8. Review.
PMID: 10950366 [PubMed - indexed for MEDLINE]
200: Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel
C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F. Related Articles, Links
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final
analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
J Clin Oncol. 2000 Aug;18(16):3025-30.
PMID: 10944137 [PubMed - indexed for MEDLINE]
Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles
Domain Links 3D Domain Links GEO DataSet Links Genome Links GEO Links Nucleotide Links
OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links
Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order
Items 1-200 of 562 of 3 Next
Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer
Jul 17 2003 11:42:11
PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books
Search PubMed Protein Nucleotide Structure Genome Books Domains 3D Domains GEO GEO
DataSets Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS
for
Limits Preview/Index History Clipboard Details
About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Privacy Policy
Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles
Domain Links 3D Domain Links GEO DataSet Links Genome Links GEO Links Nucleotide Links
OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links
Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order
Items 201-400 of 562 Previous of 3 Next
201: Doorduijn JK, Spruit P, van Der Holt B, van't Veer M, Budel L, Lowenberg B, Sonneveld P.
Related Articles, Links
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or
relapsed non-Hodgkin's lymphoma.
Haematologica. 2000 Aug;85(8):814-9.
PMID: 10942927 [PubMed - indexed for MEDLINE]
202: Mauray S, Fuzzati-Armentero MT, Trouillet P, Ruegg M, Nicoloso G, Hart M, Aarden L,
Schapira M, Duchosal MA. Related Articles, Links
Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6.
Eur J Immunol. 2000 Jul;30(7):2065-73.
PMID: 10940896 [PubMed - indexed for MEDLINE]
203: Kwong YL, Lam CC, Chan TM. Related Articles, Links
Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological
and molecular analysis.
Br J Haematol. 2000 Jul;110(1):197-202.
PMID: 10930998 [PubMed - indexed for MEDLINE]
204: Astier MP, Mayordomo JI, Abad JM, Gomez LI, Tres A. Related Articles, Links
Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with
solid tumors.
Ann Oncol. 2000 May;11(5):603-6.
PMID: 10907956 [PubMed - indexed for MEDLINE]
205: Labardini-Mendez JR, Gutierrez AA, Martinez F, Chavez AD, Morales-Polanco MR,
Sobrevilla-Calvo PJ. Related Articles, Links
[Lymphoma. Current status and treatment]
Gac Med Mex. 2000 May-Jun;136(3):221-47. Spanish.
PMID: 10893851 [PubMed - indexed for MEDLINE]
206: Drews R, Samel A, Kadin ME. Related Articles, Links
Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin.
Semin Cutan Med Surg. 2000 Jun;19(2):109-17. Review.
PMID: 10892712 [PubMed - indexed for MEDLINE]
207: Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M,
Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O'Donnell LC, Tighe MB, Risley GL, Young DC,
Bolwell BJ. Related Articles, Links
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with nonHodgkin's lymphoma.
Bone Marrow Transplant. 2000 Jun;25(12):1243-8.
PMID: 10871728 [PubMed - indexed for MEDLINE]
208: Couderc B, Dujols JP, Mokhtari F, Norkowski JL, Slawinski JC, Schlaifer D. Related
Articles, Links
The management of adult aggressive non-Hodgkin's lymphomas.
Crit Rev Oncol Hematol. 2000 Jul;35(1):33-48. Review.
PMID: 10863150 [PubMed - indexed for MEDLINE]
209: Scharf C, Brunner HP, Oechslin E, Kiowski W. Related Articles, Links
[Heart transplantation: indications and results]
Ther Umsch. 2000 May;57(5):333-8. Review. German.
PMID: 10859994 [PubMed - indexed for MEDLINE]
210: Mounier N, Haioun C, Cole BF, Gisselbrecht C, Sebban C, Morel P, Marit G, Bouabdallah R,
Ravoet C, Salles G, Reyes F, Lepage E. Related Articles, Links
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow
transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first
complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
Blood. 2000 Jun 15;95(12):3687-92.
PMID: 10845898 [PubMed - indexed for MEDLINE]
211: Macak J. Related Articles, Links
[T and NK cell peripheral tumors]
Cesk Patol. 2000 Jan;36(1):9-14. Review. Czech.
PMID: 10838752 [PubMed - indexed for MEDLINE]
212: Limat S, Woronoff-Lemsi MC, Deconinck E, Racadot E, Jacquet M, Herve P, Cahn JY.
Related Articles, Links
Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for nonHodgkin's lymphoma patients: a single centre study.
Bone Marrow Transplant. 2000 May;25(9):997-1002.
PMID: 10800070 [PubMed - indexed for MEDLINE]
213: Asaoku H. Related Articles, Links
[Hematopoietic stem cell transplantation for malignant lymphoma]
Nippon Rinsho. 2000 Mar;58(3):704-8. Review. Japanese.
PMID: 10741150 [PubMed - indexed for MEDLINE]
214: Kashimura T, Murohashi I. Related Articles, Links
[Salvage therapy in relapsed or refractory malignant lymphoma]
Nippon Rinsho. 2000 Mar;58(3):699-703. Review. Japanese.
PMID: 10741149 [PubMed - indexed for MEDLINE]
215: Lichtman SM. Related Articles, Links
Aggressive lymphoma in the elderly.
Crit Rev Oncol Hematol. 2000 Feb;33(2):119-28. Review.
PMID: 10737373 [PubMed - indexed for MEDLINE]
216: Arranz R, Sanz-Rodriguez C, Pajuelo FJ, Martinez Chamorro C, Acevedo A, Perez G,
Fernandez Ranada JM. Related Articles, Links
[Hematopoietic stem cell transplantation as salvage treatment in patients with aggressive nonHodgkin's lymphoma]
Med Clin (Barc). 2000 Feb 5;114(4):128-31. Spanish.
PMID: 10734621 [PubMed - indexed for MEDLINE]
217: Sasaki M, Matsue K, Takeuchi M, Mitome M, Hirose Y. Related Articles, Links
Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous
peripheral blood stem cell transplantation.
Int J Hematol. 2000 Jan;71(1):75-8.
PMID: 10729998 [PubMed - indexed for MEDLINE]
218: Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M, Bucalossi A, Marotta G,
Tozzi M, Lauria F. Related Articles, Links
Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in lowgrade non Hodgkin lymphoma patients.
Leuk Lymphoma. 2000 Mar;37(1-2):157-61.
PMID: 10721780 [PubMed - indexed for MEDLINE]
219: Fisher RI. Related Articles, Links
Diffuse large-cell lymphoma.
Ann Oncol. 2000;11 Suppl 1:29-33. Review.
PMID: 10707775 [PubMed - indexed for MEDLINE]
220: Jost LM, Honegger HP, Stahel RA. Related Articles, Links
[High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in
Zurich]
Schweiz Med Wochenschr. 2000 Jan 22;130(3):60-9. German.
PMID: 10683881 [PubMed - indexed for MEDLINE]
221: Santini G, Coser P, Congiu AM, Salvagno L, De Souza C, Sertoli MR, Olivieri A, Chisesi T,
Rubagotti A, Truini M, Contu A, Porcellini A, Zambaldi G, Nati S, Marino G, Rizzoli V. Related
Articles, Links
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor
cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the
non-Hodgkin's Lymphoma Co-operative Study Group.
Haematologica. 2000 Feb;85(2):160-6.
PMID: 10681723 [PubMed - indexed for MEDLINE]
222: Papadaki HA, Stefanaki K, Kanavaros P, Katonis P, Papastathi H, Valatas W, Stylianoy K,
Eliopoulos GD. Related Articles, Links
Epstein-Barr virus-associated high-grade anaplastic plasmacytoma in a renal transplant patient.
Leuk Lymphoma. 2000 Jan;36(3-4):411-5.
PMID: 10674914 [PubMed - indexed for MEDLINE]
223: Inoue R, Natazuka T, Shimoyama M, Tamekane A, Kajimoto Y, Iwata N, Matsuoka H,
Chihara K, Matsui T. Related Articles, Links
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for nonHodgkin's aggressive lymphoma: a pilot study.
Leuk Lymphoma. 2000 Jan;36(3-4):315-21.
PMID: 10674903 [PubMed - indexed for MEDLINE]
224: Jung KC, Park CS, Sohn HW, Kook MC, Chung DH, Choi YK, Hyun BH, Lee IS, Bae YM,
Song HG, Park SH. Related Articles, Links
Development of new adherent mutant from human myeloma-derived cell line: in vitro model of
anaplastic transformation of myeloma.
Mol Cells. 1999 Dec 31;9(6):657-61.
PMID: 10672934 [PubMed - indexed for MEDLINE]
225: Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, Fermand JP, Schlemmer B.
Related Articles, Links
Changing use of intensive care for hematological patients: the example of multiple myeloma.
Intensive Care Med. 1999 Dec;25(12):1395-401.
PMID: 10660847 [PubMed - indexed for MEDLINE]
226: Bouabdallah R, Coso D, Costello R, Bardou VJ, Blaise D, Xerri L, Sainty D, Maraninchi D,
Gastaut JA. Related Articles, Links
Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive nonHodgkin's lymphoma: a retrospective series on 126 patients from a single center.
Bone Marrow Transplant. 2000 Jan;25(1):35-40.
PMID: 10654012 [PubMed - indexed for MEDLINE]
227: Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Related Articles,
Links
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and
self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Blood. 2000 Feb 1;95(3):1056-65.
PMID: 10648422 [PubMed - indexed for MEDLINE]
228: Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A,
Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C. Related Articles, Links
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very
unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group.
Ann Oncol. 1999 Dec;10(12):1485-8.
PMID: 10643540 [PubMed - indexed for MEDLINE]
229: Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Related Articles, Links
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a
chance for cure?
J Clin Oncol. 2000 Jan;18(2):332-9.
PMID: 10637247 [PubMed - indexed for MEDLINE]
230: Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S. Related Articles, Links
Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients.
Am J Surg Pathol. 2000 Jan;24(1):100-6.
PMID: 10632493 [PubMed - indexed for MEDLINE]
231: Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci
MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.
Related Articles, Links
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma:
an Italian Multicenter Study.
Haematologica. 2000 Jan;85(1):52-8.
PMID: 10629592 [PubMed - indexed for MEDLINE]
232: Verdonck LF. Related Articles, Links
High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's
lymphoma.
J Clin Oncol. 1999 Sep;17(9):3003. No abstract available.
PMID: 10627188 [PubMed - indexed for MEDLINE]
233: Kaiser U, Uebelacker I, Havemann K. Related Articles, Links
Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and
lymphoblastic lymphoma: a report on 58 patients.
Leuk Lymphoma. 1999 Dec;36(1-2):101-8.
PMID: 10613454 [PubMed - indexed for MEDLINE]
234: Haq R, Sawka CA, Franssen E, Berinstein NL. Related Articles, Links
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for
relapsed/refractory aggressive non-Hodgkin's lymphoma.
Leuk Lymphoma. 1999 Nov;35(5-6):527-36.
PMID: 10609790 [PubMed - indexed for MEDLINE]
235: Auletta JJ, Shurin S. Related Articles, Links
Improved hematopoiesis using amifostine in secondary myelodysplasia.
J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):531-4.
PMID: 10598667 [PubMed - indexed for MEDLINE]
236: Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A,
Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V,
Anticoli Borza P, Cellini C, Mandelli F, Tura S. Related Articles, Links
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens
(MACOP-B and F-MACHOP) fare in the long-term?
Haematologica. 1999 Nov;84(11):996-1001.
PMID: 10553159 [PubMed - indexed for MEDLINE]
237: Simmons Z. Related Articles, Links
Paraproteinemia and neuropathy.
Curr Opin Neurol. 1999 Oct;12(5):589-95. Review.
PMID: 10590896 [PubMed - indexed for MEDLINE]
238: Schey S, Ahsan G, Jones R. Related Articles, Links
Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a
phase II single centre study.
Bone Marrow Transplant. 1999 Nov;24(9):989-93.
PMID: 10556958 [PubMed - indexed for MEDLINE]
239: Krackhardt A, Gribben JG. Related Articles, Links
Stem cell transplantation for indolent lymphoma.
Curr Opin Hematol. 1999 Nov;6(6):388-93. Review.
PMID: 10546792 [PubMed - indexed for MEDLINE]
240: Gribben JG. Related Articles, Links
Stem-cell transplantation for indolent lymphoma.
Semin Hematol. 1999 Oct;36(4 Suppl 5):18-25. Review.
PMID: 10528912 [PubMed - indexed for MEDLINE]
241: Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michallet M, Milpied N, Rio B, Cahn
JY, Molina L, Laporte JL, Guilhot F, Kuentz M. Related Articles, Links
Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding
Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ
Francaise de Greffe de Moelle.
Br J Haematol. 1999 Oct;107(1):154-61.
PMID: 10520036 [PubMed - indexed for MEDLINE]
242: Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Ferme C,
Gisselbrecht C. Related Articles, Links
Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's
disease or non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1999 Oct;24(7):747-55.
PMID: 10516678 [PubMed - indexed for MEDLINE]
243: Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K, Valerhaugen H,
Lenschow E, Kvaloy S. Related Articles, Links
High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade
B cell non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1999 Oct;24(8):865-72.
PMID: 10516698 [PubMed - indexed for MEDLINE]
244: Morishima Y. Related Articles, Links
[Hematopoietic stem cell transplantation for malignant lymphoma]
Gan To Kagaku Ryoho. 1999 Sep;26(10):1401-6. Review. Japanese.
PMID: 10500526 [PubMed - indexed for MEDLINE]
245: Hagemeister FB. Related Articles, Links
The role of ifosfamide in the treatment of lymphomas.
Leuk Lymphoma. 1999 Aug;34(5-6):433-41. Review.
PMID: 10492066 [PubMed - indexed for MEDLINE]
246: Garnier JL, Blanc-Brunat N, Vivier G, Rousset F, Touraine JL. Related Articles, Links
Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas.
Clin Transplant. 1999 Aug;13(4):305-12.
PMID: 10485371 [PubMed - indexed for MEDLINE]
247: Villeneuve L. Related Articles, Links
Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with
rhodamine derivatives.
Biotechnol Appl Biochem. 1999 Aug;30 ( Pt 1):1-17. Review.
PMID: 10467113 [PubMed - indexed for MEDLINE]
248: Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E,
Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. Related Articles,
Links
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell
Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.
J Clin Oncol. 1999 Jan;17(1):423-9. Review. No abstract available.
PMID: 10458261 [PubMed - indexed for MEDLINE]
249: Baerg J, Murphy JJ, Anderson R, Magee JF. Related Articles, Links
Neutropenic enteropathy: a 10-year review.
J Pediatr Surg. 1999 Jul;34(7):1068-71.
PMID: 10442590 [PubMed - indexed for MEDLINE]
250: Tarumi T, Sawada K, Koizumi K, Takano H, Fukada Y, Nishio M, Fujie T, Ohnishi K, Kohno
M, Sato N, Sekiguchi S, Koike T. Related Articles, Links
A pilot study of a response oriented chemotherapeutic regimen combined with autologous
peripheral blood progenitor cell transplantation in aggressive non-Hodgkin's lymphoma.
Leuk Lymphoma. 1999 Jul;34(3-4):361-71.
PMID: 10439373 [PubMed - indexed for MEDLINE]
251: Aoudjit F, Masure S, Opdenakker G, Potworowski EF, St-Pierre Y. Related Articles, Links
Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental
thymic lymphoma.
Int J Cancer. 1999 Aug 27;82(5):743-7.
PMID: 10417774 [PubMed - indexed for MEDLINE]
252: Clark AD, Shetty A, Soutar R. Related Articles, Links
Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management
of underlying myeloma.
Blood Rev. 1999 Jun;13(2):79-90. Review.
PMID: 10414944 [PubMed - indexed for MEDLINE]
253: Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl
V, Sohngen D, Engert A. Related Articles, Links
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed
or resistant lymphoma who failed cyclophosphamide mobilization.
Bone Marrow Transplant. 1999 Jun;23(12):1223-8.
PMID: 10414907 [PubMed - indexed for MEDLINE]
254: Bociek RG, Armitage JO. Related Articles, Links
Hodgkin's disease and non-Hodgkin's lymphoma.
Curr Opin Hematol. 1999 Jul;6(4):205-15. Review.
PMID: 10400368 [PubMed - indexed for MEDLINE]
255: Johns A. Related Articles, Links
Overview of bone marrow and stem cell transplantation.
J Intraven Nurs. 1998 Nov-Dec;21(6):356-60. Review.
PMID: 10392101 [PubMed - indexed for MEDLINE]
256: Friedberg JW, Freedman AS. Related Articles, Links
High-dose therapy and stem cell transplantation in follicular lymphoma.
Ann Hematol. 1999 May;78(5):203-11. Review.
PMID: 10391100 [PubMed - indexed for MEDLINE]
257: Soslow RA, Baergen RN, Warnke RA. Related Articles, Links
B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically
similar aggressive lymphomas with blastic morphology.
Cancer. 1999 Jun 15;85(12):2648-54.
PMID: 10375114 [PubMed - indexed for MEDLINE]
258: Aisenberg AC. Related Articles, Links
Primary large cell lymphoma of the mediastinum.
Semin Oncol. 1999 Jun;26(3):251-8. Review.
PMID: 10375082 [PubMed - indexed for MEDLINE]
259: Bouabdallah R, Stoppa AM, Rossi JF, Lepeu G, Coso D, Xerri L, Ladaique P, Chabannon C,
Blaise D, Bardou VJ, Alzieu C, Gastaut JA, Maraninchi D. Related Articles, Links
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in
high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an
oligocentric report on 42 patients.
Leukemia. 1999 Jun;13(6):950-6.
PMID: 10360385 [PubMed - indexed for MEDLINE]
260: Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, Gascoyne RD.
Related Articles, Links
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect
clinical presentation.
J Clin Oncol. 1999 May;17(5):1558-67.
PMID: 10334544 [PubMed - indexed for MEDLINE]
261: Boussiotis VA, Freedman AS, Nadler LM. Related Articles, Links
Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Semin Hematol. 1999 Apr;36(2):209-16. Review.
PMID: 10319389 [PubMed - indexed for MEDLINE]
262: Reiser M, Josting A, Dias Wickramanayake P, Draube A, Scheid C, Tesch H, Wolf J, Diehl
V, Engert A. Related Articles, Links
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade nonHodgkin's lymphoma.
Leuk Lymphoma. 1999 Apr;33(3-4):305-12.
PMID: 10221510 [PubMed - indexed for MEDLINE]
263: Imashuku S, Hibi S, Todo S, Sako M, Inoue M, Kawa K, Koike K, Iwai A, Tsuchiya S,
Akiyama Y, Kotani T, Kawamura Y, Hirosawa M, Hasegawa D, Kosaka Y, Yamaguchi H, Ishii E,
Kato K, Ishii M, Kigasawa H. Related Articles, Links
Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome
(HPS) in Japan.
Bone Marrow Transplant. 1999 Mar;23(6):569-72.
PMID: 10217187 [PubMed - indexed for MEDLINE]
264: Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A,
Cullen N, Macartney J, Fanslow WC, Murphy WJ. Related Articles, Links
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.
Blood. 1999 May 1;93(9):2999-3007.
PMID: 10216096 [PubMed - indexed for MEDLINE]
265: Smith ML, Newland AC. Related Articles, Links
Treatment of myeloma.
QJM. 1999 Jan;92(1):11-4. Review.
PMID: 10209667 [PubMed - indexed for MEDLINE]
266: Gahrton G. Related Articles, Links
Allogeneic bone marrow transplantation in multiple myeloma.
Pathol Biol (Paris). 1999 Feb;47(2):188-91. Review.
PMID: 10192887 [PubMed - indexed for MEDLINE]
267: Bernard M, Dauriac C, Drenou B, Leberre C, Branger B, Fauchet R, Le Prise PY, Lamy T.
Related Articles, Links
Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis
non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1999 Feb;23(4):329-33.
PMID: 10100576 [PubMed - indexed for MEDLINE]
268: Katariya K, Thurer RJ. Related Articles, Links
Malignancies associated with the immunocompromised state.
Chest Surg Clin N Am. 1999 Feb;9(1):63-77, viii. Review.
PMID: 10079980 [PubMed - indexed for MEDLINE]
269: Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E,
Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. Related Articles,
Links
International Consensus Conference on high-dose therapy with hematopoietic stem-cell
transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.
Ann Oncol. 1999 Jan;10(1):13-9. Review. No abstract available.
PMID: 10076716 [PubMed - indexed for MEDLINE]
270: Waselenko JK, Flynn JM, Byrd JC. Related Articles, Links
Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized
studies has arrived.
Semin Oncol. 1999 Feb;26(1):48-61. Review.
PMID: 10073561 [PubMed - indexed for MEDLINE]
271: Knowles DM. Related Articles, Links
Immunodeficiency-associated lymphoproliferative disorders.
Mod Pathol. 1999 Feb;12(2):200-17. Review.
PMID: 10071343 [PubMed - indexed for MEDLINE]
272: Mukai HY, Kojima H, Suzukawa K, Hori M, Komeno T, Hasegawa Y, Ninomiya H, Mori N,
Nagasawa T. Related Articles, Links
High-dose chemotherapy with peripheral blood stem cell rescue in blastoid natural killer cell
lymphoma.
Leuk Lymphoma. 1999 Feb;32(5-6):583-8.
PMID: 10048432 [PubMed - indexed for MEDLINE]
273: Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, Miyazaki Y, Moriuchi Y,
Kuriyama K, Yamada Y, Tomonaga M. Related Articles, Links
Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case
report and review of the literature.
Bone Marrow Transplant. 1999 Jan;23(1):87-9.
PMID: 10037056 [PubMed - indexed for MEDLINE]
274: Plantier-Colcher I, Dupriez B, Simon M, Detourmignies L, Jouet JP, Fenaux P, Bauters F,
Morel P. Related Articles, Links
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or
relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Leukemia. 1999 Feb;13(2):282-8.
PMID: 10025903 [PubMed - indexed for MEDLINE]
275: Hirakawa S, Kuyama M, Takahashi S, Yamasaki O, Kanzaki H, Teshima T, Harada M, Ma Y,
Kawabata T, Yoshino T, Arata J. Related Articles, Links
Nasal and nasal-type natural killer/T-cell lymphoma.
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):268-72.
PMID: 10025761 [PubMed - indexed for MEDLINE]
276: Praghakaran K, Wise B, Chen A, Schwarz K, Colombani P. Related Articles, Links
Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
J Pediatr Surg. 1999 Jan;34(1):112-5; discussion 115-6.
PMID: 10022154 [PubMed - indexed for MEDLINE]
277: Lee DA, Hartman RP, Trenkner SW, Leone JP, Gruessner R. Related Articles, Links
Lymphomas in solid organ transplantation.
Abdom Imaging. 1998 Nov-Dec;23(6):553-7.
PMID: 9922182 [PubMed - indexed for MEDLINE]
278: Koc Y, Schenkein DP. Related Articles, Links
Therapy of diffuse aggressive lymphomas.
Cancer Treat Res. 1999;99:47-73. Review. No abstract available.
PMID: 9891863 [PubMed - indexed for MEDLINE]
279: Dranitsaris G. Related Articles, Links
Treatment of non-Hodgkin's lymphoma.
Anticancer Drugs. 1998 Nov;9(10):879-88. Review.
PMID: 9890699 [PubMed - indexed for MEDLINE]
280: Morishima Y. Related Articles, Links
[Autologous peripheral blood stem cell transplantation for malignant lymphoma]
Gan To Kagaku Ryoho. 1998 Dec;25(14):2217-22. Review. Japanese.
PMID: 9881078 [PubMed - indexed for MEDLINE]
281: Euvrard S, Kanitakis J, Pouteil-Noble C, Claudy A, Touraine JL. Related Articles, Links
Skin cancers in organ transplant recipients.
Ann Transplant. 1997;2(4):28-32. Review.
PMID: 9869876 [PubMed - indexed for MEDLINE]
282: Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin
P, Preti HA, Bachier C, Cabanillas F. Related Articles, Links
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and
refractory aggressive non-Hodgkin's lymphoma.
Br J Haematol. 1998 Dec;103(3):678-83.
PMID: 9858216 [PubMed - indexed for MEDLINE]
283: Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F,
Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R.
Related Articles, Links
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an
active regimen for aggressive mantle-cell lymphoma.
J Clin Oncol. 1998 Dec;16(12):3803-9.
PMID: 9850025 [PubMed - indexed for MEDLINE]
284: Stiff PJ. Related Articles, Links
Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Oncology (Huntingt). 1998 Oct;12(10 Suppl 8):56-62. Review.
PMID: 9830634 [PubMed - indexed for MEDLINE]
285: Visonneau S, Cesano A, Tran T, Jeglum KA, Santoli D. Related Articles, Links
Successful treatment of canine malignant histiocytosis with the human major histocompatibility
complex nonrestricted cytotoxic T-cell line TALL-104.
Clin Cancer Res. 1997 Oct;3(10):1789-97.
PMID: 9815565 [PubMed - indexed for MEDLINE]
286: Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R,
Chauvin F, Philip T. Related Articles, Links
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in
relapse: analysis of the PARMA trial. Parma Group.
Blood. 1998 Nov 15;92(10):3562-8.
PMID: 9808548 [PubMed - indexed for MEDLINE]
287: Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D,
Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F. Related Articles,
Links
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the
Parma trial.
J Clin Oncol. 1998 Oct;16(10):3264-9.
PMID: 9779700 [PubMed - indexed for MEDLINE]
288: Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. Related
Articles, Links
BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to
therapy and clinical outcome.
Blood. 1998 Oct 1;92(7):2294-302.
PMID: 9746767 [PubMed - indexed for MEDLINE]
289: Penn I. Related Articles, Links
Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients.
J Hepatobiliary Pancreat Surg. 1998;5(2):157-64. Review.
PMID: 9745082 [PubMed - indexed for MEDLINE]
290: Khubaveshka B. Related Articles, Links
[Primary lymphoma of the stomach]
Khirurgiia (Sofiia). 1997;50(4):42-5. Review. Bulgarian.
PMID: 9739858 [PubMed - indexed for MEDLINE]
291: Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P, Pigneux A,
Puntous M, Agape P, Vezon G, Broustet A, Girault D, Salmi LR, Reiffers J. Related Articles, Links
Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery
following autologous blood progenitor cell transplantation in multiple myeloma patients: a
monocentric study.
Leukemia. 1998 Sep;12(9):1447-56.
PMID: 9737695 [PubMed - indexed for MEDLINE]
292: Sleight BJ, Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ, Sidman CL. Related
Articles, Links
Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation.
Bone Marrow Transplant. 1998 Aug;22(4):375-80.
PMID: 9722073 [PubMed - indexed for MEDLINE]
293: Aviles A, Diaz-Maqueo JC, Talavera A, Nambo MJ, Garcia EL. Related Articles, Links
Maintenance therapy with interferon alfa 2b in Hodgkin's disease.
Leuk Lymphoma. 1998 Aug;30(5-6):651-6.
PMID: 9711927 [PubMed - indexed for MEDLINE]
294: Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Related Articles, Links
Immunotherapy for Epstein-Barr virus-associated cancers.
J Natl Cancer Inst Monogr. 1998;(23):89-93.
PMID: 9709309 [PubMed - indexed for MEDLINE]
295: Rosler W, Manger B, Repp R, Kalden JR, Gramatzki M. Related Articles, Links
Autologous PBPCT in a patient with lymphoma and Sjogren's syndrome: complete remission of
lymphoma without control of the autoimmune disease.
Bone Marrow Transplant. 1998 Jul;22(2):211-3.
PMID: 9707034 [PubMed - indexed for MEDLINE]
296: Fouillard L, Laporte JP, Labopin M, Lesage S, Isnard F, Douay L, Lopez M, Aoudjhane M,
Zunic P, Cheron N, Stachowiak J, Lemonnier MP, Andreu G, Belkacemi Y, Noel-Walter MP,
Morel P, Fenaux P, Jouet JP, Bauters F, Najman A, Gorin NC. Related Articles, Links
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and
radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a
single institution.
J Clin Oncol. 1998 Aug;16(8):2803-16.
PMID: 9704733 [PubMed - indexed for MEDLINE]
297: Wang AY, Li PK, To KF, Lai FM, Lai KN. Related Articles, Links
Coexistence of Kaposi's sarcoma and tuberculosis in a renal transplant recipient.
Transplantation. 1998 Jul 15;66(1):115-8.
PMID: 9679831 [PubMed - indexed for MEDLINE]
298: Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp MJ, Moreau A, Dupas B,
Bulabois CE, Juge-Morineau N, Harousseau JL. Related Articles, Links
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a
pilot study.
Bone Marrow Transplant. 1998 Jun;21(12):1193-6.
PMID: 9674850 [PubMed - indexed for MEDLINE]
299: Lopez A, Palacio C. Related Articles, Links
[Treatment of aggressive non-Hodgkin's lymphomas]
Med Clin (Barc). 1998 May 9;110(16):614-8. Review. Spanish. No abstract available.
PMID: 9656199 [PubMed - indexed for MEDLINE]
300: Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J. Related Articles, Links
Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but
extramedullary relapse with plasmacytomas.
Bone Marrow Transplant. 1998 Jun;21(11):1163-5.
PMID: 9645583 [PubMed - indexed for MEDLINE]
301: Uehira K, Kagami Y, Ogura M, Suzuki R, Miura K, Tachi H, Kurokawa T, Kinoshita T,
Murate T, Nakamura S, Morishima Y. Related Articles, Links
A high dose chemoradiotherapy and peripheral blood stem cell support combined with the
CD34(+)-selection method in cyclin D1(+)-mantle cell lymphoma.
Int J Hematol. 1998 Feb;67(2):187-90.
PMID: 9631586 [PubMed - indexed for MEDLINE]
302: Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Related Articles, Links
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated
lymphoma.
Blood Cells Mol Dis. 1998 Jun;24(2):114-23.
PMID: 9628848 [PubMed - indexed for MEDLINE]
303: Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes
D, Pawelek J. Related Articles, Links
Melanoma x macrophage hybrids with enhanced metastatic potential.
Clin Exp Metastasis. 1998 May;16(4):299-312.
PMID: 9626809 [PubMed - indexed for MEDLINE]
304: Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J,
Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D. Related
Articles, Links
T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma:
clinical and molecular follow-up.
Bone Marrow Transplant. 1998 May;21(9):893-9.
PMID: 9613781 [PubMed - indexed for MEDLINE]
305: Jox A, Zander T, Kornacker M, Kanzler H, Kuppers R, Diehl V, Wolf J. Related Articles,
Links
Detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements
in a patient with Hodgkin's disease of mixed cellularity subtype at primary diagnosis and in relapse
two and a half years later.
Ann Oncol. 1998 Mar;9(3):283-7.
PMID: 9602262 [PubMed - indexed for MEDLINE]
306: Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G,
Resegotti L. Related Articles, Links
Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.
Haematologica. 1998 Apr;83(4):312-6.
PMID: 9592980 [PubMed - indexed for MEDLINE]
307: Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett TJ, Mears JG, Zangwill SD,
Addonizio LJ, Michler RE, Knowles DM. Related Articles, Links
The morphologic and molecular genetic categories of posttransplantation lymphoproliferative
disorders are clinically relevant.
Cancer. 1998 May 15;82(10):1978-87.
PMID: 9587133 [PubMed - indexed for MEDLINE]
308: Mounier N, Gisselbrecht C. Related Articles, Links
Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's
lymphoma.
Ann Oncol. 1998;9 Suppl 1:S15-21. Review.
PMID: 9581237 [PubMed - indexed for MEDLINE]
309: Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Doyen C, Morel P, Attal M, Tilly H,
Deconinck E, Gaulard P, Reyes F. Related Articles, Links
High-dose therapy followed by stem cell transplantation in partial response after first-line induction
therapy for aggressive non-Hodgkin's lymphoma.
Ann Oncol. 1998;9 Suppl 1:S5-8. Review.
PMID: 9581235 [PubMed - indexed for MEDLINE]
310: Santini G, Congiu AM, Nati S, Canepa L, Spriano M, Chisesi T, Rossi E, Vimercati R, Sertoli
MR, Figari O, Gobbi M, Piaggio G, Vassallo F, Benvenuto F, Soracco M, Miglino M, Ravetti JL,
Truini M. Related Articles, Links
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's
lymphoma with marrow involvement.
Leuk Lymphoma. 1997 Dec;26 Suppl 1:83-8.
PMID: 9570684 [PubMed - indexed for MEDLINE]
311: Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A.
Related Articles, Links
For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous
system disease mandatory? Dutch HOVON Group.
Ann Oncol. 1998 Feb;9(2):191-4.
PMID: 9553665 [PubMed - indexed for MEDLINE]
312: Jaffe ES, Wilson WH. Related Articles, Links
Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications.
Cancer Surv. 1997;30:233-48. Review.
PMID: 9547995 [PubMed - indexed for MEDLINE]
313: Freedman AS, Gribben JG, Nadler LM. Related Articles, Links
High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
Leuk Lymphoma. 1998 Jan;28(3-4):219-30. Review.
PMID: 9517494 [PubMed - indexed for MEDLINE]
314: Yang YH, Jou ST, Lin DT, Lu MY, Lin KH, Su IJ. Related Articles, Links
Ki-1 lymphoma in two children.
J Formos Med Assoc. 1998 Feb;97(2):123-6.
PMID: 9509848 [PubMed - indexed for MEDLINE]
315: Quintanilla-Martinez L, Lome-Maldonado C, Schwarzmann F, Gredler E, Reyes E, AngelesAngeles A, Fend F. Related Articles, Links
Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease
associated with Epstein-Barr virus type A.
Mod Pathol. 1998 Feb;11(2):200-8.
PMID: 9504692 [PubMed - indexed for MEDLINE]
316: Arnulf B, Copie-Bergman C, Delfau-Larue MH, Lavergne-Slove A, Bosq J, Wechsler J,
Wassef M, Matuchansky C, Epardeau B, Stern M, Bagot M, Reyes F, Gaulard P. Related Articles,
Links
Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or
skin localization.
Blood. 1998 Mar 1;91(5):1723-31.
PMID: 9473239 [PubMed - indexed for MEDLINE]
317: Jackson GH, Wood A, Taylor PR, Lennard AL, Lucraft H, Heppleston A, Robinson P, Moore
J, Proctor SJ. Related Articles, Links
Early high dose chemotherapy intensification with autologous bone marrow transplantation in
lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and
Newcastle Lymphoma Group, UK.
Leuk Lymphoma. 1997 Dec;28(1-2):127-32.
PMID: 9498711 [PubMed - indexed for MEDLINE]
318: Koskela K, Pelliniemi TT, Lakkala T, Remes K. Related Articles, Links
Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.
Bone Marrow Transplant. 1998 Feb;21(3):305-7.
PMID: 9489657 [PubMed - indexed for MEDLINE]
319: Fanin R, Silvestri F, Geromin A, Infanti L, Sperotto A, Cerno M, Stocchi R, Savignano C,
Rinaldi C, Damiani D, Baccarani M. Related Articles, Links
Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or
partial remission: a retrospective analysis of the outcome of 52 patients according to the ageadjusted International Prognostic Index.
Bone Marrow Transplant. 1998 Feb;21(3):263-71.
PMID: 9489649 [PubMed - indexed for MEDLINE]
320: Liu PP, Chen CL, Eng HL, Chen YS, Chiang YC. Related Articles, Links
Lymphoproliferative disorder after liver transplantation.
J Formos Med Assoc. 1998 Jan;97(1):59-62.
PMID: 9481067 [PubMed - indexed for MEDLINE]
321: Paltiel O, Ronen I, Polliack A, Epstein L. Related Articles, Links
Two-way referral bias: evidence from a clinical audit of lymphoma in a teaching hospital.
J Clin Epidemiol. 1998 Feb;51(2):93-8.
PMID: 9474069 [PubMed - indexed for MEDLINE]
322: Randhawa P, Whiteside T, Zeevi A, Nalesnik M, Alvares C, Gollin SM, Demetris J, Locker J.
Related Articles, Links
In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant
lymphoproliferative disease: cytokine production and effect of interferon-alpha.
In Vitro Cell Dev Biol Anim. 1997 Nov-Dec;33(10):803-8.
PMID: 9466686 [PubMed - indexed for MEDLINE]
323: Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T,
Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
Related Articles, Links
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell
transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Biol Blood Marrow Transplant. 1997 Nov;3(5):261-6. Erratum in: Biol Blood Marrow Transplant
1998;4(1):56.
PMID: 9450921 [PubMed - indexed for MEDLINE]
324: Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG,
LeBlanc M, Fisher RI. Related Articles, Links
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive
non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group
trial.
J Clin Oncol. 1998 Jan;16(1):48-55.
PMID: 9440722 [PubMed - indexed for MEDLINE]
325: Maloney DG. Related Articles, Links
Non-Hodgkin's lymphoma.
Curr Opin Hematol. 1995 Jul;2(4):255-61. Review.
PMID: 9372005 [PubMed - indexed for MEDLINE]
326: Gomez Candela C, de Cos Blanco AI, Martinez Olmos MA, Hernandez MJ, Rodriguez A,
Ojeda E, Garcia Bustos J. Related Articles, Links
[Nutritional support in bone marrow transplantation]
Nutr Hosp. 1997 Sep-Oct;12(5):263-9. Spanish.
PMID: 9410090 [PubMed - indexed for MEDLINE]
327: Phillips GL, Reece DE, Wolff SN, Goldie JH. Related Articles, Links
The use of conventional salvage chemotherapy before dose-intensive cytotoxic therapy and
autologous transplantation for aggressive-histology lymphoma: a case for re-evaluation.
Leuk Lymphoma. 1997 Aug;26(5-6):507-13. Review.
PMID: 9389358 [PubMed - indexed for MEDLINE]
328: Brynes RK, Wilson CS, Kim AB, McCourty A. Related Articles, Links
Expression of p53, MDM2, p21waf1, bcl-2, and retinoblastoma gene proteins in myelodysplastic
syndrome after autologous bone marrow transplantation for lymphoma.
Mod Pathol. 1997 Nov;10(11):1120-7.
PMID: 9388063 [PubMed - indexed for MEDLINE]
329: Skarin AT, Dorfman DM. Related Articles, Links
Non-Hodgkin's lymphomas: current classification and management.
CA Cancer J Clin. 1997 Nov-Dec;47(6):351-72. Review.
PMID: 9371057 [PubMed - indexed for MEDLINE]
330: Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E,
Planas I, Kashyap A, Spielberger R, Fung H, Wong KK, Somlo G, Margolin K, Chow W,
Sniecinski I, Vora N, Blume KG, Niland J, Forman SJ. Related Articles, Links
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during
remission in poor-risk intermediate- and high-grade lymphoma: international index high and highintermediate risk group.
Blood. 1997 Nov 15;90(10):3844-52.
PMID: 9354650 [PubMed - indexed for MEDLINE]
331: Hass R, Lopez-Guerrero JA. Related Articles, Links
Aggressive tumor growth of human TUR leukemia cells is associated with high levels of c-myc
expression and down-regulation of p20-max.
Int J Cancer. 1997 Sep 17;72(6):1113-6.
PMID: 9378547 [PubMed - indexed for MEDLINE]
332: Rizzieri DA, Chao NJ. Related Articles, Links
Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell
support.
Curr Opin Oncol. 1997 Sep;9(5):420-7. Review.
PMID: 9327219 [PubMed - indexed for MEDLINE]
333: Bartlett NL. Related Articles, Links
Treatment of aggressive histology lymphoma.
Curr Opin Oncol. 1997 Sep;9(5):413-9. Review.
PMID: 9327218 [PubMed - indexed for MEDLINE]
334: Hausdorff J, Davis E, Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C.
Related Articles, Links
Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response
to combined-modality therapy.
Cancer J Sci Am. 1997 Sep-Oct;3(5):303-11.
PMID: 9327155 [PubMed - indexed for MEDLINE]
335: Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. Related Articles, Links
High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's
lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry.
Blood. 1997 Oct 15;90(8):2921-30.
PMID: 9376572 [PubMed - indexed for MEDLINE]
336: Liu SY, Press OW. Related Articles, Links
The potential for immunoconjugates in lymphoma therapy.
Hematol Oncol Clin North Am. 1997 Oct;11(5):987-1006. Review.
PMID: 9336727 [PubMed - indexed for MEDLINE]
337: Swinnen LJ. Related Articles, Links
Treatment of organ transplant-related lymphoma.
Hematol Oncol Clin North Am. 1997 Oct;11(5):963-73. Review.
PMID: 9336725 [PubMed - indexed for MEDLINE]
338: Mundt AJ, Williams SF, Hallahan D. Related Articles, Links
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of
failure and implications for involved-field radiotherapy.
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):617-25.
PMID: 9336141 [PubMed - indexed for MEDLINE]
339: Wilson CS, Traweek ST, Slovak ML, Niland JC, Forman SJ, Brynes RK. Related Articles,
Links
Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma.
Morphologic features.
Am J Clin Pathol. 1997 Oct;108(4):369-77.
PMID: 9322588 [PubMed - indexed for MEDLINE]
340: Gisselbrecht C. Related Articles, Links
Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma.
Recent Results Cancer Res. 1998;144:15-26. Review.
PMID: 9304703 [PubMed - indexed for MEDLINE]
341: Savarese DM, Hsieh C, Stewart FM. Related Articles, Links
Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and
solid tumors.
J Clin Oncol. 1997 Aug;15(8):2981-95. Review.
PMID: 9256143 [PubMed - indexed for MEDLINE]
342: Nagele H, Kalmar P, Rodiger W, Stubbe HM. Related Articles, Links
Smoking after heart transplantation: an underestimated hazard?
Eur J Cardiothorac Surg. 1997 Jul;12(1):70-4.
PMID: 9262083 [PubMed - indexed for MEDLINE]
343: Koizumi K, Sawada K, Nishio M, Katagiri E, Fukae J, Fukada Y, Tarumi T, Notoya A,
Shimizu T, Abe R, Kobayashi H, Koike T. Related Articles, Links
Effective high-dose chemotherapy followed by autologous peripheral blood stem cell
transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis.
Bone Marrow Transplant. 1997 Jul;20(2):171-3.
PMID: 9244423 [PubMed - indexed for MEDLINE]
344: Lones MA, Lopez-Terrada D, Weiss LM, Shintaku IP, Said JW. Related Articles, Links
Donor origin of posttransplant lymphoproliferative disorder localized to a liver allograft:
demonstration by fluorescence in situ hybridization.
Arch Pathol Lab Med. 1997 Jul;121(7):701-6.
PMID: 9240905 [PubMed - indexed for MEDLINE]
345: Lee PY, Freeman NJ, Khorsand J, Weinstock MA. Related Articles, Links
Angiocentric T-cell lymphoma presenting as lethal midline granuloma.
Int J Dermatol. 1997 Jun;36(6):419-27. Review.
PMID: 9248885 [PubMed - indexed for MEDLINE]
346: Goss G, Szer J, Basser R, Fox R, Grigg A. Related Articles, Links
Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation
for lymphoma.
Aust N Z J Med. 1997 Jun;27(3):323-9.
PMID: 9227818 [PubMed - indexed for MEDLINE]
347: Natkunam Y, Elenitoba-Johnson KS, Kingma DW, Kamel OW. Related Articles, Links
Epstein-Barr virus strain type and latent membrane protein 1 gene deletions in lymphomas in
patients with rheumatic diseases.
Arthritis Rheum. 1997 Jun;40(6):1152-6.
PMID: 9182927 [PubMed - indexed for MEDLINE]
348: Martelli M, De Sanctis V, Avvisati G, Mandelli F. Related Articles, Links
Current guidelines for the management of aggressive non-Hodgkin's lymphoma.
Drugs. 1997 Jun;53(6):957-72. Review.
PMID: 9179527 [PubMed - indexed for MEDLINE]
349: Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D,
Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D. Related Articles, Links
Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poorprognosis non-Hodgkin's lymphoma.
J Clin Oncol. 1997 May;15(5):1722-9.
PMID: 9164178 [PubMed - indexed for MEDLINE]
350: Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella
C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. Related Articles, Links
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B
in aggressive B-cell lymphoma.
N Engl J Med. 1997 May 1;336(18):1290-7.
PMID: 9113932 [PubMed - indexed for MEDLINE]
351: Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, Diebold J, Le
Prise PY, Fauchet R. Related Articles, Links
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug
resistance.
Blood. 1997 Apr 15;89(8):2966-74.
PMID: 9108417 [PubMed - indexed for MEDLINE]
352: Ohnuma K, Toyoda Y, Nishihira H, Iguchi A, Honda K, Nagao T, Kigasawa H, Tanaka Y,
Kikuta H. Related Articles, Links
Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the
literature.
Leuk Lymphoma. 1997 Apr;25(3-4):387-92. Review.
PMID: 9168449 [PubMed - indexed for MEDLINE]
353: Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, Haskins S, Heerema NA,
Gharpure V, Abonour R, Srour EF, Cornetta K. Related Articles, Links
Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are
aggressive diseases with a high incidence of adverse histologic and immunobiologic features.
Am J Clin Pathol. 1997 Apr;107(4):419-29.
PMID: 9124210 [PubMed - indexed for MEDLINE]
354: Ivanyi JL, Marton E, Szabo F, Mahunka M, Kelenyi G. Related Articles, Links
[Anaplastic large cell lymphoma based on our clinicopathological cases]
Orv Hetil. 1997 Mar 30;138(13):779-84. Review. Hungarian.
PMID: 9173373 [PubMed - indexed for MEDLINE]
355: Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, Salmaso F, Mariuzzi L, Di Loreto
C, Baccarani M. Related Articles, Links
Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical
characteristics and outcome.
Haematologica. 1997 Mar-Apr;82(2):171-7.
PMID: 9175321 [PubMed - indexed for MEDLINE]
356: Gribben JG. Related Articles, Links
Bone marrow transplantation for low-grade B-cell malignancies.
Curr Opin Oncol. 1997 Mar;9(2):117-21. Review.
PMID: 9161787 [PubMed - indexed for MEDLINE]
357: Fodinger M, Mannhalter C. Related Articles, Links
Molecular genetics and development of mast cells: implications for molecular medicine.
Mol Med Today. 1997 Mar;3(3):131-7. Review.
PMID: 9095488 [PubMed - indexed for MEDLINE]
358: Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B,
Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F. Related Articles, Links
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk
aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe
d'Etude des Lymphomes de l'Adulte.
J Clin Oncol. 1997 Mar;15(3):1131-7.
PMID: 9060555 [PubMed - indexed for MEDLINE]
359: Chadburn A, Cesarman E, Knowles DM. Related Articles, Links
Molecular pathology of posttransplantation lymphoproliferative disorders.
Semin Diagn Pathol. 1997 Feb;14(1):15-26. Review.
PMID: 9044506 [PubMed - indexed for MEDLINE]
360: Tobinai K. Related Articles, Links
Chemotherapy: the more, the better in malignant lymphoma?
Cancer Chemother Pharmacol. 1997;40 Suppl:S110-4. Review.
PMID: 9272145 [PubMed - indexed for MEDLINE]
361: Ogura M, Kagami Y, Suzuki R, Miura K, Uehira K, Kurokawa T, Ito T, Kinoshita T, Emi N,
Morishima Y, Kodera Y, Ueda R. Related Articles, Links
Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+
peripheral blood stem cells purified by the immunomagnetic bead method for refractory
hematological malignancies. Nagoya CD34+ PBSCT Study Group.
Cancer Chemother Pharmacol. 1997;40 Suppl:S51-7.
PMID: 9272135 [PubMed - indexed for MEDLINE]
362: Fisher RI. Related Articles, Links
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in
non-Hodgkin's lymphoma.
Cancer Chemother Pharmacol. 1997;40 Suppl:S42-6.
PMID: 9272133 [PubMed - indexed for MEDLINE]
363: Funakoshi S, Taub DD, Asai O, Hirano A, Ruscetti FW, Longo DL, Murphy WJ. Related
Articles, Links
Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
Leuk Lymphoma. 1997 Jan;24(3-4):187-99. Review.
PMID: 9156649 [PubMed - indexed for MEDLINE]
364: Oinonen R, Franssila K, Elonen E. Related Articles, Links
Spontaneous splenic rupture in two patients with a blastoid variant of mantle cell lymphoma.
Ann Hematol. 1997 Jan;74(1):33-5.
PMID: 9031613 [PubMed - indexed for MEDLINE]
365: Liang R, Chen F, Lee CK, Kwong YL, Chim CS, Yau CC, Chiu E. Related Articles, Links
Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma.
Bone Marrow Transplant. 1997 Jan;19(1):91-3.
PMID: 9012939 [PubMed - indexed for MEDLINE]
366: Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D, Tilly H.
Related Articles, Links
Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in
patients over 60 years of age.
Bone Marrow Transplant. 1997 Jan;19(1):31-5.
PMID: 9012928 [PubMed - indexed for MEDLINE]
367: Hagberg H, Kimby E. Related Articles, Links
Treatment of aggressive non-Hodgkin's lymphoma in adults--are we doing any better?
Med Oncol. 1996 Dec;13(4):185-94. Review.
PMID: 9152968 [PubMed - indexed for MEDLINE]
368: Miyazaki H, Hirano M. Related Articles, Links
[Effective clinical use of cyclophosphamide in hematological malignancies]
Gan To Kagaku Ryoho. 1996 Dec;23(14):1891-5. Review. Japanese.
PMID: 8978792 [PubMed - indexed for MEDLINE]
369: Schouten HC. Related Articles, Links
Aggressive treatment in follicular non-Hodgkin's lymphoma.
Br J Hosp Med. 1996 Nov 20-Dec 10;56(10):525-8. Review. No abstract available.
PMID: 8958406 [PubMed - indexed for MEDLINE]
370: Pettengell R. Related Articles, Links
High-dose therapy for aggressive non-Hodgkin's lymphoma.
Br J Hosp Med. 1996 Nov 20-Dec 10;56(10):521-4. Review. No abstract available.
PMID: 8958405 [PubMed - indexed for MEDLINE]
371: Zinzani PL, Bendandi M, Visani G, Gherlinzoni F, Frezza G, Merla E, Manfroi S, Gozzetti A,
Tura S. Related Articles, Links
Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients.
Leuk Lymphoma. 1996 Nov;23(5-6):577-82.
PMID: 9031089 [PubMed - indexed for MEDLINE]
372: Infanti L, Silvestri F, Fanin R, Salmaso F, Zaja F, Barillari G, Patriarca F, Geromin A, Cerno
M, Damiani D, Baccarani M. Related Articles, Links
The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single
center experience in 72 patients.
Haematologica. 1996 Nov-Dec;81(6):521-8.
PMID: 9009439 [PubMed - indexed for MEDLINE]
373: Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Related Articles,
Links
Durable remission of a relapsing primary central nervous system lymphoma after autologous bone
marrow transplantation.
Bone Marrow Transplant. 1996 Nov;18(5):1021-3.
PMID: 8932861 [PubMed - indexed for MEDLINE]
374: Hanson MN, Morrison VA, Peterson BA, Stieglbauer KT, Kubic VL, McCormick SR,
McGlennen RC, Manivel JC, Brunning RD, Litz CE. Related Articles, Links
Posttransplant T-cell lymphoproliferative disorders--an aggressive, late complication of solid-organ
transplantation.
Blood. 1996 Nov 1;88(9):3626-33.
PMID: 8896433 [PubMed - indexed for MEDLINE]
375: Gal A, Tamir S, Tannenbaum SR, Wogan GN. Related Articles, Links
Nitric oxide production in SJL mice bearing the RcsX lymphoma: a model for in vivo toxicological
evaluation of NO.
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11499-503.
PMID: 8876164 [PubMed - indexed for MEDLINE]
376: Capria S, Vignetti M, Proia A, Caruso R, Coppola L, Orsini E, Meloni G. Related Articles,
Links
Autologous bone marrow transplantation in 44 patients with aggressive non-Hodgkin's lymphoma
at University "La Sapienza" of Rome.
Leuk Lymphoma. 1996 Sep;23(1-2):147-51.
PMID: 9021698 [PubMed - indexed for MEDLINE]
377: Kramer GS, Gatenby RA. Related Articles, Links
Malignant plasmacytoma appearing as invasive paranasal sinus disease after cardiac
transplantation.
AJNR Am J Neuroradiol. 1996 Sep;17(8):1582-4.
PMID: 8883660 [PubMed - indexed for MEDLINE]
378: Moreau P, Mechinaud F, Mahe B, Le Tortorec S, Rapp MJ, Maisonneuve H, Harousseau JL,
Milpied N. Related Articles, Links
Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow
transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1996 Sep;18(3):665-7.
PMID: 8879639 [PubMed - indexed for MEDLINE]
379: Borg A, Yin JA, Johnson PR, Tosswill J, Saunders M, Morris D. Related Articles, Links
Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic
bone marrow transplantation.
Br J Haematol. 1996 Sep;94(4):713-5.
PMID: 8826899 [PubMed - indexed for MEDLINE]
380: Vose JM, Bierman PJ, Anderson JR, Harrison KA, Dalrymple GV, Byar K, Kessinger A,
Armitage JO. Related Articles, Links
Single-photon emission computed tomography gallium imaging versus computed tomography:
predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell
transplantation for non-Hodgkin's lymphoma.
J Clin Oncol. 1996 Sep;14(9):2473-9.
PMID: 8823325 [PubMed - indexed for MEDLINE]
381: Gisselbrecht C. Related Articles, Links
Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma.
Hematol Cell Ther. 1996 Aug;38(4):297-304. Review.
PMID: 8891721 [PubMed - indexed for MEDLINE]
382: Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G,
Ruebe M, Thistlethwaite JR Jr. Related Articles, Links
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Clin Transplant. 1996 Aug;10(4):323-32.
PMID: 8884103 [PubMed - indexed for MEDLINE]
383: Brice P, Marolleau JP, Pautier P, Makke J, Cazals D, Dombret H, D'Agay MF, Benbunan M,
Gisselbrecht C. Related Articles, Links
Hematologic recovery and survival of lymphoma patients after autologous stem-cell
transplantation: comparison of bone marrow and peripheral blood progenitor cells.
Leuk Lymphoma. 1996 Aug;22(5-6):449-56.
PMID: 8882958 [PubMed - indexed for MEDLINE]
384: Aviles A, Guzman R, Delgado S, Nambo MJ, Garcia EL, Diaz-Maqueo JC. Related Articles,
Links
Intensive brief chemotherapy with hematopoietic growth factors as hematological support and
adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma.
Am J Hematol. 1996 Aug;52(4):275-80.
PMID: 8701945 [PubMed - indexed for MEDLINE]
385: Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. Related Articles, Links
Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in
Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Blood. 1996 Jul 1;88(1):242-51.
PMID: 8704180 [PubMed - indexed for MEDLINE]
386: Mentzer SJ, Longtine J, Fingeroth J, Reilly JJ, DeCamp MM, O'Donnell W, Swanson SJ,
Faller DV, Sugarbaker DJ. Related Articles, Links
Immunoblastic lymphoma of donor origin in the allograft after lung transplantation.
Transplantation. 1996 Jun 27;61(12):1720-5.
PMID: 8685950 [PubMed - indexed for MEDLINE]
387: Pohlman B. Related Articles, Links
Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Semin Oncol. 1996 Jun;23(3 Suppl 6):27-32. Review.
PMID: 8677445 [PubMed - indexed for MEDLINE]
388: Santini G, Congiu AM, Nati S, Pierluigi D, Spriano M, Chisesi T, Rossi E, Vimercati R,
Sertoli MR, Figari O, Gobbi M, Piaggio G, Vassallo F, Benvenuto F, Soracco M, Miglino M, Bruni
R, Ravetti JL, Truini M. Related Articles, Links
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's
lymphoma with marrow involvement.
Leukemia. 1996 Jun;10 Suppl 2:s88-91.
PMID: 8649061 [PubMed - indexed for MEDLINE]
389: Federico M, Clo V, Carella AM. Related Articles, Links
High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with
advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of
51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial.
Leukemia. 1996 Jun;10 Suppl 2:s69-71.
PMID: 8649056 [PubMed - indexed for MEDLINE]
390: Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H. Related
Articles, Links
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or
refractory aggressive non-Hodgkin's lymphoma.
Cancer. 1996 Jun 1;77(11):2302-7.
PMID: 8635099 [PubMed - indexed for MEDLINE]
391: Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS. Related Articles, Links
In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.
Clin Exp Metastasis. 1996 May;14(3):219-29.
PMID: 8674276 [PubMed - indexed for MEDLINE]
392: Arrese JE, Pierard-Franchimont C, Pierard GE. Related Articles, Links
Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient.
Am J Dermatopathol. 1996 Apr;18(2):196-8.
PMID: 8739996 [PubMed - indexed for MEDLINE]
393: Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, Giordano D, Occhini D,
Gatti AM, Bruni R, Spriano M, Nati S, Pierluigi D, Congiu M, Vimercati R, Ravetti JL, Federico
M. Related Articles, Links
Twelve years experience with high-dose therapy and autologous stem cell transplantation for highrisk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy.
Leuk Lymphoma. 1996 Mar;21(1-2):63-70.
PMID: 8907271 [PubMed - indexed for MEDLINE]
394: Wotherspoon AC, Diss TC, Pan L, Singh N, Whelan J, Isaacson PG. Related Articles, Links
Low grade gastric B-cell lymphoma of mucosa associated lymphoid tissue in immunocompromised
patients.
Histopathology. 1996 Feb;28(2):129-34.
PMID: 8834520 [PubMed - indexed for MEDLINE]
395: Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V,
Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F. Related Articles, Links
High-dose chemotherapy followed by autologous bone marrow transplantation versus
dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial
response to front-line chemotherapy: a prospective randomized italian multicenter study.
J Clin Oncol. 1996 Feb;14(2):534-42.
PMID: 8636768 [PubMed - indexed for MEDLINE]
396: Trumper L, Pfreundschuh M. Related Articles, Links
[High-grade non-Hodgkin lymphoma: diagnosis and therapy]
Ther Umsch. 1996 Feb;53(2):133-9. Review. German.
PMID: 8629263 [PubMed - indexed for MEDLINE]
397: Smith MR. Related Articles, Links
Non-Hodgkin's lymphoma.
Curr Probl Cancer. 1996 Jan-Feb;20(1):6-77. Review.
PMID: 8919170 [PubMed - indexed for MEDLINE]
398: Havemann K, Kaiser U. Related Articles, Links
[Autologous bone marrow transplantation as early therapy for patients with aggressive nonHodgkin's lymphoma]
Strahlenther Onkol. 1996 Jan;172(1):50-1. German. No abstract available.
PMID: 8571191 [PubMed - indexed for MEDLINE]
399: Kowal-Vern A, Swinnen L, Pyle J, Radvany R, Dizikes G, Michalov M, Molnar Z. Related
Articles, Links
Characterization of postcardiac transplant lymphomas. Histology, immunophenotyping,
immunohistochemistry, and gene rearrangement.
Arch Pathol Lab Med. 1996 Jan;120(1):41-8.
PMID: 8554443 [PubMed - indexed for MEDLINE]
400: Su IJ, Wang CH, Cheng AL, Chen RL. Related Articles, Links
Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders:
disease spectrum, pathogenesis, and management.
Leuk Lymphoma. 1995 Nov;19(5-6):401-6. Review.
PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books
Search PubMed Protein Nucleotide Structure Genome Books Domains 3D Domains GEO GEO
DataSets Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS
for
Limits Preview/Index History Clipboard Details
About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Privacy Policy
Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles
Domain Links 3D Domain Links GEO DataSet Links Genome Links GEO Links Nucleotide Links
OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links
Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order
Items 401-562 of 562 Previous of 3
401: Tobinai K. Related Articles, Links
[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant
lymphoma]
Gan To Kagaku Ryoho. 1995 Oct;22(12):1724-30. Review. Japanese.
PMID: 7574802 [PubMed - indexed for MEDLINE]
402: Gerhartz HH. Related Articles, Links
Perspective of rhGM-CSF in the treatment of neutropenic infections and aggressive lymphomas.
Stem Cells. 1995 Sep;13(5):472-6. Review.
PMID: 8528096 [PubMed - indexed for MEDLINE]
403: Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ, Fanslow WC,
Rager HC, Taub DD, Ruscetti FW, et al. Related Articles, Links
Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe
combined immune deficient mice given human peripheral blood lymphocytes.
Blood. 1995 Sep 1;86(5):1946-53.
PMID: 7544649 [PubMed - indexed for MEDLINE]
404: Fermand JP, Ravaud P, Chevret S, Leblond V, Divine M, Dreyfus F, Belanger C, Troussard
X, Mariette X, Brouet JC. Related Articles, Links
High-dose therapy and autologous blood stem cell transplantation in multiple myeloma:
preliminary results of a randomized trial involving 167 patients.
Stem Cells. 1995 Aug;13 Suppl 2:156-9.
PMID: 8520505 [PubMed - indexed for MEDLINE]
405: Cucuianu A, D'Hondt L, Collignon J, Verhulst D, Deprijck B, Chatelain C, Doyen C, Bosly
A. Related Articles, Links
High-dose cytotoxic therapy with autologous bone marrow or peripheral blood progenitor cell
transplantation in malignant lymphomas.
Rom J Intern Med. 1995 Jul-Dec;33(3-4):211-25.
PMID: 8646194 [PubMed - indexed for MEDLINE]
406: Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Related Articles, Links
Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly
aggressive tumors of host origin.
Am J Clin Pathol. 1995 Jun;103(6):748-55.
PMID: 7785662 [PubMed - indexed for MEDLINE]
407: Nagafuji K, Harada M. Related Articles, Links
[Autologous blood stem cell transplantation-current status and issues. Fukuoka Bone Marrow
Transplantation Group]
Rinsho Ketsueki. 1995 Jun;36(6):530-7. Review. Japanese.
PMID: 7643446 [PubMed - indexed for MEDLINE]
408: Fields LL, White CR Jr, Maziarz RT. Related Articles, Links
Rapid development of disseminated superficial porokeratosis after transplant induction therapy.
Bone Marrow Transplant. 1995 Jun;15(6):993-5.
PMID: 7581104 [PubMed - indexed for MEDLINE]
409: van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D,
Gajewski JL, Bellare N, Nath R, et al. Related Articles, Links
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case
for aggressive management.
J Clin Oncol. 1995 May;13(5):1096-102.
PMID: 7738615 [PubMed - indexed for MEDLINE]
410: Jost LM, Jacky E, Dommann-Scherrer C, Honegger HP, Maurer R, Sauter C, Stahel RA.
Related Articles, Links
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow
transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Ann Oncol. 1995 May;6(5):445-51.
PMID: 7545428 [PubMed - indexed for MEDLINE]
411: Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW,
Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL, et al. Related Articles, Links
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly
responding patients with aggressive non-Hodgkin's lymphoma.
N Engl J Med. 1995 Apr 20;332(16):1045-51.
PMID: 7898521 [PubMed - indexed for MEDLINE]
412: Juan MT, Sheu LF, Chang JY, Hwang WS. Related Articles, Links
Primary non-Hodgkin's lymphoma of the mediastinum: a clinicopathological report of six cases.
Zhonghua Yi Xue Za Zhi (Taipei). 1995 Apr;55(4):325-30.
PMID: 7796361 [PubMed - indexed for MEDLINE]
413: Coppetelli U, Tribalto M, Papa G. Related Articles, Links
[Peripheral stem cells: from biology to therapy]
Recenti Prog Med. 1995 Apr;86(4):164-7. Italian.
PMID: 7617960 [PubMed - indexed for MEDLINE]
414: Mendoza E, Territo M, Schiller G, Lill M, Kunkel L, Wolin M. Related Articles, Links
Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1995 Feb;15(2):299-303.
PMID: 7773222 [PubMed - indexed for MEDLINE]
415: Chebil M, Martin X, Friaa S, Ezzeddine W, Garnier JL, Desmettre O, Marechal JM, Gelet A,
Dubernard JM. Related Articles, Links
[Lymphoma with bladder involvement and renal transplantation]
Prog Urol. 1995 Feb;5(1):102-5. French.
PMID: 7719353 [PubMed - indexed for MEDLINE]
416: Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Related
Articles, Links
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of
posttransplantation lymphoproliferative disorders.
Blood. 1995 Jan 15;85(2):552-65.
PMID: 7812011 [PubMed - indexed for MEDLINE]
417: Funakoshi S, Beckwith M, Fanslow W, Longo DL, Murphy WJ. Related Articles, Links
Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice:
characterization and the role of CD40 stimulation in their treatment and prevention.
Pathobiology. 1995;63(3):133-42.
PMID: 8821629 [PubMed - indexed for MEDLINE]
418: Dillman RO, Barth NM, Mahdavi K, VanderMolen LA, Nayak SK, O'Connor A. Related
Articles, Links
The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with
autologous bone marrow transplantation in a comprehensive community cancer center.
Cancer Biother. 1995 Spring;10(1):25-36.
PMID: 7780484 [PubMed - indexed for MEDLINE]
419: Reece D. Related Articles, Links
Early autologous bone marrow transplantation (ABMT) in the treatment of Hodgkin's disease.
Leuk Lymphoma. 1995;15 Suppl 1:55-7.
PMID: 7767263 [PubMed - indexed for MEDLINE]
420: Sterling JC, Marcus R, Burrows NP, Roberts SO. Related Articles, Links
Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow
transplantation.
Clin Exp Dermatol. 1995 Jan;20(1):73-5.
PMID: 7671405 [PubMed - indexed for MEDLINE]
421: Fisher RI, Oken MM. Related Articles, Links
Clinical practice guidelines: non-Hodgkin's lymphomas.
Cleve Clin J Med. 1995;62 Suppl 1:SI6-42, quiz SI43-5. Review.
PMID: 7641398 [PubMed - indexed for MEDLINE]
422: Depuydt P, Van Hoof A, Selleslag D, Criel A, Hidayat M, Louwagie A. Related Articles,
Links
Mediastinal B-cell lymphoma with sclerosis: clinical features and treatment results in 10 patients.
Acta Clin Belg. 1995;50(3):137-43.
PMID: 7631528 [PubMed - indexed for MEDLINE]
423: Wolfe JT, Lessin SR, Singh AH, Rook AH. Related Articles, Links
Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma,
autoimmune disease, and allograft rejection.
Artif Organs. 1994 Dec;18(12):888-97. Review.
PMID: 7887825 [PubMed - indexed for MEDLINE]
424: Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C,
Herbrecht R, D'Agay MF, et al. Related Articles, Links
Comparison of autologous bone marrow transplantation with sequential chemotherapy for
intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of
464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol. 1994 Dec;12(12):2543-51.
PMID: 7527453 [PubMed - indexed for MEDLINE]
425: Sriskandan S, O'Brien ME, Smith IE, Collins P, Gore ME. Related Articles, Links
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of
doxorubicin.
Postgrad Med J. 1994 Oct;70(828):759-61.
PMID: 7831179 [PubMed - indexed for MEDLINE]
426: Lundquist DM, Stewart FM. Related Articles, Links
An update on non-Hodgkin's lymphomas.
Nurse Pract. 1994 Oct;19(10):41, 45, 49-54. Review.
PMID: 7816362 [PubMed - indexed for MEDLINE]
427: Perlroth MG, Delfino M. Related Articles, Links
[Cyclosporin in heart transplantations. The authors' personal experience]
Recenti Prog Med. 1994 Oct;85(10):471-4. Italian.
PMID: 7809459 [PubMed - indexed for MEDLINE]
428: Eghbali H, Catry-Thomas I, Soubeyran P, Bonnel C, Hoerni B. Related Articles, Links
[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of
relapsing or refractory aggressive malignant lymphoma.Study of 51 patients]
Bull Cancer. 1994 Sep;81(9):800-7. French.
PMID: 7703570 [PubMed - indexed for MEDLINE]
429: End A, Dekan G, Korn M, Helbich T, Grabenwoger M, Mitterbauer G, Stift A, Mares P,
Wekerle T, Wolner E, et al. Related Articles, Links
[Differential diagnosis of round opacities after lung transplantation]
Dtsch Med Wochenschr. 1994 Aug 19;119(33):1105-9. German.
PMID: 8070330 [PubMed - indexed for MEDLINE]
430: Morrison VA, Frizzera G, Arthur DC, Ogle KM, Hurd DD, Bloomfield CD, Peterson BA.
Related Articles, Links
Prognostic factors for therapeutic outcome of diffuse small non-cleaved cell lymphoma in adults.
Am J Hematol. 1994 Aug;46(4):295-303.
PMID: 8037180 [PubMed - indexed for MEDLINE]
431: Wolf M. Related Articles, Links
Non Hodgkin's lymphoma--diagnosis and management.
Aust Fam Physician. 1994 Aug;23(8):1491-7. Review.
PMID: 7980149 [PubMed - indexed for MEDLINE]
432: Kaplan MA, Ferry JA, Harris NL, Jacobson JO. Related Articles, Links
Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein-Barr
virus and immunoglobulin genes as markers.
Am J Clin Pathol. 1994 May;101(5):590-6.
PMID: 8178765 [PubMed - indexed for MEDLINE]
433: Haw R, Sawka CA, Franssen E, Berinstein NL. Related Articles, Links
Significance of a partial or slow response to front-line chemotherapy in the management of
intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review.
J Clin Oncol. 1994 May;12(5):1074-84.
PMID: 8164032 [PubMed - indexed for MEDLINE]
434: De Vita F, Di Grazia M, Orditura M, Saieva MR, Catalano G. Related Articles, Links
Autologous bone marrow transplantation in Ki-1 lymphoma with poor prognosis. A case report.
Recenti Prog Med. 1994 May;85(5):278-81. Review.
PMID: 8023006 [PubMed - indexed for MEDLINE]
435: Gisselbrecht C. Related Articles, Links
[Hematopoietic growth factors in practice: importance and problems]
Bull Acad Natl Med. 1994 May;178(5):781-91; discussion 791-2. French.
PMID: 7953888 [PubMed - indexed for MEDLINE]
436: Moscinski LC, Ballester OF. Related Articles, Links
Recent progress in multiple myeloma.
Hematol Oncol. 1994 May-Jun;12(3):111-23. Review.
PMID: 7525447 [PubMed - indexed for MEDLINE]
437: Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly
A, Tilly H, Boulat O, et al. Related Articles, Links
Interleukin-2 treatment in lymphoma: a phase II multicenter study.
Blood. 1994 Apr 15;83(8):2081-5.
PMID: 8161779 [PubMed - indexed for MEDLINE]
438: Exner GU, Min K, Malinin TI, Schreiber A. Related Articles, Links
[Reconstruction of segmental bone defects using massive osseous and osteocartilaginous allograft]
Schweiz Rundsch Med Prax. 1994 Mar 15;83(11):300-7. German.
PMID: 8153508 [PubMed - indexed for MEDLINE]
439: Rook AH, Wolfe JT. Related Articles, Links
Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune
disease, and allograft rejection.
J Clin Apheresis. 1994;9(1):28-30. Review.
PMID: 8195109 [PubMed - indexed for MEDLINE]
440: Salles G, Shipp MA, Coiffier B. Related Articles, Links
Chemotherapy of non-Hodgkin's aggressive lymphomas.
Semin Hematol. 1994 Jan;31(1):46-69. Review. No abstract available.
PMID: 8122135 [PubMed - indexed for MEDLINE]
441: Hellmann A. Related Articles, Links
[Interleukin-2 and its use in hemo-proliferative disorders]
Acta Haematol Pol. 1994;25(2 Suppl 1):142-7. Review. Polish.
PMID: 8067199 [PubMed - indexed for MEDLINE]
442: Heinz R, Hopfinger-Limberger G. Related Articles, Links
[Therapy of low-grade non-Hodgkin's lymphoma]
Wien Klin Wochenschr. 1994;106(10):321-6. Review. German.
PMID: 8053200 [PubMed - indexed for MEDLINE]
443: Jager U, Karth GD, Knapp S, Tueni C. Related Articles, Links
[Therapy of high-grade non-Hodgkin's lymphoma]
Wien Klin Wochenschr. 1994;106(10):315-20. Review. German.
PMID: 8053199 [PubMed - indexed for MEDLINE]
444: Ludwig H, Kuhrer I. Related Articles, Links
[The treatment of multiple myeloma]
Wien Klin Wochenschr. 1994;106(14):448-54. Review. German.
PMID: 7941591 [PubMed - indexed for MEDLINE]
445: Nagler A, Elishoov H, Kapelushnik Y, Breuer R, Or R, Engelhard D. Related Articles, Links
Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow
transplantation.
Med Oncol. 1994;11(3-4):127-32.
PMID: 7633832 [PubMed - indexed for MEDLINE]
446: O'Riordan JM, Molloy K, O'Briain DS, Corbally N, Devaney D, McShane D, Considine N,
McCann SR. Related Articles, Links
Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to
combination chemotherapy.
Br J Haematol. 1994 Jan;86(1):183-6.
PMID: 7516697 [PubMed - indexed for MEDLINE]
447: Neidhart JA. Related Articles, Links
Hematopoietic cytokines. Current use in cancer therapy.
Cancer. 1993 Dec 1;72(11 Suppl):3381-6. Review.
PMID: 8242571 [PubMed - indexed for MEDLINE]
448: Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage
JO. Related Articles, Links
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive
non-Hodgkin's lymphoma.
J Clin Oncol. 1993 Oct;11(10):1846-51.
PMID: 8105034 [PubMed - indexed for MEDLINE]
449: Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Brouet JC.
Related Articles, Links
High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma:
results of a phase II trial involving 63 patients.
Blood. 1993 Oct 1;82(7):2005-9.
PMID: 8104534 [PubMed - indexed for MEDLINE]
450: Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der
Poel S, Kaneko Y, Morgan R, Sandberg AA, et al. Related Articles, Links
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23
chromosomal translocations.
N Engl J Med. 1993 Sep 23;329(13):909-14.
PMID: 8361504 [PubMed - indexed for MEDLINE]
451: Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R,
Reyes F, Coiffier B. Related Articles, Links
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients:
application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Ann Oncol. 1993 Sep;4(8):651-6.
PMID: 7694634 [PubMed - indexed for MEDLINE]
452: Picchio GR, Cohen JI, Wyatt ER, Mosier DE. Related Articles, Links
Enhanced tumorigenicity of an Epstein-Barr virus-transformed lymphoblastoid cell line is
associated with a unique 1:18 chromosomal translocation and decreased expression of lymphocyte
function associated antigen-1a (CD11A).
Am J Pathol. 1993 Aug;143(2):342-9.
PMID: 8393615 [PubMed - indexed for MEDLINE]
453: Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES,
Herdt J, Cheson BD, et al. Related Articles, Links
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
J Clin Oncol. 1993 Aug;11(8):1573-82.
PMID: 7687667 [PubMed - indexed for MEDLINE]
454: Molica S, Tucci L, Levato D, Levato L, Manfredi L. Related Articles, Links
Combined use of interferon alpha-2, chlorambucil and prednisone in previously treated patients
with low-grade non-Hodgkin's lymphomas. Results of a phase II study.
Tumori. 1993 Jun 30;79(3):195-7.
PMID: 8236503 [PubMed - indexed for MEDLINE]
455: Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, Portlock CS, Straus DJ,
Phillips J, Fuks Z. Related Articles, Links
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous
bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
J Clin Oncol. 1993 Jun;11(6):1062-70.
PMID: 8501492 [PubMed - indexed for MEDLINE]
456: Jost LM, Pichert G, Reichlin M, Muller E, Jacky E, Honegger HP, Gmur J, Stahel RA.
Related Articles, Links
[5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion
in malignant lymphoma with a high risk of recurrence]
Schweiz Med Wochenschr. 1993 May 8;123(18):932-40. German.
PMID: 8098878 [PubMed - indexed for MEDLINE]
457: Morrison VA, McGlave PB. Related Articles, Links
Mucormycosis in the BMT population.
Bone Marrow Transplant. 1993 May;11(5):383-8.
PMID: 8504272 [PubMed - indexed for MEDLINE]
458: Jacobs P. Related Articles, Links
Hodgkin's disease and the malignant lymphomas.
Dis Mon. 1993 Apr;39(4):213-97. Review.
PMID: 8462409 [PubMed - indexed for MEDLINE]
459: Lopez-Guillermo A, Bosch F, Rozman C. Related Articles, Links
Selection of patients with aggressive lymphoma in remission candidates to autologous bone
marrow transplantation.
Blood. 1993 Apr 1;81(7):1969-70. No abstract available.
PMID: 8461481 [PubMed - indexed for MEDLINE]
460: Sawada U. Related Articles, Links
[Treatment of high risk non-Hodgkin's lymphoma]
Rinsho Ketsueki. 1993 Apr;34(4):403-10. Japanese.
PMID: 7685431 [PubMed - indexed for MEDLINE]
461: Iwen PC, Reed EC, Armitage JO, Bierman PJ, Kessinger A, Vose JM, Arneson MA, Winfield
BA, Woods GL. Related Articles, Links
Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral
stem cell transplants.
Infect Control Hosp Epidemiol. 1993 Mar;14(3):131-9.
PMID: 8478525 [PubMed - indexed for MEDLINE]
462: Bosly A, Gisselbrecht C, Coiffier B. Related Articles, Links
Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's
lymphoma: the GELA experience.
Nouv Rev Fr Hematol. 1993 Feb;35(1):21-3. Review.
PMID: 8099732 [PubMed - indexed for MEDLINE]
463: Gautier MS, Pierard GE, Andrien F, Hermanns JF, Pierard-Franchimont C, Fillet G, Lapiere
CM. Related Articles, Links
High-grade pleomorphic T cell lymphoma with restricted involvement of skin and bone marrow.
Dermatology. 1993;186(4):287-9.
PMID: 8513200 [PubMed - indexed for MEDLINE]
464: Gordon BG, Weisenburger DD, Warkentin PI, Anderson J, Sanger WG, Bast M, Gnarra D,
Vose JM, Bierman PJ, Armitage JO, et al. Related Articles, Links
Peripheral T-cell lymphoma in childhood and adolescence. A clinicopathologic study of 22
patients.
Cancer. 1993 Jan 1;71(1):257-63.
PMID: 8380117 [PubMed - indexed for MEDLINE]
465: Bosly A, Coiffier B. Related Articles, Links
[Place of autograft in the treatment of relapses of aggressive lymphoma: the GELA experience]
Pathol Biol (Paris). 1993 Jan;41(1):97. French. No abstract available.
PMID: 8316491 [PubMed - indexed for MEDLINE]
466: Gisselbrecht C, Bosly A, Lepage E, Reyes F, Philip T, Haioun C, Tilly H, Coiffier B. Related
Articles, Links
Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's
lymphoma: a review.
Ann Oncol. 1993;4 Suppl 1:7-13. Review.
PMID: 8101727 [PubMed - indexed for MEDLINE]
467: Young RC. Related Articles, Links
Etoposide in the treatment of non-Hodgkin's lymphomas.
Semin Oncol. 1992 Dec;19(6 Suppl 13):19-25. Review.
PMID: 1492224 [PubMed - indexed for MEDLINE]
468: Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, Brouet JC, Fermand
JP. Related Articles, Links
Bone densitometry in patients with multiple myeloma.
Am J Med. 1992 Dec;93(6):595-8.
PMID: 1466354 [PubMed - indexed for MEDLINE]
469: Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros
M, Devaux Y, Jaubert J, et al. Related Articles, Links
Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients
treated with the LNH-84 regimen.
J Clin Oncol. 1992 Oct;10(10):1615-23.
PMID: 1383435 [PubMed - indexed for MEDLINE]
470: Nademanee A, Schmidt GM, O'Donnell MR, Snyder DS, Parker PA, Stein A, Smith E, Lipsett
JA, Sniecinski I, Margolin K, et al. Related Articles, Links
High-dose chemoradiotherapy followed by autologous bone marrow transplantation as
consolidation therapy during first complete remission in adult patients with poor-risk aggressive
lymphoma: a pilot study.
Blood. 1992 Sep 1;80(5):1130-4.
PMID: 1515634 [PubMed - indexed for MEDLINE]
471: Borisch B, Gatter KC, Tobler A, Theilkas L, Bunch C, Wainscoat JS, Fey MF. Related
Articles, Links
Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients.
Am J Clin Pathol. 1992 Sep;98(3):312-8.
PMID: 1326891 [PubMed - indexed for MEDLINE]
472: Dodwell DJ, de Campos ES, Radford JA. Related Articles, Links
Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or
is it?
Drugs. 1992 Jul;44(1):1-8. Review. No abstract available.
PMID: 1379906 [PubMed - indexed for MEDLINE]
473: Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Related Articles, Links
Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow
transplantation.
J Clin Oncol. 1992 Jun;10(6):942-7.
PMID: 1588373 [PubMed - indexed for MEDLINE]
474: Hirano M, Okamoto M, Maruyama F, Ezaki K. Related Articles, Links
[Recent progress in the chemotherapy program and its theoretical background--malignant
lymphoma]
Nippon Rinsho. 1992 Jun;50(6):1393-9. Japanese.
PMID: 1381450 [PubMed - indexed for MEDLINE]
475: Or R, Mehta J, Nagler A, Craciun I. Related Articles, Links
Neutropenic enterocolitis associated with autologous bone marrow transplantation.
Bone Marrow Transplant. 1992 May;9(5):383-5.
PMID: 1617322 [PubMed - indexed for MEDLINE]
476: Dodd GD 3rd, Greenler DP, Confer SR. Related Articles, Links
Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised
patient.
Radiol Clin North Am. 1992 May;30(3):597-610. Review.
PMID: 1570397 [PubMed - indexed for MEDLINE]
477: Weiskirch LM, Mokyr MB. Related Articles, Links
Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with
spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Int J Cancer. 1992 Apr 22;51(1):84-92.
PMID: 1563847 [PubMed - indexed for MEDLINE]
478: Paz HL, Crilley P, Patchefsky A, Schiffman RL, Brodsky I. Related Articles, Links
Bronchiolitis obliterans after autologous bone marrow transplantation.
Chest. 1992 Mar;101(3):775-8.
PMID: 1541146 [PubMed - indexed for MEDLINE]
479: Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent
G. Related Articles, Links
Intensive combined therapy for previously untreated aggressive myeloma.
Blood. 1992 Mar 1;79(5):1130-6.
PMID: 1536941 [PubMed - indexed for MEDLINE]
480: Levy LM, Sonqishe M. Related Articles, Links
Advances in lymphoma treatment.
Cent Afr J Med. 1992 Mar;38(3):116-23. Review.
PMID: 1516119 [PubMed - indexed for MEDLINE]
481: Wong K, Waters CM, Walesby RK. Related Articles, Links
Surgical management of invasive pulmonary aspergillosis in immunocompromised patients.
Eur J Cardiothorac Surg. 1992;6(3):138-42; discussion 143.
PMID: 1567627 [PubMed - indexed for MEDLINE]
482: Topolsky D, Crilley P, Leasure N, Bulova S, Brodsky I. Related Articles, Links
Syngeneic marrow transplantation in multiple myeloma.
Leuk Res. 1992;16(4):415-6.
PMID: 1564944 [PubMed - indexed for MEDLINE]
483: Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C,
Topper RL. Related Articles, Links
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine
followed by bone marrow transplantation.
Bone Marrow Transplant. 1992 Jan;9(1):41-7.
PMID: 1543948 [PubMed - indexed for MEDLINE]
484: Armitage JO. Related Articles, Links
Autologous bone marrow transplantation for patients with aggressive non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1992;10 Suppl 1:62-3. Review. No abstract available.
PMID: 1521093 [PubMed - indexed for MEDLINE]
485: Proctor SJ, Taylor P, Mackie MJ, Donnan P, Boys R, Lennard A, Prescott RJ. Related
Articles, Links
A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's
disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working
Party.
Leuk Lymphoma. 1992;7 Suppl:17-20.
PMID: 1493453 [PubMed - indexed for MEDLINE]
486: Armitage JO. Related Articles, Links
Should bone marrow transplantation be included in the primary therapy of patients with aggressive
lymphoma?
Leuk Lymphoma. 1992;7 Suppl:1-2. No abstract available.
PMID: 1493452 [PubMed - indexed for MEDLINE]
487: Hoppe RT. Related Articles, Links
The management of Hodgkin's disease in relapse after primary radiation therapy.
Eur J Cancer. 1992;28A(11):1920-2. Review.
PMID: 1389536 [PubMed - indexed for MEDLINE]
488: Friedenberg WR. Related Articles, Links
Treatment of advanced non-Hodgkin's lymphoma in adults.
Wis Med J. 1991 Dec;90(12):676-8.
PMID: 1843059 [PubMed - indexed for MEDLINE]
489: Welch RW, Yokoyama Y, Cooper DK, Zuhdi N. Related Articles, Links
The gastrointestinal management of patients undergoing heart transplantation.
J Okla State Med Assoc. 1991 Nov;84(11):557-62.
PMID: 1757834 [PubMed - indexed for MEDLINE]
490: Colombat P, Guilhot F, Bordesoule D, Renou P, Benz-Lemoine E, Fouillard L, Drouet M,
Tanzer J, Lamagnere JP. Related Articles, Links
Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
Haematologica. 1991 Nov-Dec;76(6):479-84.
PMID: 1726492 [PubMed - indexed for MEDLINE]
491: Laurence J, Astrin SM. Related Articles, Links
Human immunodeficiency virus induction of malignant transformation in human B lymphocytes.
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9.
PMID: 1652756 [PubMed - indexed for MEDLINE]
492: Attal M, Huguet F, Schlaifer D, Payen C, Lassoued S, Laroche M, Rossi JF, Fournie B,
Mazieres B, Pris J, et al. Related Articles, Links
Maintenance treatment with recombinant alpha interferon after autologous bone marrow
transplantation for aggressive myeloma in first remission after conventional induction
chemotherapy.
Bone Marrow Transplant. 1991 Aug;8(2):125-8.
PMID: 1933053 [PubMed - indexed for MEDLINE]
493: Sopchak L, Thrush GR, Lerman SP, King SR. Related Articles, Links
Loss of myb expression in an aggressive SJL/J B-cell lymphoma.
Oncogene. 1991 Aug;6(8):1335-8.
PMID: 1886709 [PubMed - indexed for MEDLINE]
494: Dupriez B, Morel P, Fenaux P, Colcher-Plantier I, Facon T, Bauters F. Related Articles, Links
VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's
lymphoma. A report on 18 cases.
Hematol Oncol. 1991 Jul-Oct;9(4-5):259-66.
PMID: 1743628 [PubMed - indexed for MEDLINE]
495: Fouillard L, Gorin NC, Laporte JP, Douay L, Lopez M, Isnard F, Jouet JP, Walter MP, Morel
P, Fenaux P, et al. Related Articles, Links
Feasibility of autologous bone marrow transplantation for early consolidation of follicular nonHodgkin's lymphoma.
Eur J Haematol. 1991 May;46(5):279-84.
PMID: 2044722 [PubMed - indexed for MEDLINE]
496: Jones RJ. Related Articles, Links
Autologous bone marrow transplantation in hematologic malignancies.
Curr Opin Oncol. 1991 Apr;3(2):234-7. Review.
PMID: 2069987 [PubMed - indexed for MEDLINE]
497: Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W,
Weisenburger DD, Fernandez-Ranada J, et al. Related Articles, Links
Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and
BEAC with autologous bone marrow transplantation.
Blood. 1991 Apr 1;77(7):1587-92.
PMID: 2009374 [PubMed - indexed for MEDLINE]
498: Vose JM, Armitage JO. Related Articles, Links
The present status of therapy for patients with aggressive non-Hodgkin's lymphoma.
Ann Oncol. 1991 Feb;2 Suppl 2:171-6. Review.
PMID: 2049315 [PubMed - indexed for MEDLINE]
499: Loy TS, Diaz-Arias AA, Perry MC. Related Articles, Links
Familial erythrophagocytic lymphohistiocytosis.
Semin Oncol. 1991 Feb;18(1):34-8. Review.
PMID: 1992522 [PubMed - indexed for MEDLINE]
500: Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Related Articles, Links
Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow
transplantation.
Blood. 1991 Feb 1;77(3):649-53.
PMID: 1991174 [PubMed - indexed for MEDLINE]
501: Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, Armitage JO. Related
Articles, Links
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic
index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des
Lymphomes Agressifs.
J Clin Oncol. 1991 Feb;9(2):211-9.
PMID: 1703226 [PubMed - indexed for MEDLINE]
502: Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, Gisselbrecht C, Kluin
Nelemans JC, Somers R, Misset JC, et al. Related Articles, Links
PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing
randomized study (62 patients).
Ann Oncol. 1991 Jan;2 Suppl 1:57-64.
PMID: 2043500 [PubMed - indexed for MEDLINE]
503: Bierman PJ, Vose JM, Armitage JO. Related Articles, Links
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: issues and
controversies.
Leukemia. 1991;5 Suppl 1:58-62. No abstract available.
PMID: 1890868 [PubMed - indexed for MEDLINE]
504: Hawley TS, Lach B, Burns BF, May LT, Sehgal PB, Hawley RG. Related Articles, Links
Expression of retrovirally transduced IL-1 alpha in IL-6-dependent B cells: a murine model of
aggressive multiple myeloma.
Growth Factors. 1991;5(4):327-38.
PMID: 1777241 [PubMed - indexed for MEDLINE]
505: Monteverde A, Pileri S. Related Articles, Links
Lymphoproliferative diseases of uncertain classification.
Ann Ital Med Int. 1991 Jan-Mar;6(1 Pt 2):162-70. Review.
PMID: 1742152 [PubMed - indexed for MEDLINE]
506: Fermand JP, Chevret S, Hennequin C, Levy Y, Gerota J, Benbunan M, Seligmann M, Brouet
JC. Related Articles, Links
High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma.
Nouv Rev Fr Hematol. 1991;33(6):525-8.
PMID: 1687831 [PubMed - indexed for MEDLINE]
507: Simon M, Bartram CR, Friedrich W, Arnold R, Schmeiser T, Hampl W, Muller-Hermelink
HK, Heymer B. Related Articles, Links
Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical,
immunobiological and pathological study.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(5):307-19.
PMID: 1685038 [PubMed - indexed for MEDLINE]
508: Horwitz LJ, Dreizen S. Related Articles, Links
Acral erythemas induced by chemotherapy and graft-versus-host disease in adults with
hematogenous malignancies.
Cutis. 1990 Nov;46(5):397-404.
PMID: 2148142 [PubMed - indexed for MEDLINE]
509: Chao NJ, Rosenberg SA, Horning SJ. Related Articles, Links
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's
lymphoma.
Blood. 1990 Oct 1;76(7):1293-8.
PMID: 2207307 [PubMed - indexed for MEDLINE]
510: Fairley JW, Hunt BJ, Glover GW, Radley-Smith RC, Yacoub MH. Related Articles, Links
Unusual lymphoproliferative oropharyngeal lesions in heart and heart-lung transplant recipients.
J Laryngol Otol. 1990 Sep;104(9):720-4.
PMID: 2230584 [PubMed - indexed for MEDLINE]
511: Haskal ZJ, Lindan CE, Goodman PC. Related Articles, Links
Lymphoma in the immunocompromised patient.
Radiol Clin North Am. 1990 Jul;28(4):885-99. Review.
PMID: 2190275 [PubMed - indexed for MEDLINE]
512: Thomas M, Gattermann N, Schneider W. Related Articles, Links
Refractory and relapsing Hodgkin's disease: role of high-dose chemotherapy with bone marrow
transplantation.
Klin Wochenschr. 1990 Jun 5;68(11):539-44. Review.
PMID: 2198377 [PubMed - indexed for MEDLINE]
513: MacLeod CL, Fong AM, Seal BS, Walls L, Wilkinson MF. Related Articles, Links
Isolation of novel complementary DNA clones from T lymphoma cells: one encodes a putative
multiple membrane-spanning protein.
Cell Growth Differ. 1990 Jun;1(6):271-9.
PMID: 1980600 [PubMed - indexed for MEDLINE]
514: Rio B, Louvet C, Gessain A, Dormont D, Gisselbrecht C, Martoia R, Auzanneau G, Miclea
JM, Baumelou E, Dombret H, et al. Related Articles, Links
[Adult T-cell leukemia and non-malignant adenopathies associated with HTLV I virus. Apropos of
17 patients born in the Caribbean region and Africa]
Presse Med. 1990 Apr 21;19(16):746-51. Review. French.
PMID: 2140159 [PubMed - indexed for MEDLINE]
515: Fisher RI, Stiff PJ. Related Articles, Links
Treatment options for recurrent lymphomas.
Semin Oncol. 1990 Apr;17(2 Suppl 4):63-7. Review.
PMID: 1692161 [PubMed - indexed for MEDLINE]
516: Nemet D. Related Articles, Links
[Transplantation of autologous bone marrow--a new approach in the treatment of neoplastic
hematologic diseases. II. Clinical results in acute leukemia, malignant lymphoma and solid tumors]
Lijec Vjesn. 1990 Jan-Feb;112(1-2):53-8. Serbo-Croatian (Roman).
PMID: 2366622 [PubMed - indexed for MEDLINE]
517: Schneider AM, Straus DJ, Schluger AE, Lowenthal DA, Koziner B, Lee BJ, Wong G,
Clarkson BD. Related Articles, Links
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and
some high-grade non-Hodgkin's lymphomas.
J Clin Oncol. 1990 Jan;8(1):94-102.
PMID: 1688617 [PubMed - indexed for MEDLINE]
518: Suttorp M, Schmitz N, Leuschner S, Appelt M, Rister M, Schaub J. Related Articles, Links
Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow
transplantation in children with poor risk acute leukaemias.
Bone Marrow Transplant. 1989 Dec;4 Suppl 4:144-8.
PMID: 2697428 [PubMed - indexed for MEDLINE]
519: Visani G, Lemoli RM, Dinota A, Galieni P, Gobbi M, Cavo M, Tura S. Related Articles,
Links
Evidence that long-term bone marrow culture of patients with multiple myeloma favors normal
hemopoietic proliferation.
Transplantation. 1989 Dec;48(6):1026-31.
PMID: 2595763 [PubMed - indexed for MEDLINE]
520: Iggo N, Palmer AB, Severn A, Trafford JA, Mufti GJ, Taube D, Parsons V. Related Articles,
Links
Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment.
Q J Med. 1989 Oct;73(270):903-10.
PMID: 2629022 [PubMed - indexed for MEDLINE]
521: Drobyski WR, Qazi R. Related Articles, Links
Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations.
Am J Hematol. 1989 Jun;31(2):138-41. Review.
PMID: 2660545 [PubMed - indexed for MEDLINE]
522: Munk PL, Helms CA, Holt RG. Related Articles, Links
Immature bone infarcts: findings on plain radiographs and MR scans.
AJR Am J Roentgenol. 1989 Mar;152(3):547-9.
PMID: 2783808 [PubMed - indexed for MEDLINE]
523: Jones JM 2nd. Related Articles, Links
Advances in the treatment of non-Hodgkin's lymphoma.
J Med Assoc Ga. 1989 Feb;78(2):105-8.
PMID: 2918256 [PubMed - indexed for MEDLINE]
524: Sopchak L, King SR, Miller DA, Gabra N, Thrush GR, Lerman SP. Related Articles, Links
Progression of transplanted SJL/J lymphomas attributed to a single aggressive H-2Ds-negative
lymphoma.
Cancer Res. 1989 Feb 1;49(3):665-71.
PMID: 2910485 [PubMed - indexed for MEDLINE]
525: Juliusson G, Abrahamsen AF, Cavallin-Stahl E, Goldstone AH, Lister TA, Nissen NI, Robert
KH, Singer CR, Somers R, Ost A, et al. Related Articles, Links
Management of non-Hodgkin lymphoma in adults in Scandinavia, United Kingdom, and The
Netherlands. Report from the European School of Oncology intercity meeting at Huddinge
Hospital, 3rd June, 1988.
Acta Oncol. 1989;28(1):135-40. Review.
PMID: 2650721 [PubMed - indexed for MEDLINE]
526: Fermand JP, Levy Y, Gerota J, Benbunan M, Cosset JM, Castaigne S, Seligmann M, Brouet
JC. Related Articles, Links
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous
blood stem cell autograft.
Nouv Rev Fr Hematol. 1989;31(2):85-7.
PMID: 2570400 [PubMed - indexed for MEDLINE]
527: Fermand JP, Levy Y, Gerota J, Benbunan M, Cosset JM, Castaigne S, Seligmann M, Brouet
JC. Related Articles, Links
Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation
followed by blood stem cells autologous graft.
Blood. 1989 Jan;73(1):20-3.
PMID: 2562921 [PubMed - indexed for MEDLINE]
528: Berry J, Russell JA. Related Articles, Links
Salvage of relapsed malignant histiocytosis by autologous bone marrow transplant.
Bone Marrow Transplant. 1989 Jan;4(1):123-4.
PMID: 2466511 [PubMed - indexed for MEDLINE]
529: Polliack A, Uziely B, Isacson R, Lugassy G, Rochlemer S, Gez E, Libson E, Sulkes A,
Weshler Z. Related Articles, Links
Diffuse large cell non-Hodgkin's lymphoma: results of M-BACOD combination chemotherapy.
Isr J Med Sci. 1988 Sep-Oct;24(9-10):619-22.
PMID: 2462553 [PubMed - indexed for MEDLINE]
530: Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D, Filippa D, Kempin S, CastroMalaspina H, Cunningham I, et al. Related Articles, Links
Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.
J Clin Oncol. 1988 Aug;6(8):1303-13.
PMID: 3045265 [PubMed - indexed for MEDLINE]
531: Ruutu T, Volin L, Elonen E. Related Articles, Links
Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged
cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
Transplant Proc. 1988 Jun;20(3):491-3. No abstract available.
PMID: 3289191 [PubMed - indexed for MEDLINE]
532: Hotson JR, Enzmann DR. Related Articles, Links
Neurologic complications of cardiac transplantation.
Neurol Clin. 1988 May;6(2):349-65. Review.
PMID: 3047545 [PubMed - indexed for MEDLINE]
533: Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR,
Swan F, Rodriguez MA. Related Articles, Links
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Semin Hematol. 1988 Apr;25(2 Suppl 2):47-50.
PMID: 3041599 [PubMed - indexed for MEDLINE]
534: Chapuis B, Helg C, Maurice P, Aapro M, Jeannet M, Irle C, Montandon N, Kaestli M, Wyss
M, Wacker P, et al. Related Articles, Links
[Super intensive treatment followed by bone marrow autograft in cases of hematologic neoplasms
and solid tumors]
Schweiz Med Wochenschr. 1988 Mar 12;118(10):341-6. Review. French.
PMID: 2452479 [PubMed - indexed for MEDLINE]
535: Gisselbrecht C, Lepage E, Brice P, Tredaniel J, Gerota I. Related Articles, Links
[The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma]
Nouv Rev Fr Hematol. 1988;30(1-2):131-4. Review. French.
PMID: 2455276 [PubMed - indexed for MEDLINE]
536: Bear PA, Moodie DS. Related Articles, Links
Malignant primary cardiac tumors. The Cleveland Clinic experience, 1956 to 1986.
Chest. 1987 Nov;92(5):860-2.
PMID: 3665601 [PubMed - indexed for MEDLINE]
537: Hoppe RT. Related Articles, Links
The non-Hodgkin's lymphomas: pathology, staging, treatment.
Curr Probl Cancer. 1987 Nov-Dec;11(6):363-447. Review.
PMID: 3125008 [PubMed - indexed for MEDLINE]
538: Bierman P, Armitage JO. Related Articles, Links
Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Oncology (Huntingt). 1987 Nov;1(9):11-21. Review.
PMID: 3079492 [PubMed - indexed for MEDLINE]
539: Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F,
Daley H, Yeap B, et al. Related Articles, Links
Prolonged disease-free survival after autologous bone marrow transplantation in patients with nonHodgkin's lymphoma with a poor prognosis.
N Engl J Med. 1987 Jun 11;316(24):1499-505.
PMID: 3295542 [PubMed - indexed for MEDLINE]
540: Schirrmacher V, Josimovic-Alasevic O, Osawa H, Diamantstein T. Related Articles, Links
Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of
animals bearing IL-2 receptor positive tumours with high or low metastatic capacity.
Br J Cancer. 1987 Jun;55(6):583-7.
PMID: 3113470 [PubMed - indexed for MEDLINE]
541: Bonadonna G, Bajetta E. Related Articles, Links
Guidelines to modern treatment of non-Hodgkin's lymphomas.
Acta Haematol. 1987;78 Suppl 1:157-62. Review.
PMID: 3124440 [PubMed - indexed for MEDLINE]
542: Skarin AT. Related Articles, Links
Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas.
Semin Oncol. 1986 Dec;13(4 Suppl 5):10-25. Review. Erratum in: Semin Oncol 1987 Mar;14(1):lii.
PMID: 2432666 [PubMed - indexed for MEDLINE]
543: Jiddane M, Nicoli F, Diaz P, Bergvall U, Vincentelli F, Hassoun J, Salamon G. Related
Articles, Links
Intracranial malignant lymphoma. Report of 30 cases and review of the literature.
J Neurosurg. 1986 Nov;65(5):592-9.
PMID: 3772444 [PubMed - indexed for MEDLINE]
544: Inoue T, Masaoka T. Related Articles, Links
[Bone marrow transplantation with preparation involving total body irradiation of leukemia and
malignant lymphoma]
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):911-21. Japanese.
PMID: 3516076 [PubMed - indexed for MEDLINE]
545: Delisle MB, Bouissou H, Saidi A. Related Articles, Links
What's new in cerebral pathology in acquired immune deficiencies?
Pathol Res Pract. 1986 Mar;181(1):85-92. Review.
PMID: 3010263 [PubMed - indexed for MEDLINE]
546: de Gast GC, Verdonck LF, Kreeft HA. Related Articles, Links
Cytotoxic T-cell capacity after autologous bone marrow transplantation.
Exp Hematol. 1985 Sep;13(8):741-4.
PMID: 2995101 [PubMed - indexed for MEDLINE]
547: Brown NO. Related Articles, Links
Surgery in hematopoietic tumors.
Vet Clin North Am Small Anim Pract. 1985 Jul;15(4):827-34. Review.
PMID: 3898537 [PubMed - indexed for MEDLINE]
548: Castro CJ, Klimo P, Worth A. Related Articles, Links
Multifocal aggressive lymphoma of the gastrointestinal tract in a renal transplant patient treated
with cyclosporin A and prednisone.
Cancer. 1985 Apr 15;55(8):1665-7.
PMID: 3884129 [PubMed - indexed for MEDLINE]
549: Philip T, Biron P, Philip I, Favrot M, Souillet G, Philippe N, Herve P, Plouvier E, Bernard JL,
Raybaud C, et al. Related Articles, Links
Massive therapy and autologous bone marrow transplantation in very bad prognosis Burkitt's
lymphoma.
IARC Sci Publ. 1985;(60):419-34.
PMID: 3905593 [PubMed - indexed for MEDLINE]
550: Kirchner HH, Engert A, Diehl V. Related Articles, Links
Experimental chemotherapy of heterotransplanted Hodgkin- and non-Hodgkin-lymphoma cell lines
in nude mice.
Behring Inst Mitt. 1984 May;(74):329-36.
PMID: 6477360 [PubMed - indexed for MEDLINE]
551: Cleary ML, Warnke R, Sklar J. Related Articles, Links
Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis
based on immunoglobulin-gene rearrangements.
N Engl J Med. 1984 Feb 23;310(8):477-82.
PMID: 6363929 [PubMed - indexed for MEDLINE]
552: Rosloniec EF, Kuhn MH, Genyea CA, Reed AH, Jennings JJ, Giraldo AA, Beisel KW,
Lerman SP. Related Articles, Links
Aggressiveness of SJL/J lymphomas correlates with absence of H-2Ds antigens.
J Immunol. 1984 Feb;132(2):945-52.
PMID: 6606680 [PubMed - indexed for MEDLINE]
553: Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J, Parlier Y, Lopez M,
Oppenheimer M, Lecomte D, et al. Related Articles, Links
Autologous bone marrow transplantation in the treatment of poor prognosis non-Hodgkin's
lymphomas.
Eur J Cancer Clin Oncol. 1984 Feb;20(2):217-25.
PMID: 6368242 [PubMed - indexed for MEDLINE]
554: Gyger M, Perreault C, Carnot J, Boileau J, Bonny Y. Related Articles, Links
Treatment of therapy-induced preleukemic syndrome.
Blut. 1984 Feb;48(2):117-20.
PMID: 6365206 [PubMed - indexed for MEDLINE]
555: Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J, Parlier Y, Oppenheimer
M, Lecomte D, Lopez M, et al. Related Articles, Links
[Non-Hodgkin's malignant lymphoma. Therapeutic value of autologous bone marrow
transplantation]
Presse Med. 1983 Sep 10;12(31):1917-23. French.
PMID: 6226002 [PubMed - indexed for MEDLINE]
556: Gyger M, Perreault C, Boileau J, Aymard JP, Bonny Y, Lacombe M, Lavallee R, d'Angelo G,
Tawil E. Related Articles, Links
Restoration of normal hematopoiesis by bone marrow ablation and allogeneic marrow
transplantation in a case of Hodgkin's disease therapy-related preleukemia.
Blood. 1983 Jun;61(6):1275-7.
PMID: 6340758 [PubMed - indexed for MEDLINE]
557: Horschowski N, Sainty D, Muratore R. Related Articles, Links
[Pinkus' lymphoma. Review of the literature apropos of a case]
Ann Med Interne (Paris). 1983;134(8):739-41. French.
PMID: 6607695 [PubMed - indexed for MEDLINE]
558: Levine AS, Brennan MF, Ramu A, Fisher RI, Pizzo PA, Glaubiger DL. Related Articles,
Links
Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment
on nutrition and drug resistance.
Cancer Res. 1982;42(2 Suppl):774s-781s.
PMID: 6799196 [PubMed - indexed for MEDLINE]
559: Young LS. Related Articles, Links
Nosocomial infections in the immunocompromised adult.
Am J Med. 1981 Feb;70(2):398-404.
PMID: 7008588 [PubMed - indexed for MEDLINE]
560: Bear RA, Cole EH, Lang A, Johnson M. Related Articles, Links
Treatment of acute renal failure due to myeloma kidney.
Can Med Assoc J. 1980 Oct 18;123(8):750-3.
PMID: 7004618 [PubMed - indexed for MEDLINE]
561: Sheil AG, May J, Mahoney JF, Horvath JS, Johnson JR, Tiller DJ, Stewart JH. Related
Articles, Links
Incidence of cancer in renal transplant recipients.
Proc Eur Dial Transplant Assoc. 1980;17:502-6.
PMID: 7017697 [PubMed - indexed for MEDLINE]
562: Sheil AG, Mahoney JF, Horvath JS, Johnson JR, Tiller DJ, Kelly GE, Stewart JH. Related
Articles, Links
Cancer following renal transplantation.
Aust N Z J Surg. 1979 Dec;49(6):617-20.
PMID: 393229 [PubMed - indexed for MEDLINE]
Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles
Domain Links 3D Domain Links GEO DataSet Links Genome Links GEO Links Nucleotide Links
OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links
Show: 5 10 20 50 100 200 500 Sort Author Journal Pub Date Text File Clipboard E-mail Order
Items 401-562 of 562 Previous of 3
Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer
Jul 17 2003 11:42:11